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Foreword
The Globelics network and its Secretariat (www.
globelics.org) have committed to deliver an Annu-
al Thematic Report that communicates important 
insights from research on innovation and develop-
ment to stakeholders such as donor organisations 
and policy makers. Earlier reports have related in-
novation to respectively inclusive development, 
low-carbon development and natural resource-
based development (see www.globelics.org/publi-
cations/globelics-thematic-review/).
The Globelics network was founded by econo-
mists linking innovation to economic development 
and catching-up. Increasingly, it has been broad-
ened to include scholars with a sociological or po-
litical science background who come from related 
fields such as science and technology studies and 
other parts of the development studies field. The 
authors of this report are two such individuals. 
Margrethe and Rebecca are members of the Af-
ricaLics Secretariat and, along with other research-
ers in the Globelics family, have brought important 
new perspectives to the network. 
The diversity in the range of researchers in the 
Globelics network is reflected in the wide span of 
research approaches that characterises the contri-
butions to the Globelics annual conferences. Glo-
belics is one of the few networks where there is an 
ongoing dialogue and cross-fertilisation between 
innovation studies, development studies and sci-
ence and technology studies. This report draws 
upon these different perspectives but the emphasis 
is especially on the latter two. This foreword intro-
duces concepts and ideas that have been developed 
within socio-economic approaches to innovation 
as a background and inspiration for the analysis in 
this report.
Innovation studies give prominent attention to 
certain components of the health system. The phar-
maceutical sector is the most research intensive of 
all industrial sectors and it is one where intellectual 
property rights play a major role (Yacoub, 2008, 
Rashmi, 2008). Countries where Research and 
Development is responsible for a high proportion 
of Gross National Product will typically host a big 
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pharmaceutical sector. The ongoing innovations in 
medical instruments give important insights in how 
new products come about in an interaction with 
advanced users and how they are sometimes even 
developed by the users themselves. Von Hippel 
(1976) refers to scientific instruments as one tech-
nology field where user innovations are frequent. 
And some of the new technologies that are seen as 
the ones that will dominate the future – genetic en-
gineering and biotechnology – have so far found 
their most important and lucrative applications 
in the health sector. Having a strong industry that 
addresses the health sector may therefore be seen 
as constituting a national competitive advantage 
(Nogueira, Britto and Vargas, 2015).
Information and communication technologies 
have already transformed activities in the health 
sector making it possible to make more systematic 
use of data, and they might – together with na-
notechnology and biotechnology – lead us toward 
a completely new understanding of human health 
and well-being where specific diseases are foreseen 
and treated before they actually become diagnosed. 
Again, keeping at the forefront in such technologi-
cal areas may be seen as a way to establish a future 
national competitive advantage (Perez, 2014).
Therefore, there is a link between the ambitions 
of the national health system and the national 
competitiveness of the entire economy. A coun-
try with technologically advanced medical ser-
vices offers an interesting market for producers 
of drugs and instruments. The link between do-
mestic users and producers may reflect proximity 
but it might also be the result of policy-led pub-
lic procurement strategies. In the beginning of 
the new Millennium, China’s political leadership 
signaled that from now on they would give prior-
ity to indigenous innovation. They promoted the 
use of public procurement because of the impact 
it would have (and indeed has had) on improving 
the dynamic capabilities of Chinese enterprises 
(Gu et al., 2008). 
The production of pharmaceuticals and medi-
cal instruments are research intensive activities and 
therefore research policy is of special importance for 
the health system. At the same time, the fact that 
health is an important aspect of human well-being 
makes it legitimate for governments to allocate 
substantial resources to research. While there is a 
negative view on selective technology and industrial 
policy in the US, there is little doubt that the very 
substantial public support to health related research 
has been a major factor in supporting a strong in-
dustrial capacity in pharmaceutical companies in 
the US (Nelson, 1988, p. 321).
The importance of health technologies for com-
petitiveness is reflected in international economic 
relations. Most global research takes place in high 
income countries and, given that much of it is sup-
ported by tax payers’ money and addressing mar-
kets in the rich countries, the focus of the research is 
upon health related problems within the rich coun-
tries. As a response to the relative neglect of finding 
cures for diseases which place a heavy burden on 
low income countries in the Global South, specific 
programs that relate to specific ailments such as TB 
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and HIV/AIDS have been implemented. But the 
production of these drugs remains principally lo-
cated in the high income countries and in a few 
low and middle income countries such as India and 
Cuba. One type of barrier for establishing more lo-
cal production is the intellectual property regime 
that is part of the WTO rules. The US pharma-
ceutical sector has been instrumental in pushing 
the US government drive for global protection of 
intellectual property rights (Rasigan, Mbula and 
Ndabeni, 2013).
This report does not focus on how to develop 
domestic production capacity in drugs and instru-
ments. In many low income countries, developing 
significant domestic production capacity in the 
pharmaceutical sector may be a challenge because 
the opportunities are limited and the barriers are 
too high to overcome. But for middle income coun-
tries with ambitions to engage in new technological 
fields such as combinations of information technol-
ogy, nano-technology and biotechnology, develop-
ing domestic production capacities is an important 
issue. According to recent research on catching-up, 
engaging in the most rapidly changing technolo-
gies is one of the few ways to break out of the so-
called middle income trap (Lee, 2013). For those 
countries, the national health system represents a 
potential for learning by interacting with compe-
tent users. For them, the design of global rules of 
intellectual property rights is critical for what op-
tions they should go for. All these issues have been 
covered in research presented at Globelics confer-
ences (see Annex 2).
This year’s Globelics Thematic Review draws on 
research findings presented at Globelics confer-
ences and wider research by scholars within the 
network and beyond. It presents a research based 
framework for the design and management of na-
tional health systems in low income countries. 
The focus is on innovations that contribute to 
shaping, maintaining and renewing health sys-
tems that should be socially inclusive, well-func-
tioning and coherent. The overriding perspective 
is on how such systems can be designed so that 
they contribute to the well-being of citizens. This 
has implications for defining the scope of the sys-
tem – it goes beyond the treatment of diseases and 
includes preventive action. It also goes beyond a 
techno-economic perspective on innovation. The 
report gives special attention to the important 
role of social innovation and system design. The 
report makes a distinction between product in-
novation and social innovation. The conclusions 
and recommendations that are provided at the 
end of the report are relevant for public policy 
action including governments partnering with pri-
vate and civic organisations.
In conclusion, it is obvious that the theoreti-
cal framework developed by neoclassical econo-
mists is too narrow when it comes to analysing 
the drivers, processes and outcomes of innovation 
and that evolutionary economics perspectives are 
more promising in this respect. When it comes to 
analysing the role of innovation in health systems 
in low income countries, evolutionary economics 
needs to be combined with the STS tradition link-
vi   GLOBELICS THEMATIC REVIEW
ing science and technology to societal issues with 
focus on the social and political processes that 
shape such systems. 
This report provides an important starting point 
in terms of combining the two approaches, com-
plementing the efforts of individual researchers and 
research groups within the Globelics community. I 
hope that the report will start a wider discussion in 
the health field on the role and function of innova-
tion in strengthening health systems, but also that 
it will start new debates within the innovation field 
on the importance of a multidisciplinary approach. 
Prof. Bengt-Åke Lundvall
Globelics Secretariat
Aalborg University
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This report is the fourth in a series of Globelics The-
matic Review reports prepared during the period 
2011 to 2016. The objective of the Globelics The-
matic Reviews is to communicate insights from the 
community of scholars in the Global Network for 
the Economics of Learning, Innovation, and Com-
petence Building Systems (Globelics) to policy cir-
cles and development donor organisations. 
The Globelics Thematic Reviews constitute a 
commitment made to the Swedish International 
Development Corporation (Sida) in connection 
with a 2011 grant for the Globelics Secretariat lo-
cated at Aalborg University. The reviews give an 
overview of research outcomes related to a particu-
lar topic as well as reflections on policy implica-
tions. Previous reports have focused on innovation 
and development, innovation for low carbon energy 
development and innovation for natural resource 
management. This year’s report focuses on health 
systems strengthening and the role of innovation.
Rebecca Hanlin and Margrethe Holm Andersen 
wrote the report, which also counts on contribu-
tions by Bengt-Åke Lundvall (foreword) and Joan-
na Chataway (post-script). 
The report has been developed through a com-
prehensive desk review of current literature on 
health innovation research from within the global 
health field as well as from within the innovation 
studies field, especially the Globelics community. It 
has also benefitted from a consultative process with 
members of the Globelics community and those 
from outside the community providing comments 
and feedback on the report’s ideas and drafts of the 
report. The report was developed over a 16-month 
period from March 2015 to July 2016. 
Likewise, we would like to thank those review-
ers (a mix of innovation scholars and health policy 
scholars) who found time to review earlier drafts of 
the report in September 2015 and in the first half 
of 2016. Particular thanks are due to Judith Sutz, 
Smita Srinivas and Louise Hansen for their in-
depth and valuable comments. We are particularly 
grateful to Bengt-Åke Lundvall for challenging our 
thinking as the report was developed.
Preface
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The authors are also thankful to Nina Kotschen-
reuther for editorial support and to Emil Axel 
Størner for the identification of Globelics Confer-
ence papers within the field of health and innova-
tion. 
We hope you will enjoy reading the report.
Rebecca Hanlin, Innovation and Development 
Specialist, AfricaLics/ACTS 
Margrethe Holm Andersen, Senior Advisor, Glo-
belics Secretariat/Aalborg University
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1. Introduction
In early 2016, the Gavi (the Vaccine Alliance, for-
merly known as the Global Alliance for Vaccines 
and Immunisation) announced it had signed an 
‘advance market commitment’ with Merck to bulk 
purchase its Ebola vaccine, even before it has been 
licensed, to ensure stockpiles are available and ready 
for the next outbreak of the virus. In Sub-Saharan 
Africa, incidences of malaria have been drastically 
reduced due to the introduction of long lasting in-
secticide treated mosquito net coverage campaigns. 
As a result, four countries (Namibia, Eritrea, Togo 
and Mali) saw their post-neonatal death rates re-
duced by over 20% between 2001 and 2010 (Eisele 
et al., 2012). In Brazil, since the introduction of a 
universal health insurance scheme funded through 
general taxation in the late 1980s, the percentage 
of the population now able to access healthcare ser-
vices is 70%. Similarly, in Thailand, an alternative 
government health insurance scheme has reduced 
the percentage of the population without health-
care coverage from 30% to less than 4% (WHO, 
2010). Cuba is renowned for having one of the 
best public health services in the world because of 
its system whereby all newly qualified doctors go to 
work in rural areas and its emphasis on preventive 
health (Keck and Reed, 2012). In India, a low cost 
prosthetic was invented in 1968 – the Jaipur foot – 
providing a low-cost prosthetic for those unable to 
pay for more elaborate alternatives. Some 1.3 mil-
lion artificial limbs have been fitted – free – through 
the work of the Jaipur foot organisation, BMVSS, 
based in India (BMVSS, 2013). In a further case 
from India, the Aravind Eye Hospitals have de-
veloped a differential pricing system and a highly 
efficient organisational set up allowing them to 
provide high quality eye operations to the poor ex-
tremely quickly (Aravind Eye Care System, 2015). 
In the UK, the ‘Healthy Liverpool’ programme in-
troduced in 2015 aims to tackle the massive burden 
on the national health service in its city (as a result 
of an increasingly elderly population and unhealthy 
lifestyles) by focusing on prevention and having 
health and social care organisations work together 
to find policy and programmatic solutions (Sim, 
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2015). Finally, in Finland, expectant mothers since 
1949 have received a ‘baby box’ containing all the 
items they need to look after their newborn baby 
including its first crib – the box itself. This led to a 
rapid reduction in infant mortality in the country 
within the first 10 years of the boxes becoming rou-
tine part of pre-natal care (Kobayashi, 2013).
What do all of the above have in common? They 
are all examples of innovations that have been in-
troduced and which have improved, or are expect-
ed to improve, health outcomes around the world, 
sometimes extremely quickly and effectively. 
When most people think of innovations in the 
health arena, they think of new drugs or vaccines 
being developed; maybe of new improvements 
in health information systems. The above exam-
ples include a few such technological innovations. 
However, most of them involve the introduction 
of a new organisational approach or a new way of 
packaging and implementing healthcare. These are 
also forms of innovation; what can be termed ‘so-
cial innovations’ as opposed to merely technological 
product innovations.1  
1 In this report, we refer to a very black-and-white 
distinction of ‘technological product innovation’ on 
the one side and ‘social innovation’ on the other. We 
have done this deliberately, in line with current pol-
icy dialogue in the health sector, but recognise that 
this is not in line with much innovation thinking. 
Many innovation scholars have always seen elements 
of organisational and social innovation elements as 
being essential to successful technological innova-
tion and therefore inseparable from any definition 
Many governments in emerging economies have 
been focusing increasingly on developing effective 
innovation policies (Goedhuys et al., 2015) but 
there is also increasing awareness of the importance 
of this at a sectoral level. Innovation is increasingly 
recognised as crucial for better healthcare solutions 
and necessary if health outcomes are to be im-
proved. Governments around the world are intro-
ducing innovation into health discussions. Some, 
such as Brazil, have developed national policies to 
promote the use of science, technology and innova-
tion for health or, like South Africa, have developed 
dedicated biotechnology strategies with a strong 
emphasis on feedbacks into the healthcare system. 
In many high income countries, there is recogni-
tion of the need to focus more specifically on health 
innovation and particularly on ensuring that health 
innovations are developed and diffused into the 
healthcare system. Thus, in the UK, a reorganisa-
tion of the National Health Service in 2013 led to 
the creation of Academic Health Science Networks 
bringing together clinicians, academics and the pri-
vate sector to develop and diffuse new technologies 
into the National Health Service. 
These activities at a national sectoral level have 
occurred at the same time as discussions within the 
global health arena on the role of innovation for 
improved healthcare and health systems function-
ing. For example, the World Health Organisation 
(WHO) has emphasised the importance of inno-
of technological innovation. We discuss this in more 
depth in Chapter 3.
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vation as one of the foundational stones of the 
building blocks of a health system (WHO, 2007). 
In another example, the Council on Health Re-
search for Development (COHRED) has cham-
pioned the importance of all forms of research 
and innovation in order to “deliver sustainable 
solutions to the health and development problems 
of people living in low and middle-income coun-
tries” (COHRED, 2013).
Part of the interest in health innovation has un-
doubtedly been the result of the ‘Gates effect’ (Okie, 
2006). The rise in funding by the Bill and Melinda 
Gates Foundation in the area of health research has 
significantly enhanced the attention given to health 
product development. This coupled with the work 
of the Global Fund for AIDS, Tuberculosis (TB) 
and Malaria and that of Gavi, which both focus on 
encouraging access to medicines in low and middle 
income countries. These organisations resulted in 
a rise in investment by private and public research 
organisations, especially through what are known 
as ‘global health partnerships’ (Buse and Harmer, 
2004), in new health product development (vac-
cines, drugs and diagnostics) or improved deploy-
ment of existing health products in low and middle 
income countries. 
Unfortunately, the majority of the discussion 
around health innovations continues to be domi-
nated by discussions on the need for new or im-
proved health technologies including new (and 
often expensive) types of medicine; tangible health 
products that can be easily seen and understood. 
Less attention has been spent on the organisational 
and process innovations – the social innovations 
– outlined in the first paragraph, which are also 
required to ensure that health outcomes are im-
proved. This report argues that this is unfortunate 
and needs to change. Process, organisational and 
systems level innovations are, in fact, often what is 
needed to make healthcare systems function effec-
tively; these social innovations are key to strength-
ening health systems. 
The need to consider innovation in a broader 
context is the starting point of this report. Work 
from within the academic field of innovation and 
development studies provides evidence of the rel-
evance of thinking more widely about the types of 
innovation that take place within health systems.
The second starting point for this report relates 
to the need to ensure a better connection between 
health and development issues and to do away 
with the silos and disconnects that exist in the in-
ternational development and health policy fields 
at national, regional and global levels. Specifically, 
the disconnects revolve around the relationship be-
tween health and development and the best ways to 
promote both.
The relationship between health and develop-
ment has been acknowledged for many years, most 
notably in the World Development Report 1993 
(World Bank, 1993) and its follow-up in 2013, 
‘Global Health 2035: A world converging within a 
generation’ (Jamison et al., 2013). It is recognised 
that good health provides opportunities for im-
proved educational attainment and work efficiency 
(through reduced absenteeism) leading to better 
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possibilities to move out of poverty. On the other 
side of the argument, it is recognised that those 
with more economically stable households often 
have the ability to pay for better healthcare and 
therefore are less likely to be absent from school 
or work in the first place. Both reports conclude 
that it is wise to ‘Invest in Health’ to paraphrase 
the 1993 report. 
Both of these reports have been controversial for 
various reasons, most notably for their focus on the 
economic side of the issues at the expense of the so-
cial and political constraints that influence the level 
of success of health policy implementation and sub-
sequent healthcare provision. The Social Determi-
nants of Health Commission and resulting report 
(Marmot et al., 2008) noted that factors within the 
social environment and related lifestyles are as im-
portant, if not more so, than direct healthcare and 
treatment of diseases to ensuring the wellbeing of 
individuals everywhere in the world. 
Three other related additional concerns with re-
gards to the focus of current dominant discourses in 
health policy circles include the following:
1 The continued existence of policy ‘silos’: There 
are a few examples of health and social care agen-
cies talking together and sometimes – over na-
tionally important health issues – discussion and 
action with subsequent agreement from multi-
ple government ministries. However, for the 
most part, health and other policy arenas (e.g. 
industrial policy, finance policy, education poli-
cy) are ‘siloed’ and rarely try to ensure that their 
goals are matched or that issues are approached 
from a holistic view. This is often matched at the 
practice level by a lack of discussion and action 
across traditional disciplinary boundaries (e.g. 
between social workers, doctors, nurses, housing 
officers, teachers etc.) which further exacerbates 
the silos.
2 The need for a broader approach to strength-
ening of national health systems: Early efforts 
to strengthen national health systems through 
Sector Wide Approaches (SWAps) were chal-
lenged in the late 1990s and early 2000s by the 
re-emergence of emphasis on so-called ‘vertical 
programmes’ to tackle specific diseases, notably 
HIV/AIDS, TB or malaria. Realising the prob-
lems related to the vertical approaches there 
has, in recent years, been a growing emphasis 
on health systems strengthening and the need 
to ensure that all projects and programmes fit 
within national health system priorities and re-
quirements. However, more could still be done 
to apply a wider lens that focuses on more than 
simply healthcare systems.
3 The increased emphasis on results-based-man-
agement: The extent to which the above two 
issues have arisen is linked to the form and con-
tent of evidence based policy discussions and 
the resulting type and form of measurement of 
health systems and government performance 
that is undertaken. In some cases, this has led to 
an excessive focus on documenting and measur-
ing results at the expense of ensuring direct at-
tention to users in the healthcare system.
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As a result of the above, a range of different perspec-
tives can be observed that dominate health policy 
discussions at national, and particularly global, 
Health as a means 
to economic 
growth 
Health as a means to 
achieve social devel-
opment and reduction 
of inequality 
→ Health as an integrated element of 
and contributing factor to economic 
and social development built on eq-
uity and inclusion
Health as absence of 
disease
Health as wellbeing → Health as wellbeing
Firms and private 
sector as drivers
Role of other actors, es-
pecially state
→ Complex network of actors
Supply driven Demand driven → Problem driven
Knowledge as sci-
ence, technology and 
innovation (STI)
Knowledge as doing, 
using and interacting 
(DUI)
→ Multiple flows of knowledge and power 
(STI and DUI)
Health innovation as 
new products
Social innovation is key → Multiple types of innovation and combi-
nations of innovations required
Table 1 Health policy discussions and development: from two overarching opposing  
approaches to an integrative approach
levels. These fit within one of two overarching ap-
proaches outlined in the first or second column in 
Table 1 below.
Source: Authors
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On one side, you have those that see the goal of 
development as economic growth, place an empha-
sis on a narrow definition of health and regard the 
private sector as the key driver in healthcare delivery 
and management. In this overarching approach the 
market for health and healthcare is dominated by 
the supply side and solutions focus on science and 
technological innovations (STI) solutions; particu-
larly the introduction of tangible products.
In the converse approach, development goals are 
defined much more broadly in terms of wellbeing 
with a larger role to be played by the state and the 
end user of healthcare as the market is dominated 
by the demand side. Within such an approach, 
knowledge requirements are also defined more 
broadly with an emphasis placed on doing, using 
and interacting (DUI) leading to a focus on social 
innovations.
These two overarching approaches are at either 
end of a spectrum of perspectives. As such, the 
majority of perspectives that are presented in aca-
demic and policy literature fall somewhere between 
these two approaches. That said, debates are often 
discussed as being polarised across one or more of 
these divides (Mackintosh and Mugwagwa, 2014; 
Cassiolato and Soares, 2015). Table 1 provides, in 
columns 1 and 2, useful ’ideal types’ for use as fo-
cusing devices for the various different arguments 
that are shared around the world against which an 
alternative juxtaposition can be made.
This report will argue that an alternative juxtapo-
sition is needed; an approach that is more integra-
tive and which is outlined in column 3 of Table 1. 
Such an approach sees the role of development as 
being to meet both economic and social develop-
ment in order to support equity and inclusion. As 
such, the definition of health emphasises wellbeing. 
This approach recognises a complexity of actors 
involved in designing, delivering and monitoring 
health and wellbeing activity. As such, the approach 
stresses the importance of a problem based focus 
to market driven solutions, utilising multiple flows 
of knowledge and innovation within the context of 
multiple positive and negative power flows.
Specifically, work from within the Globelics com-
munity (and more generally from within the Inno-
vation Studies and Science and Technology Studies 
fields) over the past 10 years has highlighted the 
usefulness of thinking in terms of ‘health innova-
tion systems’, learning and competence building 
systems, to address these disconnects. Such work 
has focused on, but is not limited to:
1 Thinking and conceptualising health and inno-
vation systemically and in a wider perspective 
as to who are the actors, and in what spheres 
does health policy and healthcare take place 
both in the immediate vicinity of the hospital 
or clinic but also much more broadly in so-
ciety and throughout the value chain(s)  
2 Reviewing the role of partnerships and networks 
of actors in the development of research capacity 
related to health and health innovation systems
3 Considering the implications of new technolo-
gies – ICT, biotechnology, nanotechnology, syn-
thetic biology – on the future of healthcare and 
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health systems, particularly in relation to low 
and middle income economies 
4 Investigating the viability and opportunities of 
local pharmaceutical production including is-
sues of finance and human resources 
5 Researching issues of intellectual property rights 
(IPRs), trade relations and governance on local 
and international pharmaceutical production 
and research including South-South collabora-
tion local, regional and international.
This report will review current work in these areas 
and others to provide the latest thinking on how 
health and development can benefit from thinking 
from within innovation related perspectives. Inves-
tigating health systems through an innovation and 
development studies lens – in terms of health in-
novation systems – provides an alternative way of 
considering the underlying requirements for suc-
cessful innovation throughout a health system. In 
this way, it provides a new set of insights into how 
health systems, especially in low income settings, 
might be more effectively strengthened so that they 
can provide high quality healthcare that is acces-
sible to all and promotion of healthy livelihoods 
more generally. 
The Globelics Thematic Report and Series 
This report therefore asks readers to rethink the 
role of innovation in health systems strengthen-
ing in two ways. First, by taking a wider defini-
tion of what is meant by the terms ‘health’ and 
‘innovation’. Second, by providing an alternative 
integrative policy lens through which to develop 
plans for the strengthening of health systems at a 
country level. This alternative lens sees social in-
novation as the cement that binds the building 
blocks of health systems strengthening together 
and not simply as a sub-set of one of the building 
blocks. In so doing, it aims to reignite the debate 
on the role of innovation and particularly its role 
as a mechanism for building stronger and more 
sustainable health systems. 
It is able to do this by drawing on the work of 
academic scholars from around the world work-
ing in the field of innovation and development. 
These make up members of the Globelics commu-
nity who have been working to advance academic 
thinking and policy analysis of the linkages between 
innovative activity and economic and social devel-
opment since the early 1990s. 
This report is one of a series of Globelics Themat-
ic Review reports prepared during the period 2011 
to 2016. Each report, and a set of related dissemina-
tion activities, focuses on a specific issue of interest 
and aims to communicate insights from the Glo-
belics community to a wider audience, forwarding 
these into wider policy circles and overseas develop-
ment assistance organisations. The Globelics The-
matic Reviews constitute a commitment made to 
the Swedish International Development Corpora-
tion (Sida) in connection with a 2011 grant for the 
Globelics Secretariat located at Aalborg University. 
The reviews give an overview of research outcomes 
related to a particular topic as well as reflections on 
policy implications. Previous reports have focused 
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on: innovation and development, innovation for 
low carbon energy development, and innovation 
for natural resource management.
Methodology
This report has been developed through a com-
prehensive desk review of current literature on 
health innovation research from within the global 
health field as well as from within the innovation 
studies field, especially the Globelics community. 
It has also benefitted from a consultative process 
with members of the Globelics community and 
those from outside the community providing 
comments and feedback on the report’s ideas and 
drafts of the report. The report was in develop-
ment over a 16-month period from March 2015 
to July 2016. Further details of the methodology 
are outlined in Annex 1. 
Report format
The report starts in Chapter 2 with an outline of 
different ways of thinking about health, health sys-
tems and health systems strengthening. The Chap-
ter outlines the importance of:
1 Thinking about health as more than absence of 
disease
2 Considering issues of equity and wellbeing
3 Focussing on health systems strengthening but 
moving beyond a simple focus on more efficient 
healthcare solutions to a wider focus on more ef-
ficient wellbeing and livelihood solutions. 
In Chapter 3, the report moves on to ways of re-
thinking health innovation. It discusses some of 
the latest work on technological innovations but 
also introduces examples of social innovations re-
lated to health and wellbeing for all. These social 
innovations include process or intra-organisational 
innovations, inter-organisational innovations, insti-
tutional innovations and systems level innovations 
in healthcare. It introduces the idea of health inno-
vation systems; the idea that successful technologi-
cal and social innovation for better health requires 
a supportive enabling environment. Specifically, it 
argues that:
4 For the promotion of improved wellbeing and 
sustainable livelihoods there is a need for sys-
tems level changes
5 This requires social innovation in multiple 
spheres, not just technological innovation
6 Social innovation creates, and is key to cre-
ating, the learning and competence building 
that enables a system to adapt and change to 
new circumstances
7 One approach to recognising the importance of 
social innovation for technological product in-
novation has been the promotion of the concept 
of ‘health innovation systems’
Chapter 4 introduces an integrative analytical lens 
for analysing policies for health and wellbeing sys-
tems strengthening. Specifically, the lens recom-
mends looking at the whole system and the way 
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to ensure all elements of the system are included, 
while juggling multiple knowledge, power and pol-
itics flows. The lens provides an opportunity, at a 
very high level, to consider deficiencies in a national 
health system in order to know where to focus more 
attention in order to strengthen the system into a 
health and wellbeing system where innovation is 
endemic. In turn, this should help movement away 
from policy silos that often occur and create more 
effective health systems able to secure health and 
wellbeing for all. Reviewing two situational cases of 
health problems from India and Kenya, the frame-
work highlights:
8 That the building blocks of the health system 
need ‘cement’ to bind them together; social 
innovation provides this ‘cement’ through the 
creation of system building competences
9 That knowledge (and politics) flows as deter-
minants of systems strengthening are centrally 
important
10 The importance of active government and regu-
latory support for systems strengthening to 
ensure a facilitatory enabling environment 
whereby knowledge flows are promoted and 
politics flows become positive rather than neg-
ative in nature
11 Such an approach moves away from ideas of 
‘healthcare systems’ to the idea of ‘innovative 
health and wellbeing systems’ for sustainable 
economic and social development’
The final Chapter, Chapter 5, provides a short con-
clusion to the report, recapping the key points. It 
outlines the arguments of the report that social in-
novation is as central, if not more so, as techno-
logical product innovation for the future of health 
and wellbeing systems strengthening. It argues that 
there is a need for changes within the policy process 
to effectively encourage greater levels of social in-
novation. Outlining various deliberations for policy 
makers, the Chapter reflects on these in the context 
of ideas on the future prospects for health systems 
in low and middle income countries and provides 
recommendations on how to move discussions and 
action forward through new research and collabora-
tions that create opportunities for learning cultures 
in the research and policy spheres as well.
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2. Rethinking health and health systems
Key points
1 We need to think about health as more than 
absence of disease
2 This includes placing an importance on issues 
of equity and wellbeing
3 In view of this wider approach, the concept of 
health systems strengthening is important but 
must move beyond a simple focus on more 
efficient healthcare solutions to a wider focus 
on more efficient wellbeing and livelihood so-
lutions. 
As the world moves towards meeting the Sus-
tainable Development Goal (SDG) 3 related to 
health, it is useful to start by taking stock of the 
world’s health and progress towards the provision 
of health for all. The previous Millennium Devel-
opment Goals (MDGs) gave countries an earlier 
focusing device on which to measure, amongst 
other things, a country’s progress towards achiev-
ing a healthier population. The results of efforts 
to meet the health MDGs have been substantial 
but have not always met the targets set. Child 
mortality (MDG4) dropped by over 50% in ab-
solute global terms from 1990 to 2015 (although 
the original target of a two-thirds reduction was 
not met). Global maternal mortality (MDG5) 
dropped by nearly half (but again did not meet its 
two-thirds reduction target). The target on HIV/
AIDS (MDG6) was not met although access to 
antiviral treatment increased by over 50%.
However, while being useful measuring devices 
on a global scale, these high-level figures miss out 
the nuances at national level. When you consider 
country level results, many African countries missed 
their targets for child and maternal mortality. Many 
countries in Asia and Latin America did much bet-
ter. Unfortunately, virtually no regions of the world 
did well with regards to MDG6 (CDG, 2015). Fig-
ure 1 outlines the status of some of the best and 
worst performing countries identified by WHO in 
2012 as ‘Countdown countries’ or those that were 
unlikely to meet health related MDGs 4 and 5 with 
regards to maternal and child health. 
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Figure 1 Data for four of the best and worst performing countdown countries with regards to MDGs 4 and 5
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While the MDGs provided a way of measuring 
progress globally, regionally and nationally towards 
improving the status of population health, they 
only focused on a few areas of health. Critics ar-
gued that they did not include non-communicable 
diseases (Seffrin, 2009), mental health (Miranda 
and Patel, 2007) or disabilities (Wolbring, 2011). 
Others have commented on the fact that they did 
not include a focus on the underlying strength of 
health systems (Haines & Cassels, 2004; Keyzer & 
Van Wesenbeeck, 2006).1  
The SDGs have been developed to be more in-
clusive in nature. While there is only one overall 
SDG for health (SDG 3: Ensure healthy lives and 
promote wellbeing for all at all ages), the proposed 
indicators to measure progress against this goal are 
much broader than those set for MDGs 4, 5 and 
6. As such, the indicators include a wider range of 
diseases, road traffic accidents, mental health and 
substance abuse. SDG3 also includes indicators 
relating to access to healthcare services, training of 
healthcare workers and early warning systems. 
The inclusion of these latter health systems-re-
lated issues are important because the SDGs will 
only be met if there is more investment, more up-
take and more systems strengthening. The Global 
Health 2035 modelling scenario found that if low 
and middle income countries increased their finan-
cial investment in health – with help from others 
1 For a good review of the limitations of the MDGs, 
see Fehling et al. (2013) which outlines a review of 
academic papers critiquing the MDGs up to 2013. 
through donor assistance – it would be possible 
to see a ‘grand convergence’ of health outcomes 
whereby the disparities between the health out-
comes of the rich and poor nations of the world 
are significantly reduced (Jamison et al, 2013). The 
largest cost requirement in the scaling up of health-
care is in the area of health systems strengthening. A 
2015 report estimated the cost of scaling up health-
care using a range of scenarios, with and without 
investment in additional research and development 
(R&D) for new technologies. They found that for 
low income countries:
“HSS [Health system strengthening] is 
the biggest driver of overall incremental 
costs, comprising more than 70% of costs 
in 2015 and falling to 56% in 2030. Of 
these HSS costs, the dominant component 
is infrastructure, including equipment and 
vehicles. An important outcome from such 
investments is that it leads to a functional 
health system platform for service delivery 
that can tackle other long-term health 
challenges, not just infections and RM-
NCH [Reproductive, maternal, neonatal 
and child health] conditions. The cost of 
scaling up the new health interventions 
generated by investments in R&D is es-
timated at an additional incremental cost 
of $2.5-$3.5B per year for low income 
economies, or about 10–15% of the total 
cost, depending on the year.... From a cost-
benefit standpoint, the projected enhanced 
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investment scenario with R&D would 
represent a highly attractive investment. 
The cost per death averted in this scenario 
starts at US$11,600 in 2015 (the time of 
maximum investment in HSS and before 
the interventions are fully scaled up) and 
declines to US$4,300 by 2030.” (Boyle et 
al., 2015:10; italics in original)
But many countries have a long way to go. The 
worst performing countries in Figure 1 have gov-
ernments that are challenged by a range of fac-
tors (from on-going war and political uncertainty 
to poor education and training systems to large 
population sizes) that mean small financial invest-
ment in health when measured as a per capita 
amount. The result is that these countries suf-
fer from chronic shortages of well trained staff 
and inadequate health facilities. Table 2 (next 
page) provides a comparison of their situation 
as opposed to that of the top performing coun-
tries using a few indicative indicators of health 
systems performance. This is not to say that the 
four countries representing the top performers in 
the countdown countries do not have issues of 
their own; they were identified as part of a group 
of 75 countries least likely to meet the MDGs 
4 and 5 by the Countdown to 2015 project. In 
fact, when you compare them to the situation in 
the UK, which topped a recent Commonwealth 
Fund report comparing health systems (Davis et 
al., 2014), or with France, which came top in the 
WHO 2000 World Health Report that was the 
first to rank health systems, the differences in 
health systems becomes very stark indeed.
The idea that health systems strengthening was 
an important element in achieving improved health 
outcomes was publically proposed at a global health 
policy level in the early 2000s, especially with the 
publication of the WHO’s World Health Report 
in the year 2000. Since then debates about what 
constitutes a ‘health system’ and how it is possible 
to ‘strengthen’ a health system have gathered pace. 
One starting point for these debates is differing ap-
proaches to the definition of health. 
Definitions of health
In 1948, the WHO defined health as “a state of 
complete physical, mental and social well-being 
and not merely the absence of disease or infirmity” 
(WHO, 2006). Despite this, many would argue 
that there has been a tendency at various times, be-
tween 1948 and today, to focus on the latter part of 
the definition with good health equating to the ab-
sence of disease and infirmity only. Some argue this 
is because of a historical mind-set that commodi-
fies every aspect of life where “the institutionalised 
mainstream health system is portrayed as products 
and services emanating from the operations of a 
global medical industry which is becoming increas-
ingly financialised” (Maharajh, 2015: 60; his em-
phasis). Others argue it is more an issue of ease; 
that it is easier to tackle disease and physical illness, 
especially within resource-constrained settings. A 
major example of these different approaches to de-
fining health occurred in the global health policy 
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Table 2 Health systems performance by indicative indicators for selected countries (latest 
figures available)
Health expenditure per 
capita, current US$
Hospital beds per 
1,000 people
Nurses and midwives 
per 1,000 people
Physicians per 
1,000 people
UK 3,685 2.9 8.8 2.8
France 4,955 6.4 9.3 3.2
Selected top performing countdown countries
Brazil 947 2.3 7.6 1.9
China 375 3.8 1.9 1.9
Peru 347 1.5 1.5 1.1
Mexico 674 1.5 2.5 2.1
Selected worst performing countdown countries
Central African Republic 13 1 0.3 0.0
Chad 34 No data 0.2 0.0
Sierra Leone 92 0.4 0.2 0.0
Source: World Bank database/ world development indicators; http://databank.worldbank.org/ (accessed 07/08/16). All data 
for years post 2010, other than nurse/midwife/ physician data for CAR (2009) and Chad (2006) and hospital beds in Sierra 
Leone (2006). Somalia has been removed because there is no data for any of these indicators for the past 10 years available.
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field in the 1970s and 1980s. International policy 
swung between that which focused on promoting 
‘selective biomedical interventions’ (programmes 
to reduce specific high-burden diseases) to that 
which focused on more comprehensive healthcare 
solutions (focusing on strengthening a wider set of 
healthcare services). 
The pendulum of this argument since the early 
2000s has increasingly swung again in favour of 
wider definitions of health and the importance of 
universal healthcare coverage. The first signs of 
this are often linked to the WHO’s Commission 
on Social Determinants of Health which ran from 
2005 to 2008, although the debate was already 
present in the 1990s (c.f. Marmot and Wilkinson, 
1999). The work on social determinants of health 
emphasised the inability of healthcare provision 
around the world to focus on wider issues beyond 
the treatment of disease. The approach emphasises 
the importance of thinking about a much wider set 
of social and economic factors that influence health 
and wellbeing. The social determinants of health 
are defined as “the conditions in which people are 
born, grow, work, live, and age, and the wider set 
of forces and systems shaping the conditions of 
daily life. These forces and systems include eco-
nomic policies and systems, development agendas, 
social norms, social policies and political systems.” 
(WHO, 2016a)
This discussion on social determinants is allied to 
a debate that started much earlier with critiques of 
the 1993 World Development Report (c.f. Anand 
and Hanson, 1997 and 1998). This is a debate on 
equity and inequality in health and, allied to this, 
a wider debate on the role of social justice in, and 
for, health. There are significant discussions as to 
the best way to regard equity and equality in health 
from the work of Whitehead, 1992, to Culyer and 
Wagstaff, 1993 through to Braveman and Gruskin, 
2003, Marmot et al, 2008 and a special issue of the 
American Journal of Bioethics (Preda and Voigt, 
2015). Essentially, this debate questions whether 
health inequalities can be summed up as referring 
to differences in health while health inequities are 
differences in health that are unjust and unfair. 
The result of these various different debates is 
that in 2008 and 2009 a discussion took place in 
the British Medical Journal on the subject of how 
health is defined. It led to the development of an 
alternative definition to that agreed by the WHO 
in 1948. The alternative definition defines health 
as “the ability to adapt and self-manage” in the face 
of social, physical, and emotional challenges (Jadad 
and O’Grady, 2008). 
Furthermore, efforts since 2012 to get more 
countries to provide universal health coverage are 
seen as a means of addressing health inequities, 
health inequalities, and social inequalities in health 
(Reid, 2015). The idea of universal health coverage 
fits with the wider agenda of the WHO of ‘Health 
for All’ and is the idea that “all people obtain the 
health services they need without suffering financial 
hardship when paying for them” (WHO, 2016b). 
The ‘call to arms’ for universal health coverage has 
led to an increasing emphasis being placed on the 
development or revival of social insurance systems 
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across the world from the USA through Kenya to 
Vietnam as a pillar of a functioning health system. 
Health systems
The World Health Report 2000 signalled a new 
era in global health debates. For the first time, it 
attempted to rank countries based on their health 
systems performance in reducing disability ad-
justed life years. While the ranking system itself 
was highly controversial, the discussion it opened 
relating to the definition of a health system and 
components required to strengthen it has proved 
popular (McKee, 2010). The result has been an 
increased interest for the last 15 years on health 
systems strengthening within global health discus-
sions and, increasingly, also at the level of national 
government around the world.2
There is no one single definition of what a ’health 
system’ is (Atun, 2012). It may be argued to be 
a ‘means to an end’ or a system which ‘exists and 
evolves to serve societal needs’ with ‘components’ 
that “…can be utilized as policy instruments to 
alter the outcomes” (Hsiao, 2003; cited in Atun, 
2012). A health system has also been described as 
‘all the activities whose primary purpose is to pro-
2 We would argue that this development was sparked 
off   by the recognition in the early 1990s (Gilson 
and Raphaely, 2008) of the need for more criti-
cal health policy analyses focusing on the context 
in which health policy was developed and imple-
mented, bringing in the issues of politics, process 
and power (Walt, 1994).
mote, restore or maintain health.’ (WHO, 2000: 
p.5). These definitions take into account not only 
the healthcare elements of a health system, i.e. the 
treatment of disease and illness. They also take into 
account the wider definition of health as a state of 
complete physical, mental and social well-being.
The components of a functioning health system, 
as initially laid out in the World Health Report 
2000, have become widely used in global health 
but also, more importantly, in national level dis-
cussions over the past 10 years. The components 
of the health system outlined were: service pro-
vision, resource generation, financing and stew-
ardship (WHO, 2000). Policy makers and others 
have since refined the definition and expanded to 
six ‘building blocks’ of a health system. These are 
outlined in Figure 2 and include: leadership and 
governance; healthcare financing; health work-
force; medical products and technologies or access 
to medicine; information and research or health 
information systems; and service delivery (WHO, 
2007; WHO, 2015).3
3 There are others that have been put forward by the 
World Bank, Reich and others (see Shakarishvili et 
al., 2010 and WHO, 2010) but the term build-
ing blocks and these six elements are frequently 
referred to in the global health literature and have 
become a starting point for a sector-wide moni-
toring framework on health systems performance 
(WHO, 2010). 
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Figure 2 WHO’s health system framework
Leadership/governance
System building blocks
Improved health (level and equity)
Goals/outcomes
Health care financing Responsiveness
Health workforce Financial risk protection
Medical products, tecnologies Improved efficiency
Information and research
Service delivery
Access 
Coverage
Quality Safety
System building blocks Goals /outcomes
Source: http://www.wpro.who.int/health_services/health_systems_framework/en/; (accessed 07/03/16)
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Health systems strengthening
Just as the term ’health systems’ is hard to pin down, 
so too is the concept of ’health systems strength-
ening’ (Shakarishvili et al., 2010). Shakarishvili et 
al. (2010) define health systems strengthening in 
terms of interventions that are conducted to en-
hance one of the health system’s ’components’ 
or building blocks (for example, capacity build-
ing, data collection or organisational reforms). 
Frenk (2010) takes a systems based approach to 
the discussions and sees four elements to health 
systems strengthening, rememberable through 
the abbreviation LIST: leadership, institutions, 
systems building and technologies. Such a defini-
tion is couched in terms of the six building blocks 
earlier presented for health systems but empha-
sises, in greater depth, the importance of the in-
terconnections, power and politics that make up 
a system – taking a set of disparate actors from 
simply working together to functioning for the 
benefit of a wider goal; a greater whole. Such a 
notion of systems and the interconnections be-
tween actors has become increasingly important 
within the global health community discussions 
in recent years and therefore we will return to this 
later in the Chapter.
For now, it is important to mention two things 
with regards to this wider definition of health sys-
tems. First, such a recognition of the complexity of 
actors in the system is important. Systems are or-
ganic and determined by the actions of the actors 
and institutions involved and the power and poli-
tics flows that result. This is illustrated by any num-
ber of public debates regarding how best to fund 
healthcare with limited resources. For example, the 
long standing overarching debates on comprehen-
sive as opposed to selective healthcare were part of 
a much wider political debate taking place at the 
time (Lawn et al., 2008). In another example, the 
more recent discussion on whether to focus health 
spending on very expensive individualised drugs to 
tackle the rise of non-communicable diseases (es-
pecially cancers) or tried and tested alternatives is 
influenced by various industry actors and patient 
groups (c.f. different arguments by Savard, 2013; 
Hedgecoe, 2004; Needham, 2014).
Second, all of this has taken place within a con-
text of controversy as a result of the debate as to 
whether health systems strengthening is still too 
narrow in its focus and dominated by technical 
solutions rather than systemic approaches that fo-
cus on more holistic efforts. These debates have 
been vocally played out in the debate regard-
ing the role of global health initiatives (Hafner 
& Shiffman, 2013; Marchal, Cavalli, & Kegels, 
2009; Storeng, 2014) but also rage in the research 
arena on health systems strengthening (Adam et 
al., 2012a; Frenk, 2010).
The World Health Report 2000 also coincided 
with the introduction of the MDGs. These goals 
provided the world with a policy-focusing device 
(Verspagen, 2013) for international, national and 
local actions taken to address the multiple issues af-
fecting the world. High on this list were a set of 
global health issues, namely child mortality, ma-
ternal mortality and the morbidity and mortality 
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caused by three ’big’ diseases: HIV/AIDS, Malaria 
and Tuberculosis. These health related goals focus 
heavily on reduction of disease burden, particularly 
in low and middle income countries (vis a vis coun-
tries of the so-called ’global North’). This inequality 
between the health prospects for populations in dif-
ferent countries was a major reason for the World 
Health Report’s focus on health systems perfor-
mance in 2000 (McKee, 2010). 
These differences remain fifteen years later and 
provide a continually valid reason for the continued 
focus on health systems strengthening. Over the last 
15 years, the focus on health systems strengthening 
has continued to gain ground because of continued 
concerns over the lack of capacity within low and 
middle income countries (and at times even coun-
tries in the global North) to manage their health 
systems. The issue of management or ’governance 
and leadership’ to use the building block terminolo-
gy (or ‘stewardship’ to use the World Health Report 
of 2000 definition and that of Saltman and Fer-
roussier-Davis (2000)) is the major issue that needs 
resolving. It is also one on which all authors appear 
to agree; without good leadership and governance, 
the rest of the blocks will fail to stand up strong. 
These discussions tend to focus on the importance 
of leadership at a national level. However, govern-
ance issues are important at a global level, too. The 
debate (c.f. Clift, 2014) on the effectiveness of the 
WHO to fulfil its mandate to act as “the directing 
and coordinating authority on international health 
work” (WHO, 2013) is one such example. So too 
are debates on the power of global health actors, 
be they the various Global Health Initiatives, new 
donors on the scene such as the Gates Foundation, 
or the increasing power of some newly innovative 
countries (see below). 
The debates on the actors within the system and 
their influence is one of a number of debates that 
add nuance to the discussions on health systems 
strengthening. Another important debate is that re-
lating to how international development assistance 
more generally is provided to low and middle in-
come countries. The final relevant debate to men-
tion here is that relating to the way the impact of 
health interventions and health systems strengthen-
ing are measured. These debates (outlined below) 
have influenced the way health systems function 
on the ground in different countries and therefore 
determine the extent to which these systems have 
been able to strengthen or build up the relevant ca-
pacities and capabilities to provide accessible and 
affordable healthcare to the whole population. 
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The mid 1990s saw the rise of a new set of actors on the global health scene 
with the rise of innovative partnerships to develop or improve access to new 
or improved drugs, vaccines or diagnostics. These started small but have 
since become dominant players on the global health arena providing the 
majority of funding for global health research, rivalling the US National 
Institutes of Health (Moran et al., 2010). The biggest of these, known as 
Global Health Initiatives (World Health Organization Maximizing Posi-
tive Synergies Collaborative Group, 2009) include the Global Fund for 
AIDS, TB and Malaria and the Gavi Alliance. Both of these work with 
governments and the private sector to stimulate the manufacture and sup-
ply of new or improved vaccines, drugs or diagnostics and, in more recent 
years, also their successful introduction into health systems at country level.
These new organisational forms have transformed not only the global 
resource flows for health but also the wider governance of global health, 
changing the balance of power at the global health policy level (Rushton 
and Williams, 2011) determining what countries and other actors in the 
health system globally and nationally focus attention on. This relates back 
to the debates on the role and power balance between the WHO; the GHIs 
and new donors, especially the Bill and Melinda Gates Foundation (Mar-
tens and Seitz, 2016).
Global Health Initiatives and the Gates Foundation are, however, not 
the only influences to change the landscape of global health governance 
in recent years. Increasingly important is the rise of a group of ‘innova-
tive developing countries’ or IDCs (Morel et al, 2005a). These are a set 
of countries including India, China, South Africa, Brazil, that have dis-
rupted the traditional innovation paths within the global pharmaceutical 
industry (Hwang and Christensen, 2008). These countries have become 
leading producers of low-cost, high volumes of generic drugs that chal-
lenge the dominance of the leading pharmaceutical manufacturers in Eu-
rope and the US.
Who governs the global health arena?
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The second area of debate to introduce here is related to the issue of interna-
tional development assistance and its impact on health spending at national 
level. Development assistance for health (DAH) has been steadily rising 
peaking at US$ 38 billion in 2013; in 2015 the figure was US$ 36.4 billion 
(Dieleman et al., 2016). DAH, the provision of financial and in-kind sup-
port through development assistance channels (Moon and Omole, 2013), 
is predominately provided by governments, the US government provid-
ing nearly 35% (Dieleman et al., 2016). The majority of DAH is focused 
on single issues (HIV/AIDS, maternal and child health getting the lions 
share), while support for health systems strengthening receives very little; 
just 7.3% of total DAH in 2015 (Dieleman et al., 2016). This support for 
health systems strengthening has increasingly been focused on encouraging 
more coordination across departments through a focus on ‘sector wide ap-
proach programmes’ and ‘basket funding’. Some donors are also increasing-
ly providing this as general budget support; allowing national governments 
to decide how best to spend the money. However, in all cases there is an 
increasing focus – demand even – that money is spent in priority areas (see 
debate 3 below) and through increasingly coordinated systems whether at 
national government level or within the UN system (i.e. the UN ONE ini-
tiative aims to have all activity going through one organisation – one leader, 
one fund, one budget, one programme etc.) (Moon and Omole, 2013). 
How should development assistance be provided?
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In the late 1990s, the TEHIP project monitored health needs of two dis-
tricts in Tanzania and fed the results into healthcare planning to ensure 
resources were disbursed to the essential interventions. The project also ana-
lysed the effectiveness of this evidence based policy approach to healthcare 
planning. The project was a resounding success showing massive improve-
ment in health outcomes – child mortality fell by 40% in the two districts 
over the 5 years in which the project was implemented (ODI, n.d.). 
Evidence based policy (EBP) gained ground partly as a result of the 
World Development Report 1993 entitled ‘Investing in Health’. This 
World Bank report argued that: “given the scarcity of available resources 
for health, especially in low income countries, the planning for and set-
ting of priorities for essential health interventions should be based on 
burden of disease and cost-effectiveness analysis. The analysis of health 
systems showed that many low and middle income countries misallocate 
these scarce health resource s toward cost-effective interventions, coupled 
with inefficiencies in planning and highly centralized decision-making.” 
(Neilson and Smutylo, 2004: p.12)
The call for more effective use of resources is a sensible one but the EBP 
movement has been called into question (Black and Donald, 2001) for its 
linear focus on the relationship between evidence, policy and impact. That 
said, the recent popularity of the ‘randomistas’ (Ravallion, 2009) and de-
bates about research impact (c.f. Mendez, 2012; Davis et al., 2003; Lavis et 
al., 2005) shows that this approach is far from having been forgotten about 
and argues that it does have its benefits (Bosch-Capblanch et al., 2012). 
One reason for this is perhaps the increasingly scarce financial resources be-
ing put into global health issues, following the latest financial crisis. There 
are increasing calls for greater discussions with regards to ‘value for money’ 
(c.f. Glassman et al., 2013). Such arguments also feed into wider and older 
discussions on stewardship of health systems and discussions around the 
rise of new public management strategies in healthcare situations (Ferlie, 
1996). The increased focus on results has – in some countries – let to an 
excessive focus on documentation and monitoring (Dahler-Larsen, 2012) 
and criticism that all the efforts to collect data and document actions in 
health systems and related ‘care’ systems, e.g. for the elderly, takes away time 
and energy from direct interaction with those needing care and attention.
How can policy lead to better impact?
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The rise of health systems 
and policy research
As outlined above, since the World Health Report 
of 2000 there has been an increasing emphasis 
placed on social science research as well as bio-
medical research for health systems strengthening. 
Specifically, there has been an increasing emphasis 
within global health discussions on the need for 
more research on health systems, health policy and 
implementation science. There are several journals 
now dedicated to this type of research starting with 
the early establishment in 1996 of the Journal of 
Health Services Research and Policy, the BioMed 
Central Journal of Health Services Research which 
includes a section dedicated to health systems of 
low and middle income countries (from 2000) and 
Health Research Policy and Systems (since 2003). 
There has been an increasing emphasis – along-
side the growing awareness for prevention ap-
proaches and institutional and organisational 
change in research – on the implementation of 
healthcare and health policy (Hales et al., 2016). 
In addition, there has been an increasing focus on 
research into the functioning and strengthening of 
health systems. This includes discussions on what 
comprises a health system, aimed at understand-
ing the importance of not just each building block 
but how they fit together and affect each other; 
often taking a complex adaptive systems approach 
(see for example Adam and de Savigny, 2012). 
This work has been championed by the Alliance 
for Health Systems and Policy Research as well as 
COHRED through their annual meetings and re-
ports.4  Perhaps the biggest sign of this change has 
been the World Health Report 2013 that focused 
on the role of health research for universal health 
coverage and specifically the need to strengthen 
national health research systems. 
Health Policy Research Systems are argued to be 
research that:
”seeks to understand and improve how 
societies organize themselves in achieving 
collective health goals, and how differ-
ent actors interact in the policy and imple-
mentation processes to contribute to policy 
outcomes. By nature, it is interdisciplinary, 
a blend of economics, sociology, anthro-
pology, political science, public health and 
epidemiology that together draw a com-
prehensive picture of how health systems 
respond and adapt to health policies, and 
how health policies can shape − and be 
shaped by − health systems and the broad-
er determinants of health.” (Alliance for 
Health Policy and Systems Research, 2011; 
cited in Gilson, 2012: p21.) 
Gilson (2012: p. 21) argues that it is 
“a multidisciplinary research field, distin-
guished by the issues and questions ad-
dressed through the research rather than 
4 See http://www.who.int/alliance-hpsr/en/ and 
www.cohred.org 
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by a particular disciplinary base or set of 
methods” and that it: “includes research 
that focuses on health services as well as on 
the promotion of health in general; 
includes concern for global and interna-
tional issues as well as national and sub-na-
tional issues, as global forces and agencies 
have important influences over health sys-
tems in low  and middle income countries; 
encompasses research on or of policy, 
which means that it is concerned with how 
policies are developed and implemented 
and the influence that policy actors have 
over policy outcomes – it addresses the 
politics of health systems and health sys-
tem strengthening; promotes work that 
explicitly seeks to influence policy, that is, 
research for policy.”  
As such, Gilson (2012: p30) goes on to point out 
that it is research that occurs at the intersection of 
health systems and health policy being concerned 
with system functioning and policy change. It 
therefore is more than just research on health sys-
tems or on health policy. It is concerned with all 
building blocks within the health system and not 
just the health service delivery building block. As a 
result, it can be differentiated from implementation 
research or operations research. 
At the heart of health systems and policy re-
search is an understanding of the health system 
– what it is and how it works. In the last 10 years, 
this research has been heavily influenced by sys-
tems thinking and particularly complex adaptive 
systems thinking (de Savigny and Adam, 2009). 
Systems thinking places an emphasis on the in-
teractions and connections between the different 
actors that make up a ’system’. Complex adaptive 
systems thinking can be described as a system 
that adapts and evolves through self-organisation 
of a complex set of interconnected parts (de Savi-
gny and Adam, 2009). 
While it is often difficult to boundary a system, 
the idea of using systems thinking is that it helps to 
move beyond the linear approach or even the circu-
lar approach of research to policy to implementa-
tion to evaluation/further research etc. It introduces 
the importance of feedback loops and contexts that 
make the process ’messy’. In this way, despite the 
fact that it could be argued that the field received a 
boost from the rise of evidence based policy (EBP), 
this field of research is at odds with the linear mod-
els of the policy process put forward by the EBP lit-
erature. It is perhaps no surprise, then, that many of 
the writers who critiqued the dominant approach 
to studying health policy and utilised more non-
linear policy process approaches (notably Gill Walt 
and Lucy Gilson) have become some of the core 
researchers within the health systems and policy 
analysis literature.
It is worth noting that, up to this point, we have 
been referring to health systems and policy research 
very generally, although implicitly with a focus on 
research targeted to low and middle income coun-
tries. This field of research is, however, divided 
into research focused on the global North and that 
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focused on low and middle income countries. A 
review of the literature on ‘health innovation’ con-
ducted for this report revealed that the majority of 
papers from within the health journals reviewed 
were focused on the healthcare systems in the global 
North, specifically the UK, US and to a lesser ex-
tent Scandinavian countries (see Chapter 3). 
Interestingly, these papers focused on innovation 
in healthcare delivery or healthcare services more 
than innovation for health systems strengthening, 
implicitly or explicitly, while the papers from low 
and middle income countries focussed more on is-
sues related to health systems strengthening. This 
might have to do with two trends. First, the domi-
nant role in the Global South of global health pro-
grammes which – especially in their early years of 
existence – tended to bypass and even undermine 
national health systems rather than strengthen 
these. Second, health systems in the Global North 
have for a period of time been seen as more well-
functioning than those in the low and middle in-
come countries. This situation is now potentially 
changing due to the new challenges that national 
health systems in the Global North are facing (e.g. 
caused by people living longer, access to new and 
very expensive medicines etc.). 
Perspectives from innovation studies 
on health and health systems
The innovation systems literature came out of dis-
cussions taking place with regards to the uneven 
development of countries around the world and 
the idea that different innovation capacities could 
be an explanatory factor for inequities and inequali-
ties. Hence, at the heart of these discussions has 
always been a focus on issues of equity and equal-
ity or rather the need to understand why there is 
inequality and inequity in the world and to provide 
solutions to reduce these. 
While initially focused on issues relating to eco-
nomic development more generally, the perspective 
has increasingly considered specific development 
challenges such as health, education and housing 
(Cassiolato and Soares, 2015). This shift in em-
phasis in part reflects wider development debates, 
which during the 1970s and 1980s focused on pov-
erty as measured in economic terms (often Gross 
Domestic Product (GDP) per capita). Since then, 
broader interpretations of poverty as lack of possi-
bilities, voice etc. as advocated by United Nations 
Development Programme (UNDP) and other UN 
agencies have been promoted and even picked up 
by the World Bank (one of the original promoters 
of defining poverty in economic terms).
This also relates to discussions within the interna-
tional development policy community with regards 
to inclusion and development. Since the late 2000s, 
there has been an increasing emphasis within the 
donor and multilateral community on the idea of 
‘inclusive development’. This is defined in terms of 
what it is not, thus:
“Starting with growth, which has a tight 
and well accepted definition as an increase 
in real per capita income, pro-poor growth 
is identified as that which also reduces 
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income poverty. Inclusive growth is that 
which is accompanied by lower income in-
equality, so that the increment of income 
accrues disproportionately to those with 
lower incomes. With these definitions, 
growth can be pro-poor without being in-
clusive, since (as happened in many coun-
tries over the past two decades) growth 
can be accompanied by falling poverty but 
rising inequality. The concept of develop-
ment differs from growth in expanding the 
focus from income alone to other dimen-
sions of well being, in particular education 
and health. Inclusive development thus re-
fers to the improvement of the distribution 
of well being along these dimensions at 
the same time as the average achievement 
improves. The MDGs identify a number 
of these dimensions, and provide a good 
framework for measuring and identify-
ing inclusive development.” (Kanbur and 
Rauniyar, 2009)
This is an important set of discussions because it 
furthers the debates about the relationship between 
health and economic development. Specifically, 
the notion of inclusive innovation brings in issues 
of inequality and inequity that are often missing 
from discussions on economic development. It 
also highlights the need to consider the overlap be-
tween policy discussions, notably health or social 
policy and economics-related policies of trade, fi-
nance, innovation etc.
Since the first discussions on the relationship be-
tween innovation and economic growth, scholars in 
the field have been asking questions regarding the 
nature and purpose of economic growth, the forms 
of economic growth and increasingly whether that 
growth is inclusive. This fits with wider debates that 
are taking place within international development 
around inclusive development, inclusive growth 
and pro-poor growth within the World Bank, 
OECD/bilateral agencies and the UN system. Such 
discussions have realised the need to move beyond 
technological innovation in formal science institu-
tions and also consider innovation elsewhere (Utz 
and Dahlman, 2007).
However, much of these policy discussions are 
still rhetoric and therefore a range of writers, no-
tably from within the Globelics community, have 
spent time academically critiquing current debates 
in this area. These scholars (Cozzens and Kaplinsky, 
2009; Lorentzen, J. and Mohamed, 2009; Arocena 
and Sutz, 2012; Papaioannou, 2014; Foster and 
Heeks, 2013) argue for much deeper analysis of the 
relationship between innovation, inequality and in-
clusivity. Such a focus is also not confined to those 
in the innovation systems field; see for example Sen 
(2002). As a result, the Globelics Thematic Report 
(GTR) of 2011/12 defines inclusive development 
in a very different way to Kanbur and Rauniyar 
(2009) above. The GTR of 2011/12 defines inclu-
sive development as:
“a process of structural change which gives 
voice and power to the concerns and as-
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pirations of otherwise excluded groups. It 
redistributes the incomes generated in both 
the formal and informal sectors in favour 
of these groups, and it allows them to shape 
the future of society in interaction with 
other stakeholder groups.” (Johnson and 
Dahl Andersen, 2012: 25).
As a result, some have argued that any analysis of 
health innovation should focus at the level of the 
‘local’ only because it lends itself well to the study 
of specific issues where inequality and social exclu-
sion are major issues, e.g. health (Cassiolato and 
Soares, 2015). From a political economy perspec-
tive, Srinivas (2012) argues in a similar fashion 
that studies of innovation systems need to focus 
on the importance of sub-level systems because of 
the growth of urban centralised innovative activ-
ity. Such perspectives are important because of an 
increasingly dominant emphasis placed on global 
level action, especially in light of globalisation and 
the argument that ‘we are all connected now’ (Lee, 
2003). Such arguments gain momentum as a re-
sult of global health outbreaks such as severe acute 
respiratory syndrome or SARS, Ebola or Zika. 
That said, there is no doubt that global level forces 
have shaped and continue to shape health systems 
strengthening efforts at a national level as the dis-
cussions above on the emergence of new actors and 
debates highlights. 
Thus, in this vein, this report is written from the 
perspective that all activity within any system of in-
novation should work to meet developmental goals 
of the communities impacted.5 This increasingly 
means finding creative ways of maximising both 
business and social value at both local and global 
levels. That said, this report focuses specifically on 
considering these issues from the perspective of na-
tion states; this is because it is here that health sys-
tems are primarily devised and supported. 
With regards to specific studies from the innova-
tion studies field within the health sector, studies 
focus on many aspects of health related social de-
velopment from water and sanitation (Cozzens and 
Catalan, 2008) to the development of new medi-
cal technologies (Arocena and Sutz 2012; Bianchi, 
2014) and access to rural health services (Kraemer-
Mbula, 2013). 
Most of these studies reflect the need to add a 
normative dimension to innovation policy and 
related policies of trade, industrialisation etc. The 
studies are often set within a specific framework 
focusing on the importance of inclusion and the 
need for innovations to meet the needs of the 
poorest. This mirrors calls within the health poli-
cy field to ensure an equity and equality stance to 
health policy (Piot, 2012; Wagstaff, 2002). There 
5 While this is how it all ought to work; this is not 
how it often realistically works. In reality there are 
many other issues and interests at play – including 
not least the profitmaking imperative of the private 
sector – that means that innovation systems do not 
necessarily work to the benefit of the communities. 
The result is that are both winners and losers of in-
novation.
44   GLOBELICS THEMATIC REVIEW
are a number of studies that now empirically show 
(through in-depth analysis of case studies) that 
locally focused health innovation policy and sys-
tems that focus on meeting inclusion, equity and 
equality goals can work in a number of different 
settings around the world (see Cassiolato and 
Soares, 2015, for one compendium of such cases).
The extension of this argument is that, by hav-
ing normatively focused policy, it provides the op-
portunity for the right forms of innovation to be 
developed. However, this depends, ultimately, on 
the quality of the system available, i.e. whether one 
is working within a system characterised by ‘abun-
dance’ or ‘scarcity’ (Srinivas and Sutz, 2008). Frugal 
innovations are considered key here (Sutz, 2014). 
Such a focus is similar to discussions that have tak-
en place within the cross-over area of health and 
innovation discussions around the role of disruptive 
innovations (Smith, 2007; Hwang and Christens-
en, 2008; Brook, 2009) and discussions on how 
to make health innovation more ‘valuable’ to meet 
‘downstream’ (health outcome) issues (Lehoux et 
al., 2008). Frugal innovation is important here 
(Jamison et al, 2013).
There are also a set of discussions on the type of 
policy support required and where policy support is 
provided. Recognising that policy and action doesn’t 
occur in a vacuum, especially in a dynamic and evo-
lutionary system, the change in one area of policy 
will not always lead to everyone ‘winning’ and can 
lead to situations of ‘policy resistance’ (Kraemer-
Mbula, 2013). Others have therefore suggested that 
focus needs to be on policy implementation more 
than policy development (Mugwagwa et al., 2015)
Summing up
This Chapter has outlined the different types of 
thinking with regards to definitions of health, 
health systems and health systems strengthening 
since the WHO first defined health in 1948 to the 
present day. These discussions – within the health, 
international development and innovation fields – 
have been influenced by, and help shape, a series 
of key events, publications and debates; some of 
which have been outlined in brief above.
This Chapter has specifically reflected on the first 
two rows of Table 1, as outlined in Chapter 1:  
Health as a means to 
economic growth 
Health as a means to achieve 
social development and reduction 
of inequality 
→ Health as an integrated element of and con-
tributing factor to economic and social devel-
opment built on equity and inclusion
Health as absence 
of disease
Health as wellbeing → Health as wellbeing
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It has discussed different thinking put forward as 
to how health may be defined. Following this re-
view, the report will define health in a much wider 
sense than simply as the absence of disease and ill-
ness to incorporate issues of wellbeing. 
This Chapter has also introduced the intercon-
nections between health of populations and eco-
nomic and social development and the major 
debates with regards to these interconnections, in-
cluding those from within the innovation studies 
fields. Following a review of these debates, this re-
port takes as its starting point the idea that health 
is an integrated element of, and contributing fac-
tor to, economic and social development. 
The report takes specific cognoscente of the pow-
er and politics flows within these debates and how 
these determine whose arguments are discussed and 
acted upon in health policy and practice arenas. As 
such, the report will discuss how best to strengthen 
health systems and the relationship between health 
and economic or social development to encourage 
equity and inclusion. 
In so doing, it takes a normative position on 
what the goal of health systems should be. Health 
systems are in this context seen as comprising the 
building blocks of leadership and governance, 
financing, human resources, the inputs of prod-
ucts and technologies, information and research 
as well as service delivery.  However, this report 
will place an emphasis on not only these building 
blocks but also, and more importantly, the issue of 
interconnections and complexity within systems. 
These systems are the subject of the latter part of 
the next Chapter.  
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Tosamaganga hospital: maternity ward (Photo: Medici con l’Africa Cuamm, 27/1-2012. 
https://www.flickr.com/photos/mediciconlafrica/8401509513)
Hospital Geral de São Mateus, infant ward (Photo: Alexandre Moreira/A2 Photografy, 8/4-
2014. https://www.flickr.com/photos/governosp/13722499764)
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3. Rethinking health innovation
Key points
1 For the promotion of improved wellbeing and 
sustainable livelihoods there is a need for sys-
tem level changes
2 This requires social innovation in multiple 
spheres not just technological (product) inno-
vation
3 This social innovation creates the learning and 
competence building that enables a system to 
adapt and change to new circumstances
4 One approach to recognising the importance 
of social innovation for technological product 
innovation has been the promotion of the con-
cept of ‘health innovation systems’
The two pictures (previous page) show a maternity 
ward in Tanzania and an infant ward in Brazil. At 
first glance, they suggest very different experienc-
es and quality of care available based on the dif-
ferences in equipment and general surroundings 
shown in the photos. However, the key to good 
health outcomes for maternal and child health – as 
with any health aspect – is the quality of care and 
not just the latest equipment. Since the first ’Good 
health at low cost’ report in 1985 (Halstead et al., 
1985) there has been increasing recognition that 
examples exist of countries managing to achieve 
high rankings in health outcomes indicators de-
spite not being able to spend huge amounts per 
capita on health facilities or necessary technology 
or human resources for these facilities. The first re-
port singled out countries such as Cuba and the In-
dian state of Kerala while a 2011 follow-on report 
highlighted the examples of Bangladesh, Ethiopia, 
Kyrgyzstan, Thailand, and the Indian state of Ta-
mil Nadu (Balabanova et al., 2013). 
Key to the success of countries like Cuba, Bang-
ladesh and Ethiopia have been process, organisa-
tional, institutional innovations as well systems 
level action, and not just access to new technologi-
cal product innovations. The introduction of these 
– what we term ‘social innovations’ – assists and 
enhances further the strengthening of the health 
systems creating a mutually reinforcing cycle. 
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Therefore this Chapter introduces a discussion 
of different definitions of innovation, collapsing 
them into two overarching types: technological 
(product) innovations and social innovations. It 
should be noted that classifying the innovations 
in this way does not correlate to many definitions 
from the economics field. Schumpeter (1934), 
for example, discussed the existence of five dif-
ferent types of innovation: product, process, 
markets, supply/materials or business models. 
Schumpeter’s ‘product innovation’ we equate 
with Jin’s (2005) definition of ‘hard technolo-
gies’ or technologies that are in fact physical ar-
tefacts. The last four of Schumpeter’s innovation 
types we categorise as types of social innovations. 
These include Jin’s idea of ‘soft technologies’ or 
the combinations of knowledge, skills, routines 
and organisation required to operate a physi-
cal artefact (Mokyr, 2003; Burgess and Gules, 
1998) but also, which artefacts are necessary for 
the operation of any social activity. In this way, 
it is similar – but again fundamentally different 
– from the definition of social innovation used 
in the business management literature. Social in-
novation definitions in this literature range from 
that which sees it as anything that isn’t product 
innovation to, increasingly, the idea that it is any 
innovative activity that has a social purpose, i.e. 
benefits society as opposed to benefitting business 
(Pol and Ville, 2009). 
The way we use the concept of social innovation 
fits the definition already in use within discus-
sions on health innovation. Specifically, Gardner 
et al (2007) see social innovations as those that 
are not product innovation and which build sys-
temic capabilities (while recognising that they are 
intertwined and difficult to separate). In this vein, 
interestingly, the World Health Report 2013 ar-
gues that research is needed which “must explore 
the development and use of both “software” (such 
as schemes for financial protection and simpli-
fied approaches to treatment) and “hardware” 
(research and development for commodities and 
technology)” (WHO, 2013: p. xii).
The Chapter then goes on to discuss how the 
idea of social innovation is well suited to the idea 
of systems thinking and introduces the notion 
of a ’health innovation system’. Literature from 
within innovation systems thinking focuses on 
how forms of social innovation (as defined by us 
in this report) are essential for the development 
and strengthening of systems capabilities. Despite 
the idea that product innovation can create and 
encourage industrial development (UNIDO, 
2016), these other types of innovation – especial-
ly institutional and organisational forms of social 
innovation – assist in this process and strengthen 
the likelihood of sustainability of health systems 
at large.
Unfortunately, the field of health and health-
care around the world is still focused heavily on 
product innovation which can be seen in the so-
lutions being put forward to tackle health prob-
lems. Thus, this Chapter finishes with an explora-
tion of the extent to which social innovation is a 
focus of attention in policy and academic circles.
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Types of innovation
The debates introduced in the last Chapter regard-
ing the best means to improve health of popula-
tions can be traced back many years starting in 
recent history from the Alma Ata conference of 
1978. This conference marked the first interna-
tional gathering of individuals calling for com-
prehensive healthcare packages and ’health for 
all’. It led to a division in the healthcare commu-
nity about the best way to develop healthcare and 
healthcare systems, sharpened by the international 
economic crisis of the 1970, to focus on com-
prehensive or selective healthcare interventions 
(UNICEF, 2008). These debates were the pre-
curser for the next four decades of debates on the 
pros and cons of single issue/ top-down/ vertical/ 
medicalisation approaches as opposed to compre-
hensive/ bottom-up/ horizontal/ social determi-
nants led approaches. Many of these debates focus 
on the relative merits of focusing on technological 
(product) innovations or social innovations. 
There is now a much stronger recognition of 
the need to look past many of the dichotomous 
debates of the past relating to whether interven-
tions should be top-down or bottom-up in de-
velopment or whether planning should be done 
vertically by health issue or horizontally for the 
system as a whole. Since the mid-1990s with the 
increased interest on more nuanced health policy 
analysis and, more recently, the focus on under-
standing health systems more effectively, it would 
appear that the balance of opinion has swung in 
favour of the comprehensive, horizontal debates; 
as the recent calls and action towards universal 
health coverage suggests. 
However, the rise of the product development 
partnerships (PDPs) and global health initiatives 
(GHIs) in the late 1990s and 2000s has kept 
the spotlight on technological product innova-
tion even though many of the PDPs and GHIs 
have been integrating elements of health systems 
strengthening into their activities. Thus there is 
still a context of controversy as, particularly for 
the global health initiatives (Hafner & Shiff-
man, 2013; Marchal, Cavalli, & Kegels, 2009; 
Storeng, 2014), to whether health systems 
strengthening is still too narrow in its focus and 
dominated by technical solutions rather than sys-
temic approaches that focus on more holistic ef-
forts. These debates also rage in the research arena 
on health systems strengthening (see Adam et al., 
2012b; Frenk, 2010).
This report discusses the existence of two over-
arching types of innovation (technological prod-
uct innovation and social innovation) as a result 
of two dichotomous approaches within the health 
field to the solutions needed for improvements to 
a country’s health and wellbeing. Technological 
innovations are those new combinations of ele-
ments to produce hard technologies (new or im-
proved products or artefacts). Social innovation 
then becomes a ‘catch-all’ category for all other 
forms of innovation including improvements in 
the process of production or delivery of a hard 
technology as well as new or improved organisa-
tional or institutional arrangements. 
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Definition of health innovation: new products 
or processes, organisational and institutional 
arrangements that are new to a context or new 
to the world, which create public health value 
or reduce disease burden leading to improved 
livelihoods and wellbeing. 
Our definiton of health innovation in this context 
is based on the recognition that the majority of in-
novation is not ‘radical’ in its activity – it does not 
bring wholly new products into existence – but is 
primarily the result of incremental innovation or 
small changes in the way products and processes are 
made and delivered. At the same time, and allied to 
this, there is recognition in many sectors that basic 
science has not been where most innovation occurs 
(Chalmers et al., 2014 cited in Chataway et al., 
2015). Similar findings and arguments have been 
made in the global health field where it’s widely rec-
ognised that there has been a slowing down of the 
identification of new chemical entities reducing the 
number of new drugs on the market, particularly 
for neglected diseases of the poor (Lancet, 2011; 
Grabowski and Wang, 2006; Pedrique et al., 2013; 
Pecoul et al., 1999). It also mirrors calls in the glob-
al health field for a need to move beyond patents 
and publications and focus on the real health needs 
of those more affected by health problems through 
new financing mechanisms (e.g. Correa, 2012).
Technological (product) innovation
The development of new products and their subse-
quent introduction to new contexts has long been 
an important boost for health and healthcare. Ex-
amples include: the immensely improved ability to 
treat infections with the introduction of penicillin; 
the ability to eradicate small pox after the introduc-
tion of the small pox vaccine; the massive impact 
that the availability of anti-retroviral drugs has had 
on the HIV/AIDS incidence and mortality rates 
and; the impact of SMS-texting services in increas-
ing access to services or drug compliance.
The impact, and potential benefit, of different 
forms of technological innovation have been dis-
cussed in terms of ‘revolutions’, particularly in the 
recent past. The 2000s were heralded as the start 
of a biotechnology revolution for the healthcare 
industry, while some saw it as the start of an era 
of revolutionary genomics. The 2010s have been 
heralded as a digital revolution for the healthcare 
industry while others are enthused by the potential 
of nanotechnology and newer emerging technolo-
gies such as 3D printing. Each of these – neatly for 
us – provides a way of classifying different types of 
technological product innovation that have been 
important for improving healthcare provision op-
tions and reducing mortality or morbidity in recent 
years, starting with the precursor revolution relating 
to so-called ‘blockbuster drugs’.
The blockbuster drug and new 
chemical entity revolution
Following World War 2, the pharmaceutical indus-
try – predominantly focused in high income coun-
tries – became increasingly vibrant with the devel-
opment of in-house R&D facilities and dedicated 
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search strategies to locate new chemical entities 
(Malerba and Orsenigo, 2002). The result was that 
by the 1980s the world was witnessing an era of 
so-called ‘blockbuster drug’ development of drug 
products with a value of between US$ 300 and 
3000 million (Achilladelis and Ankonakis, 2001). 
Examples of blockbuster drugs are Lipitor (atorv-
astatin), a cholesterol reducing statin developed by 
Warner Lambert in the mid-1980s; Plavix (clopi-
dogrel), an anti-blood clotting drug developed by 
Sanofi and; Actos, an anti-diabetes drug developed 
by Takeda (Hannigan et al., 2013). 
The blockbuster drug revolution was supported 
by the emergence of biotechnology which enabled 
much more targeted screening of new chemical 
entities (NCEs) and compounds (Achilladelis and 
Ankonakis, 2001). At the same time it was ham-
pered by a slowdown in the ability to find NCEs 
(Grabowski and Wang, 2006) (although new data 
(Ward et al., 2013) suggests that by looking over a 
longer period of time there is not a large reduction 
in the discovery of NCEs).
Unfortunately, many low and middle income 
countries were unable to access blockbuster drugs 
due to the intellectual property regime in place at 
the time. This made these drugs prohibitively ex-
pensive for low and middle income country gov-
ernments with limited financial resources. At the 
same time, most of these drugs focused on treating 
illness and disease that was less prevalent in low 
and middle income countries in the 1980s and 
early 1990s. Organisational and institutional inno-
vations to incentivise development of appropriate 
medicines and make them available at lower cost 
will be discussed under social innovations below.
The genomics and biotechnology revolution
The development of biotechnology not only 
made the search for NCEs easier but has also been 
seen as heralding in the opportunity to solve the 
world’s health problems (Singer and Daar, 2001). 
Biotechnology involves the utilisation of organ-
isms found in the human body as well as outside 
(e.g. bacteria) to make useful products, such as 
vaccines or a diagnostic product. The related 
area of genomics is the study of genes in humans 
or animals and the relationships between these 
genes. There are therefore several ‘genome pro-
jects’ which focus on mapping all the genes inside 
a human being or animals like mice or monkeys 
or mosquitos in order to understand how disease 
and illness occurs and how the body reacts to dis-
ease and illness. 
The genomic era is heralded as having started 
with the sequencing of the human genome in 
2003 (Guttmacher and Collins, 2003). In recent 
years, we have witnessed an increase in the abil-
ity to use genomic medicine and science to help 
produce new curative treatments in the form of 
things like stem cell therapies for blood and im-
mune system conditions and disease and some 
cancers. However, the study of different genomes 
in humans but also in animals and insects has 
been heralded as leading to important discoveries 
with respect to many tropical diseases and diseas-
es affecting resource-poor environments around 
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the world. Specifically genomics (and biotechnol-
ogy more generally) is said to provide (Daar et al., 
2002; Pang, 2009):
• Faster identification of pathogens for improved 
detection of disease
• Cheaper, quicker and more accessible point-of-
care diagnostics
• Improved vaccines and drug discovery and de-
velopment as well as enhanced monitoring of 
resistance to vaccines and drugs
• More effective vector control mechanisms 
While the genomic era and the biotechnology 
revolution was heralded as creating opportunities 
for a range of therapeutic and preventive applica-
tions for improved health, some have argued that 
the idea is a ‘myth’ following a traditional pattern 
of incremental technological diffusion (Nightin-
gale and Martin, 2004). Others highlight that the 
traditional barriers and challenges to the use of 
such technologies, including lack of training and 
knowledge, poor facilities and funding, still plague 
many resource poor countries; despite some exam-
ples to the contrary (Coloma and Harris, 2009). 
As such, the idea of a ‘post-genomic era’ is com-
mon. With this concept, scientists and researchers 
recognise that, while the introduction of the study 
of genomics has created a plethora of potential 
areas of analysis and investigation, there is still a 
huge gap existing between this and the resulting 
creation of new drugs, vaccines and diagnostics 
(Chanda and Caldwell, 2003). 
The digital healthcare revolution
A Goldman Sachs 2015 report talks of the potential 
afforded by a digital healthcare revolution to drasti-
cally change the way healthcare takes place and 
reduce the soaring costs of healthcare in the US. It 
argues that information communication technolo-
gies (ICT) will allow for the increased provision of 
healthcare advice at a distance through telehealth 
and e-health options. Such thoughts have also been 
echoed in terms of the potential for e-health and 
ICT technologies to transform healthcare in re-
source poor settings. Of particular interest are:
• The potential of telemedicine to increase access 
to qualified medical advice at a distance through 
online communication and file sharing mecha-
nisms; 
• Mobile phone apps that remind individuals to 
take their medication at particular times or of 
the timing of anti-natal classes or children’s’ vac-
cine schedules
• Decision support tools to enhance the adminis-
tration of hospitals and clinics providing com-
puterised patient records, for example.
Despite all the enthusiasm, there are also words 
of caution as a result of the difficulty to scale up 
many of these examples that are still at a pilot 
stage (Green, 2010; Westbrook et al., 2009). That 
said, the continued success of the diffusion of 
mobile phone technologies in resource poor set-
tings in Africa keeps momentum on the potential 
that such technologies may have. A further new 
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turn in these discussions is the role of ’big data’ 
and the use of large datasets that can be analysed 
with high powered computers to chart potential 
impacts of epidemics or the future trends in dis-
ease (Hay et al., 2013.).
Emerging and converging technologies 
The list of product based technological revolutions 
in healthcare continues. For example, nanotech-
nology – the use of minute materials to produce 
new products – became a key issue for discussion 
following the biotechnology and genomic revolu-
tions. It is argued to provide opportunities for more 
effective drugs, vaccines and diagnostics while na-
noparticles can also lead to the creation of medi-
cal devices that are more durable (Bennett-woods, 
2011). In the ICT sector, interest is turning to the 
use of 3D printing as a means to provide custom 
made prosthetics or medical devices (Michalski and 
Ross, 2014). Finally, there is increasing recognition 
that many of these technological advances are being 
used in combination, creating the concept of ‘con-
verging technologies’ (Bainbridge, 2003).
The two sets of overarching fields of focus (health 
policy and innovation studies) come at the impor-
tance of technological product innovation from 
two very different perspectives. For those from the 
health field the emphasis is on how these innova-
tions can lead to improved healthcare solutions 
thus reducing illness, disease burden and premature 
deaths across the population. The majority of the 
literature outlined above focuses on the latter ele-
ment; the ultimate impact of these technologies on 
health. A sub-set of literature focuses on the impact 
of these technologies on health service delivery and 
improvements in healthcare provision. 
That said, in several industrialised countries, 
health policy is increasingly recognising the rela-
tionship between health innovation and economic 
growth. One such example is the Academic Health 
Innovation Networks in the UK, mentioned earlier 
in this report. A 2015 impact report on these net-
works’ activities highlighted how the networks cre-
ated 138 new business opportunities through con-
tracts, leveraged 10 million GBP of funding, and 
several have developed contracts with overseas com-
panies to license in products, sell products abroad 
or work on collaborative R&D products (ASHN, 
2015). In some countries, the pharmaceutical in-
dustry is a large contributor to the economy. China, 
through its ‘Key Drug Innovation’ project in 2007, 
has been massively investing in the sector in order 
to increase the percentage share of the pharmaceuti-
cal industry in its economy (Hu et al., 2016). 
Unsurprisingly therefore, there is a stream of re-
search within the innovation studies field that has 
investigated the impact of health product inno-
vation on economic growth paths. This includes 
research very squarely focused on the history and 
structure of the sector (Pisano, 1997; Malerba and 
Orsenigo, 2002; Garavaglia et al., 2012). There 
is research investigating the costs of the pharma-
ceutical development process and implications 
on the sustainability of the pharmaceutical sector 
(c.f. DiMasi et al., 2016 and the work of the Tufts 
Center for the Study of Drug Development). Oth-
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er research investigates the pharmaceutical and 
biotechnology sectors and how to promote their 
innovation systems (c.f. McKelvey, 2008; McKel-
vey et al., 2004). More broadly, there is work that 
focuses on the impact of the pharmaceutical sec-
tor as a driver for catching-up and/or industrialisa-
tion (c.f. Mackintosh et al, 2016; Srinivas, 2012; 
Gadelha et al., 2008; Huang, 2012; Ramani and 
Guennif, 2012). 
Much of this latter work has focused on the 
social innovation required for successful product 
innovation. Issues that are discussed in this litera-
ture are related to the intra-organisation of firms 
and business models that are utilised. Other issues 
addressed include the inter-organisation of firms, 
networking and partnerships undertaken. A fur-
ther set of issues address the institutional environ-
ment that pharmaceutical firms and other prod-
uct technology firms are influenced by, such as the 
regulatory environment and the level of public 
funding of health R&D. 
Social (process, organisational, 
institutional and systems) innovations
Thus, product technology innovation is dependent 
on allied social innovations. These can be innova-
tions that improve the way a product is produced 
(process innovation) or the way products are used 
by healthcare professionals and delivered or used to 
patients (organisational innovations). Also impor-
tant are informal and formal ‘rules of the game’, the 
underlying values and norms that determine how 
products are introduced and used (institutional 
innovations). Less often considered, but perhaps 
more important, are also systems innovations that 
refer to the competence building connections that 
ensure that all the other forms of social innovation 
as well as product innovation can be successful.
As such, some scholars (Jensen et al., 2007) have 
made the distinction between two modes of inno-
vation. The first mode of innovation they term the 
‘science, technology and innovation mode’ (STI-
mode) while the second they term the ‘doing, using 
and interaction mode’ (DUI-mode). It is argued 
that without the latter, the former cannot be suc-
cessful (Freeman, 2002). The idea of STI mode in-
novation is based on the fact that the introduction 
of some new technologies can take place as a result 
of the production and use of codified knowledge; 
knowledge that is written down and easily con-
veyed from one person to another. The blueprints 
for a new medical device design or the recipe for 
a new drug formulation are such examples. How-
ever, there has been increasing recognition of the 
importance of DUI modes of innovation both in 
their own right and for the successful completion of 
the STI mode of innovation. In the DUI mode of 
innovation, the emphasis is on the creation of new 
technologies through informal learning processes 
and tacit knowledge. Nelson (2008) discuss the rel-
evance of the DUI mode or ‘social technologies’ for 
the STI mode or physical technologies through the 
lens of cookery:
“…a recipe characterisation of what needs 
to be done represses the fact that many 
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economic activities involve multiple ac-
tors, and require some kind of a coordinat-
ing mechanism to assure that the various 
aspects of the recipe are performed in the 
relationships to each other needed to make 
the recipe work. The standard notion of a 
recipe is mute about how this is done… 
[We] propose that it might be useful to call 
the recipe aspect of an activity its “physical” 
technology, and the way work is divided 
and coordinated its “social” technology.” 
(Nelson, 2008:1-11)
As outlined at the start of this Chapter, we see so-
cial innovations – what some refer to as social tech-
nologies and the WHO has discussed as ‘software’ 
technologies – as referring to improvements in the 
process of production or delivery of a hard tech-
nology as well as new or improved organisational 
or institutional arrangements. In addition, it also 
covers the issue of systems level connections that 
are necessary for effective learning, capability build-
ing and knowledge flows aimed at ensuring a well-
functioning health system.
Process innovation and intra-organisational innovation
Process innovation relates to the ways in which 
a technological product innovation is improv ed 
through changes in its production process (Schum-
peter, 1911 cited in Edquist et al., 1998). Pro-
cess innovation can be divided into that which 
is technological (i.e. the introduction of robots 
into the manufacturing process to increase accu-
racy of manufacturing) or it can be organisational 
(i.e. the introduction of new ways of managing 
the factory floor such as the use of ‘lean produc-
tion’ techniques) (Edquist et al., 1998). Process 
innovation was traditionally argued to take place 
later in the lifecycle of a product when first-mover 
advantage had been lost and incremental innova-
tion was being concentrated on (Utterback and 
Abernathy, 1975). That said, there has been rec-
ognition of the importance of process innovation 
throughout the product innovation lifecycle, espe-
cially in high-tech sectors such as the pharmaceu-
ticals sector (Pisano, 1997). 
This report has placed process innovation with-
in the category of social innovation and not tech-
nological innovation. Our decision is based on 
the recognition of the underlying importance of 
learning and knowledge on process development 
activities (Pisano, 1997) within health systems 
and a focus on health systems and not simply firm 
level innovation. 
Therefore, to the extent that we can focus on 
individual firms, this report is predominately in-
terested in the role of organisational level process 
innovation changes within a firm’s production ac-
tivities. In this context, process development at firm 
level is “a capability-creating activity involving the 
translation of technical knowledge into operating 
routines.” (Pisano, 1997: 26). 
Increasingly, the discussion on such intra-organ-
isational process innovation in firms involved in 
health innovation cannot be divorced from inter-
organisational innovations. This is because of the 
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increasing movement from what has been termed 
Schumpeter Mark I to Schumpeter Mark II forms 
of innovation whereby firms move from innovat-
ing in isolation (Mark I) to innovating through 
networks (Mark II). It has been put forward that 
firms are increasingly having to integrate knowl-
edge internally from multiple sources (Hobday et 
al., 2005), or, become knowledge brokers, mean-
ing that they have the skills  to find the knowledge 
and capabilities required and work to bring these 
together from a diverse set of locations (Brusoni et 
al., 2001). 
Thus, this report also recognises another form 
of process innovation; the introduction of new ap-
proaches to how healthcare delivery is undertaken. 
An example of such a process innovation would be 
a shift from pre-booked appointments to a ‘drop-in, 
first-come-first-served’ system of doctors’ appoint-
ment within a health service facility to increase 
throughput of patients. Another example would be 
the introduction of Six Sigma or Lean production 
into hospital care to enhance the quality of services 
provided at the least cost (de Koning et al., 2006).
Inter-organisational innovation
As outlined above, health innovation has increas-
ingly become much more networked and collabo-
rative in recent years; including through mergers 
and acquisitions or takeovers (Grabowski and Kyle, 
2008). These are seen as a means of boosting inter-
nal capabilities and of ‘systems integration’. Higgins 
and Rodriquez (2006) found that in a survey of 
160 pharmaceutical acquisitions reviewed between 
1994 and 2001 the vast majority had led to posi-
tive gains for the companies. In fact, it is possible to 
argue that it has become commonplace to assume 
that biotechnology firms would reach a certain size 
and then be bought out by a larger pharmaceutical 
firm who had the funds to take product develop-
ment to the expensive clinical trial stages.
However, while originally these mergers and ac-
quisitions led to large firms with all the capabilities 
bought in-house, increasingly the nature of sys-
tems integration is changing. On the one hand, 
you have the internalisation of biopharmaceutical 
R&D within large pharmaceutical firms reducing 
the need for specialist biotechnology firms (Niosi, 
2013). On the other hand, there is an increasing 
focus on contracting out various elements of the 
pharmaceutical production process to multiple 
companies around the globe in the form of out-
sourcing increasingly offshore in emerging econo-
mies such as India (Krishna et al., 2012). 
Changing inter-organisational relations aren’t 
confined to only those between private for-profit 
pharmaceutical and biotechnology firms, as debates 
with regards to the role of the public sector in health 
product innovation highlight. In fact, the role of 
the public sector in financing basic science in a 
number of key areas has been recognised of late (c.f. 
Mazzucato, 2015). Two-thirds of all funding for 
neglected disease R&D currently comes from high 
income governments and multinationals, according 
to the 2015 G-Finder report. The US government, 
through its National Institutes for Health, provides 
two thirds of this funding (Policy Cures, 2015).  
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In the arena of global health and the develop-
ment of drugs, vaccines and diagnostics for diseases 
predominately affecting low income countries, the 
majority of the collaborations with government 
funded basic and applied science institutions take 
place through what have been termed ‘global health 
partnerships’ or as PDPs (Policy Cures, 2015; Pol-
lastri, 2014; Chataway et al., 2011). PDPs started 
in the mid-1990s but gathered momentum in the 
2000s as a means of encouraging collaboration be-
tween pharmaceutical companies and non-profit 
actors to search for new or improved solutions to 
the world’s health problems (Buse and Walt, 2000; 
Buse and Harmer, 2004). Their efforts have resulted 
in the commercialisation of new drugs, significant 
leads in the development of new vaccines and diag-
nostics as well as capacity building efforts through 
the building up of new research staff and facilities 
in a number of low income countries around the 
world. Perhaps more importantly, PDPs as an inter-
organisational innovation create the opportunity 
for the essential ‘learning by doing’ that is required 
for successful product development to take place, 
recognising the difficulty of simply promoting the 
STI mode of innovation (Mahoney, 2011).
The difficulty, outside of PDP type mechanisms, 
for universities and public research institutions to 
link with commercial companies in low and mid-
dle income countries has been catalogued well in 
Latin America. Rodriguez and Dutrenit (2010), for 
example, have highlighted how Mexico has weak 
Public Research Organisations (in the form of uni-
versities and public research institutes) in terms of 
capacity and capabilities, and local health inno-
vation firms weak in absorptive capacity to work 
with them. However, this is not always the case as 
the experience of Fiocruz, the largest public health 
research institute in Brazil, with GlaxoSmithKline 
(GSK), the multinational pharmaceutical com-
pany, shows (Porto et al., 2012). The partnership 
between Fiocruz and GSK has led to a number of 
drugs and vaccines being developed since the start 
of their partnership in 1985 including the intro-
duction of some of them, notably the dengue fever 
vaccine, being added to the national immunisation 
schedule in 2010. 
However, organisational innovation in the health-
care sector is not only about the coming together of 
private firms or private firms with public entities. 
There is also a wider set of inter-organisational in-
novations that have been taking place and that are 
promoted to create more effective product innova-
tion and improved healthcare services. These other 
organisational innovations relate to the creation of 
clusters of organisations as a result of arguments 
that proximity and location matter in creating im-
proved opportunities for innovative activity to take 
place (Cooke, 2001). For example, India’s phar-
maceutical sector is predominately centred around 
key urban centres, where internationally renowned 
medical schools and universities feed the sector’s 
need for qualified researchers and technicians 
(Athreye et al., 2009). In Brazil, the Minas Gerais 
pharmaceutical cluster is similar (Cassiolato et al., 
2011). Biotech clusters were initiated in Egypt and 
South Africa in the early 1990s to enhance pro-
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ductivity in the sector (Uctu and Pillay, 2012). In 
Pakistan, a surgical instrument cluster in Soilkot is 
the second largest producer of surgical equipment 
in the world (the first being in Germany) and it has 
survived and thrived because of the proximity of 
the different manufacturers to each other (Navdi 
and Halder, 2005; Haneef, 2016).
In these previous examples of inter-organisation-
al innovation, the networking and collaboration 
have taken place in order to bring together discrete 
knowledge or capabilities so that new products or 
healthcare solutions can be developed and diffused. 
However, organisational innovation can also take 
place as a result of what has been termed ‘scarcity 
conditions’ (Sutz, 2014). Situations where there is 
a strong demand for new technologies or more ef-
ficient technologies but a lack of interest by tradi-
tional players (i.e. established for-profit firms) result 
in making other actors come together and develop 
health innovation where they normally wouldn’t. 
Such innovations are what can be termed ‘below 
the radar innovations’ (Kaplinsky et al., 2009) in 
that they are not readily known about, or consid-
ered as important, by governments and other rel-
evant stakeholders. 
Again, much of the above discussion has so far 
discussed inter-organisational innovation relating 
to the health product innovation process. How-
ever, inter-organisational innovation is also proving 
important in healthcare delivery. This involves the 
contracting out or empowerment of new forms of 
staff to undertake new or alternative roles in the 
healthcare delivery system (sometimes referred to as 
‘task-shifting’) or the use of alternative, community 
based, health clinics for basic services using nurses 
rather than doctors surgeries (Robinson and Smith, 
2008; Goodman et al., 2010). For example, El Ari-
feen et al. (2013) highlight how a move towards the 
use of community level health personnel in Bang-
ladesh in routine healthcare resulted in improved 
healthcare services. In Zambia, community health 
assistants are being deployed to bring health work-
ers to communities and improve health service de-
livery (Zulu et al., 2015). 
These discussions have focused on country level 
inter-organisational innovations. However, increas-
ingly, as a result of globalisation, the networks and 
collaborations between organisations take place 
across geographical boundaries. There is some in-
teresting work that has been considering the poten-
tial value of South-South partnerships and collabo-
rations, i.e. those between different organisations 
based in various low and middle income countries, 
over the more dominant North-South partnerships 
and collaborations (Thorsteinsdottir and Chatur-
vedi, 2014; Thorsteinsdottir et al., 2010). This fits 
within wider work from innovation studies that 
considers the relative merits of innovation originat-
ing from India or China for Africa (c.f. Kaplinsky 
and Hanlin, 2016) because the former is seen to 
be designed with those operating conditions and 
cultural contexts in mind that are also found in the 
African context. 
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Institutional innovation
The importance of institutional innovation is often 
overlooked in health policy discussions. However, 
facilitatory institutions and institutional arrange-
ments are fundamental for successful innovation of 
any type (technological, project or organisational in 
nature). There are three main areas where institu-
tional innovation is necessary. These are in the areas 
of governance, regulation and finance.
Institutions are often defined as ‘rules of the 
game’ (c.f. North, 1990). These can be formal rules 
and laws as exemplified by government legislation 
or international standards or they can be more in-
formal rules and norms that reflect how people ex-
pect to live and work (these are sometimes referred 
to in terms of cultural norms). At the same time, 
institutions sometimes refer to organisations and 
organisational structures. Therefore, the state, i.e. 
government and its various organs, can be defined 
as an institution. In many instances, the state is 
juxtaposed against another institution, the market. 
In reality, these are not single organisations but are 
made up of multiple organisations (different min-
istries and organs of state on the one hand and dif-
ferent private for-profit and non-profit actors on 
the other). These come together to ensure that the 
state and market are key institutions that provide 
useful (or, in some cases, unhelpful) institutional 
innovations that help or hinder technological in-
novation and improved health services delivery. In 
addition, the state and market are themselves in-
fluenced by, and create, formal and informal rules 
of the game. The ways in which these multiple or-
ganisations can be and are combined in different 
countries and contexts differ and analysis of these 
combinations are required to a) explain differences 
in health outcome and b) improve policies for en-
suring more equitable health outcomes. The 4Fs 
framework introduced in Chapter 4 provides one 
means to conduct such an analysis.
Considering issues of institutional innovation is 
important because - as others have argued in the 
case of African countries (Al-bader et al., 2010), 
while we would argue that it is relevant across the 
globe - there is significant health research going on, 
but this research often does not lead to the devel-
opment of new technologies. The reason for this 
is partly the lack of positive institutional innova-
tions, relating to regulation and global governance 
structures that are restricting the development of 
domestic capabilities. 
Governance related institutional innovations
In recent years, the health innovation field has 
seen a number of governance related institutional 
innovations become prominent, especially at the 
global level. New actors on the global health inno-
vation scene are changing the dynamics of health 
innovation and even healthcare delivery systems 
around the world. Notable here are the Global 
Fund for AIDS, TB and Malaria and Gavi; two 
global health partnerships that were created to in-
centivise health product development in the early 
2000s. Another example is the Bill and Melinda 
Gates Foundation, which is the largest funder of 
health innovation outside of the US National In-
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stitutes of Health (Policy Cures, 2015). These or-
ganisations have changed the way health innova-
tion takes place, by disease, location and timeline, 
in terms of the focus areas considered. As such, 
these organisations are increasingly responsible for 
the ‘steering’ of both global and national health 
innovation activities. 
The notion of ‘steering’ (as opposed to ‘rowing’) is 
used to explain the current concept of ‘governance’ 
(as opposed to ‘government’) in health innovation 
activities (Lyall and Tait, 2005). It links to the no-
tion of ‘stewardship’ that was raised in Chapter 2 
and a change in the way that attitudes to govern-
mental control over health innovation and health 
systems strengthening has changed in recent years.  
That being said, the rise of new actors on the 
global health scene and their governance role has 
not been without critique (Rushdon and Williams, 
2009; Frenk and Moon, 2013). There is no doubt 
that GHPs have led to increased interest by global 
pharmaceutical firms in diseases affecting the poor-
est populations in the world. However, these firms 
are unlikely to change their business models and 
will remain dedicated to high income, high-return 
markets of the North. At the same time, newer 
firms in emerging economies that are becoming 
‘ones to watch’ globally are also likely to focus in-
creasing amounts of attention on the more profit 
providing disease profiles of the North; despite the 
changing epidemiological profile of lowincome 
countries (Chataway et al., 2011). 
As such, there is still an important role to be 
played by national governments and state apparata 
in ensuring successful health innovation (Kale, 
2013; Bloom et al., 2014 and; Arora, 2007). Spe-
cifically important governance related institutional 
innovations by the state include the provision of 
facilitatory rules, laws and policies for health in-
novation activities. Examples of where these have 
been provided include the promotion of link-
ages between stakeholders for pharmaceutical pro-
duction and health service delivery in Tanzania 
(Szogs, 2014), Rwanda (Simiyu et al., 2010) and 
Brazil, India and China (Mcmahon and Thor-
stiensdóttir, 2011). 
There is a further set of organisations that pro-
vide important governance related institutional in-
novation in the health innovation field, which until 
recently have often been overlooked: the industry 
associations (Papaioannou et al., 2015). These net-
works of organisations – such as the International 
Federation of Pharmaceutical Manufacturers or 
country level versions of the same or those related 
to doctors, nurses, pharmacists – are examples of 
organisational innovations. They are also facilitators 
of institutional innovations because they often have 
the ability to influence the norms, rules and values 
of their members as well as the wider health system 
in which they have influence.
Regulation and IPR related 
institutional innovations
The role of governments in supporting institutional 
innovations is played at an organisational level, a 
governance level and at a regulatory level. It is to 
this last area that we now turn. It has been argued 
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that governments play a key role in providing a sup-
portive regulatory environment to those involved in 
health innovation; particularly domestic industry 
(t’Hoen, 2006). As such, there is a series of regula-
tion related institutional innovations possible; some 
orchestrated at a national level and some – and 
perhaps increasingly so – at a global level. As with 
governance related institutional innovations, these 
innovations can have negative or positive effects on 
other innovation and health delivery efforts. 
Perhaps the most obvious regulation related in-
stitutional innovation is also the most controversial 
one. This is the Trade Related Intellectual Property 
Rights (TRIPS) connected legislation around the 
world, introduced in the 1990s and updated in 
various ways since then. These on the one hand in-
sisted that patent protection be upheld around the 
world (potentially increasing the cost of drugs but 
also giving firms more control over how and where 
their products were marketed). On the other hand, 
the laws also gave countries an opportunity to cir-
cumvent the rules and compulsorily license the pro-
duction of copies of expensive drugs from abroad 
in local factories (potentially reducing the cost of 
drugs and increasing the potential for a viable local 
generics industry). 
Some would argue that these IPR laws have been 
conducive to a country’s innovative potential pro-
viding an opportunity for countries to move into 
new drug production areas (e.g. Rashmi (2011) 
with respect to India; Oliveria et al (2004) on Bra-
zil). Others have been less positive about their im-
pact (Urias and Furtado (2009) on Brazil or Guen-
nif and Mkufa (2013) on Thailand). This has not 
just been an argument for mainstream pharmaceu-
tical production but also has played a role in the 
traditional medicines area (Madhavan, 2008).
A more recent, but no less controversial, regu-
lation related institutional innovation is that of 
‘open innovation’. This term encapsulates the idea 
that firms no longer innovate in a ‘closed’ environ-
ment, i.e. in internal R&D labs, but instead must 
frequently connect and network with others to 
gain knowledge and skills for successful innovation 
(Chesbrough, 2003). Key to the success of ‘open 
innovation’ is the idea that there is no proprietary 
ownership of ideas but that firms and other ac-
tors collaborate freely although obviously in a way 
where each party gains. As such, there have been 
calls for less emphasis on publishing and patents 
and more on incentives to network and conduct 
research (e.g. Stiglitz, 2007)
Finance related institutional innovations
Another institution that is increasingly being rec-
ognised as important, particularly in light of the 
universal healthcare coverage discussions, is that of 
finance. The most well known of the finance re-
lated institutional innovations are again – as with 
the governance related institutional innovations – 
those that are based at a global level. Examples of 
these include the Advanced Market Commitments 
for pneumonia vaccines (Batson et al, 2006); an 
R&D fund (Balasegaram et al., 2015) and the 
more recent Global Health Technology Fund (htt-
ps://www.ghitfund.org/). These were developed to 
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provide an incentive mechanism for the develop-
ment of drugs, vaccines and diagnostics for dis-
eases that were being neglected by pharmaceutical 
industry firms around the world. These are finan-
cial instruments that, in the case of the Advanced 
Market Commitments, are administered by Gavi. 
As such, they were designed with a similar but still 
different mandate to Gavi and the Global Fund for 
HIV/AIDS, TB and Malaria, which are organisa-
tions and not simply financial instruments.  How-
ever, these latter organisational innovations have 
also been termed financial innovations by some 
authors (c.f. Atun et al., 2012).
These instruments have traditionally focused on 
large industry players – the globally active phar-
maceutical companies from the North (the likes 
of GSK, Merck etc.) as well as the South (such as 
Cipla and Rambaxy from India). However, there 
is a significant amount of local manufacturing of 
medicines, i.e. in low and middle income coun-
tries for their home markets, especially in Africa 
(Mackintosh et al., 2016). Much of this manufac-
turing is not concerned with novel drugs or vac-
cines but with so-called ‘me-too’ drugs, i.e. cop-
ies of drugs that have come off-patent or generic 
drugs (Banda et al, 2016). The manufacture of 
novel drugs or the production of the active phar-
maceutical ingredients to produce these drugs are 
costly exercises and a combination of economies 
of scale and high levels of regulation in the form 
of Good Manufacturing Practices prohibit many 
African countries, especially, in developing more 
advanced pharmaceutical production capabilities 
(Mackintosh et al., 2015). In the case of African 
countries – where pharmaceutical production is at 
its lowest – it has been argued that what is needed 
are finance innovations, namely public procure-
ment related instruments (Chataway et al., 2015) 
supported by facilitatory regulatory instruments 
such as conducive tax and duty regimes (West and 
Banda, 2015). However, above all, what is needed 
for African pharmaceutical industries to develop is 
good sources of foreign direct investment and to 
a lesser extent (because of its limited availability) 
venture capital funding (West and Banda, 2015). 
West and Banda (2015), however, state that these 
will not be useful if pharmaceutical firms – but 
also the financial firms – do not have the requisite 
capabilities or ‘know-how’ (Jensen et al., 2007) to 
understand the workings of the financial instru-
ments or the market in which the firms operate. 
While West and Banda (2015) do not see much 
hope for venture capital funds at present  for Af-
rican pharmaceutical companies, this does not 
mean to say that they haven’t proved important 
players already. Masum et al. (2010) highlight 
the role of venture capital firms, such as Acumen 
Fund and Bioventures, for the development of a 
number of key health innovations in Africa and 
argue that venture capital does have a place for 
health innovation efforts on the continent.
Systems innovation
Finally, systems innovation - another form of social 
innovation - will be touched upon. The idea that 
you can have such innovation is relatively new in 
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the health policy field but has been an important 
part of the innovation studies literature since the 
1990s. An example of this type of innovation may 
be derived from a review of the Tanzanian (when 
compared to Ghanaian) introduction of vouchers 
for malaria prevention (see de Savigny et al., 2012). 
Tanzania introduced a pilot voucher scheme in 
the late 1990s, which was rolled out nationwide 
from the mid-2000s. Vouchers for a subsidised 
insecticide treated mosquito net were provided to 
women attending reproductive and child health 
clinics with 80% of nets being redeemed (de Sav-
ingy et al., 2012). In contrast, the Ghanaian scheme 
never succeeded because internal system functions 
were not enhanced. The authors argue that this 
is because “external ideas, events and actors were 
more prominent in driving events.” (de Savigny et 
al., 2012: iv42).
There has been increasing recognition in recent 
years of the need to think in terms of a health system 
as introduced in Chapter 2. What such thinking – 
both from within the health policy field (taking in-
spiration from complex adaptive systems thinking) 
and the innovation systems field – argue in this re-
gard is twofold. First, successful innovation requires 
a recognition of all the actors involved, of how they 
fit together and then of the necessary practical steps 
to encourage them to work together. Recognising 
the different elements and actors involved in the 
innovation process, it is important to understand 
more deeply how they interact and the roles they 
play in the system. Second, in order for the actors 
to work together more effectively, there is a need to 
understand how learning and knowledge is trans-
ferred between the different parts of the system to 
create a greater whole. 
Systems innovation is about achieving the right 
mix of all other forms of social and technological 
innovation. Conceptually, this requires new ways of 
thinking about the definitions and processes of in-
novation and healthcare delivery. 
Focusing on innovation and health 
systems level innovations
A number of innovation and health scholars and 
practitioners have been converging in recent years 
around the idea of ‘systems innovation’. This comes 
as increasing numbers of scholars and practitioners 
focus on wider definitions of innovation; on differ-
ent types of social innovation and not just on prod-
uct technologies. Alongside this are those that focus 
on the marriage of innovation systems thinking and 
health systems thinking. Allied to this, in turn, is 
a set of literature on the role of capacity building, 
especially scientific/biomedical research capacity 
building in low and middle income countries, and 
its ability to disrupt innovation pathways. 
Much of this recognition comes from a set of 
wider discussions on how to understand and pro-
mote more effective global health policy, particu-
larly with a focus on the impact for low and mid-
dle income countries. However, some of it – see for 
example Sakellarides (2008) – comes from discus-
sions focused very much on European or North 
American based health systems. 
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At the centre of these discussions are a series of 
new systems based terms for helping conceptualise 
health innovation. These include: health innova-
tion systems (Morel et al., 2005a); health innova-
tion networks (Morel et al., 2005b) and; global 
health research and innovation systems (Matlin and 
Samuels, 2009). These concepts see innovation – as 
we do in this report – as encompassing a set of ac-
tivities (organisational and institutional), processes 
or products which are new to a context (rather than 
new to the world) and which create public health 
value or reduce disease burden. In such a wider defi-
nition, health innovation refers to a range of differ-
ent types of activity aimed at improving efficiency 
and efficacy in any or all of the WHO building 
blocks of a health system. 
The development of the concepts of health in-
novation systems, health innovation networks 
and global health research and innovation systems 
came about because of an interaction with inno-
vation systems thinking by those working in the 
global public health arena. The three terms are 
connected but different. The term ’health innova-
tion system’ was coined by Morel and colleagues 
(2005a) following a workshop in Bellagio in 2004 
which brought together health scholars and in-
novation scholars to discuss how to move forward 
health product innovation for neglected diseases. 
They defined a health innovation system as includ-
ing ”interlinked components including education, 
R&D, manufacture, domestic and export mar-
kets, intellectual property management, regulatory 
systems and the national policies that affect all of 
these (including public‐private partnerships).”  
Key to the success of a health innovation system, 
they argue, is the recognition of the interlinkages, 
the ’dynamics linkages’, between the different ele-
ments of the system. They go on to argue (as do 
some of the authors in a similar paper; Morel et al. 
(2005b)) that recognising the global nature of inno-
vative activity there is a need to focus on developing 
networks of actors involved in health innovation 
or ’health innovation networks’, especially those 
involving South-South collaborations, to ensure 
maximum cross-fertilisation of ideas and action in 
the most relevant formats. The idea of a health in-
novation system has been diagrammatically visual-
ised in Figure 3.
This field of thought was further enhanced by a 
paper in 2007 by Gardner et al., which focuses on 
the difference between technological and social 
innovation. It makes the point that technologi-
cal innovation focuses on the development and 
deployment of ’cost-effective products’, but more 
important than this - because technological inno-
vation depend on them - are two other forms of 
innovation, namely social innovation or ’distribu-
tion mechanisms for essential goods and services’ 
and, even more important, ’adaptive innovation’ 
or the contextualisation of the first two types into 
local settings.
Two years later, a further paper (Matlin and 
Samuels, 2009) was published that moved the dis-
cussions in this area further forward, entitled ’The 
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Source: Morel et al. (2005b)
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Global Health Research and Innovation System’. 
The paper described the need to look more closely 
at the ’overlapping domains of research and inno-
vation’ as a result of the increasing emphasis being 
placed on research for health and the ’growing com-
plexity of the architecture of global health research’. 
The paper recognises technological innovation and 
social innovation a la Gardner et al. (2007) and ar-
gue that they are intertwined and complementary 
to each other. They see an intersection of activity 
in the middle of research systems and innovation 
systems where health research comes together. They 
see this happening within the context of a wider ex-
ternal environment of ’drivers, incentives and mo-
tivations, promoters and barriers’ with positive and 
negative feedback loops. As such, the paper appears 
to draw on innovation systems thinking as well as 
systems thinking from the health field.  Thus, they 
focus on different elements of the system as being 
both actors as well as innovative activity (to create 
products or processes), but they also focus on the 
flows and relationships between each of these as 
outlined in Figure 4.
Disconnects remain
Despite the rhetoric within recent reports of inno-
vation or innovative solutions and the increasing 
emphasis placed on health systems strengthening, 
this set of literature that married together health 
systems, health policy and innovation systems ap-
proaches has not flourished. Although references 
are made to this literature – for example, Howitt 
et al.’s 2012 Lancet commissioned ‘Technologies 
for Global Health’ report includes a definition of 
health innovation taken from the seminal paper 
introducing the concept of global health and re-
search systems (Matlin and Samuels, 2009) - cur-
rent global health discussions and, more impor-
tantly, country level debates, appear to shy away 
from thinking beyond innovation as a process in 
the development and commercialisation of a tech-
nological product.
This difficulty in sustaining a momentum be-
tween health researchers and innovation research 
has been put down to the fact that the scholars in-
volved in these discussions still come from distinct 
fields of thought which rarely come together (Han-
lin, 2008; Srinivas, 2012; Sutz and Srinivas, 2008; 
Mackintosh et al., 2016). Others have recognised 
the difficulties also: 
Lehoux et al. (2008): “Innovation design-
ers rarely tap into the knowledge generated 
by health services researchers while health 
services researchers often fail to provide 
key insights about the comparative value of 
emerging innovations.” (Italics in original)
Culliton and Kennedy (2008): “An intel-
lectual chasm exists between those who 
do innovative research and those who de-
liver it.”
Gardner et al. (2007): “Unfortunately 
‘technological utopians’ and ‘systems uto-
pians’ seem to speak different languages; at 
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worse, they compete fiercely for finance re-
sources in the global health field.”
Interestingly, one argument as to why a focus on 
technologies and technological product innova-
tion has dominated is the growth in one of the 
new organisational innovations. The strong pres-
ence of new organisational forms on the global 
health scene, notably the product development 
partnerships and global health initiatives such as 
the International AIDS Vaccine Initiative, PATH 
(formerly known as the Program for Appropriate 
Technology in Health) and Gavi, have pushed a 
focus on biomedical research and access to medi-
cines at the expense of wider discussions on the 
enabling environment needed or the social inno-
vation for health systems strengthening. The result 
is a continued dominance of debates by techno-
logical product innovations. 
The emphasis is still on technological 
(product) innovations
A review of reports that have put forward solu-
tions for global health problems in recent years 
(see Table 3) outlines the continued significant 
focus on technological innovation at the expense 
of social innovations. 
The earliest report outlined in Table 3 is the Lan-
cet Commission’s Technology for Global Health 
2012 report. It takes a broad definition of technol-
ogy as highlighted by the list outlined in Table 3. It 
refers to technology not just in terms of physical ar-
tefacts but also in terms of less tangible knowledge 
associated with technologies. They define health-
care innovation using a definition by Matlin and 
Samuels (2009) as “any initiative that takes novel 
ideas, inventions, or processes and applies them to 
achieve improved health and greater health equity” 
(Howitt et al., 2012: p. 4). However, only three of 
the technologies mentioned in the Lancet report 
move beyond tangible product innovations into the 
category of social innovations as defined in this re-
port, namely: medical and surgical procedures, sup-
port systems and organisational systems. This leaves 
out a whole range of social innovation options that 
offers great potential for improving national health 
systems. 
On the other hand, when discussing health re-
lated breakthroughs, the ’50 Breakthroughs Re-
port’ by Buluswar and colleagues at the Institute for 
Globally Transformative Technologies, Lawrence 
Berkeley National Laboratory only refer to what we 
consider to be technological product innovation. 
However, they do acknowledge that technologies 
(products) are not a panacea:
“technology is not essential to solving 
many of the problems surrounding global 
poverty. Tremendous progress can be made 
through institutional reform, infrastruc-
ture development, education, access to user 
finance, behaviour change, and other poli-
cy and social interventions. Indeed, even 
when technology is necessary, it cannot 
achieve meaningful impact on its own.” 
(LIGTT, 2014: 8)
PATH’s IC2030 30 most promising innovations (2015; www.ic2030.org) 
Innovations for maternal, newborn, and child health
New formulations of oxytocin 
Uterine balloon tamponade 
Handheld device to measure blood pressure 
Simple, safe device for assisted delivery 
Chlorhexidine for umbilical cord care
Kangaroo mother care
New neonatal resuscitators 
New treatments for severe diarrhea 
Rice fortification 
New tools for small-scale water treatment 
Portable pulse oximeters to measure oxygen 
Better respiratory rate monitors
Innovations for reproductive health 
Expanded access to implants and intrauterine devices 
Injectable contraceptives 
One-year contraceptive vaginal ring
Innovations for combating infectious diseases
Protective malaria vaccine candidates
Malaria transmission-blocking vaccine 
Potent, single-dose antimalarial drug 
Expanded use of rapid malaria tests 
Broadly neutralising antibodies in HIV vaccines
Long-acting injectable antiretrovirals
Oral pre-exposure prophylaxis 
Novel multidrug treatment regimen for TB 
New vaccines to prevent TB 
Nucleic acid amplification tests
Innovations addressing noncommunicable diseases 
Polypill
Broader use of HPV vaccine
Task-shifting for diabetes care 
mHealth innovations 
Portable, affordable screening for eye problems
LIGTT’s 50 breakthrough technologies report (2014)
Vaccines for HIV/AIDS, Malaria and TB
Single dose/short course TB drugs
Improved longer lasting ART
Complete cure drug for malaria
‘Clinic in a box’ – inexpensive suite of integrated devices that make up key requirements for a clinic in low resource setting
Automated and multiplex diagnostic immunoassays
New long lasting, non-chemical spatial insect repellents
Low cost portable, solar powered refrigerators
New generation of homes with solar lights and toilets built in for urban poor
Nutrient dense, culturally appropriate foods for infants to supplement breastfeeding
Lancet Commission’s Technologies for Global Health report (Howitt et al., 2012)
Health technologies
Medical devices
Biologics
Drugs
Medical and surgical procedures
Support systems
Organisational systems
Technologies for health
Agricultural equipment
Bioengineered foods
Road safety technologies
Sanitation
Table 3 Solutions proposed for current global health problems
Source: Authors
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However, it then goes on to state that the report has 
decided to focus “on problems for which new tech-
nologies are critical.”  It does not, however, appear 
to offer a justification for this decision. 
The third report that we reviewed was PATH’s 
Innovation Countdown 2035 report (see www.
ic2030.org). Again, this report lists a range of tech-
nologies; all but one of which is a physical product. 
The only technology going beyond technological 
product innovation would be that of task shifting 
in diabetes care. 
The dominance of technological product inno-
vation within policy reports over and above other 
forms of innovation mirrors arguments made in 
Chapter 2 with regards to the debates on defini-
tions of health and ways of measuring the perfor-
mance of health systems. As outlined in Chapter 2, 
these have often found it easier to focus on measur-
ing progress in relation to burden of illness and dis-
ease at the expense of a number of wider issues such 
as the social determinants of health, including the 
presence or absence of a functioning health system.
The tide appears to be changing…
The reports that we have reviewed all come from 
the health policy field. Similar reports do not ap-
pear to exist from an innovation policy perspec-
tive. Therefore, to understand the exact nature of 
this separation, we conducted a wider literature 
review to determine how ‘health innovation’ as 
a concept has been considered in the literature 
and how this has changed over time. The literature 
review focussed on journals associated with either 
public health or health policy and papers published 
in those journals from 2000, the year of the World 
Health Report focusing initially on health systems, 
to June 2015. The methodology of the literature re-
view is outlined in Annex 1. Of the 220 papers that 
were identified between these dates, 93 were re-
jected after a review of their abstracts. This left 127 
papers which were included in the review exercise. 
The review found that 40% (n=52) of papers 
focused on low or middle income countries either 
through a specific country focus or as a result of 
focusing on global health issues more generally. 
The other 60% were focused on the global North, 
mostly focused on specific country level studies in 
the UK or US. 
Surprisingly, just under 40% of the papers 
(n=47) focused on what we would term social in-
novation and what Gardner et al. (2009) describe 
as the organisation and distribution of health re-
lated goods and services. That said, few of them ex-
plicitly referred to this as social innovation. Only 
16% (n=21) of the papers had an explicit, clearly 
specified focus on technological innovation, i.e. 
healthcare products (biomedical or IT mostly). 
The review also revealed the following four sub-
sets of discussions within the papers:
1 Diffusion of innovation 
There were a set of papers (n=25) within the re-
view which focused on diffusion of innovation, 
many of them referencing Roger’s theory of inno-
vation diffusion (2010). Most of these focused on 
diffusion of technological innovation in European 
 HEALTH SYSTEMS STRENGTHENING   71
or North American settings. However, eight of 
the papers were focused on innovation diffusion 
in low or middle income countries. This number 
is relatively high because a number of the papers 
are connected to each other being either studies 
from the same overarching project (PHIRE) or re-
sponses to a published letter, discussing diffusion 
(Baker, 2003).
2 Disruptive innovation
A much smaller set of papers discussed the role 
of disruptive innovation, including two papers 
(Hwang and Christensen, 2008; Smith and Chris-
tensen, 2007) involving Clayton Christensen who 
introduced the idea of disruptive innovation into 
business management analysis in the early 2000s. 
In total, 10 papers discussed disruptive innovation. 
The majority of these papers did this in the context 
of health systems in the global North. Two papers 
(Dandonoli, 2013; Sinha and Barry, 2011) dis-
cussed disruption in the context of global health. 
All the papers highlight the possibility of a set of 
innovations – some technological, some social – 
that could change – disrupt – the way healthcare is 
delivered. These range from the use of open inno-
vation to cheaper technologies (such as the idea of 
a low cost ‘lab on a stick’) or social innovations that 
link to how doctors are deployed or care services 
are delivered. 
3 Knowledge, learning and research
A further set of 11 papers looked at the relation-
ship between knowledge and learning in the fields 
of research and innovation. Often, this work was 
influenced by thinking from within the knowledge 
management field. As such, these papers are related 
at times to a broader discussion within the global 
health community on knowledge exchange, knowl-
edge translation and knowledge brokering (see 
“Bridging the Know–Do Gap in Global Health” 
(2004) for an example of this literature). Much of 
the work in the literature search was focused on 
the high income country context and in all cases 
the emphasis was on how networks and collabo-
rative exchange are necessary to enable the more 
difficult-to-access-knowledge that is harder to learn 
and transfer (tacit knowledge, learning by doing). 
One paper (Green, 2010) specifically talked about 
‘systems level learning’ but the others implied the 
importance of organisational and systems related 
social innovation for ensuring successful techno-
logical development and the building of stronger 
health systems. Two of these papers (Walshe and 
Davies, 2013; Nwaka et al, 2012) discuss the im-
portance of knowledge exchange and learning from 
the context of arguments on the benefits of scien-
tific research. This relates to a set of arguments – 
much wider than expressed in this literature review 
– on the role of health research for improved inno-
vation and strengthened health systems (as outlined 
in Chapter 2).
4 Innovation studies references
Even though this literature review only focused on 
journals that are associated with either public health 
or health policy, there is still a sizeable discussion 
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of innovation studies thinking in this material, and 
some thinking on systems type perspectives – often 
through implicit discussions of social innovations. 
Most of this refers to Roger’s diffusion theory or 
Christensen’s idea of disruptive innovation. How-
ever, another set of papers is linked to the health 
innovation system literature earlier described, while 
a fourth is influenced by the work in the health sys-
tems field on complex adaptive systems thinking.
 
The findings of the literature review highlight that 
the disconnects between the two fields of health 
and innovation can be, and are being, broken 
down. However, the pull of technological innova-
tion to remain the major focus of many of these pa-
pers remains strong. Even at the height of interest 
in the health innovation system ideas, one of the 
papers reviewed (Morel et al, 2005a), in their dis-
cussion of health innovation systems, justify their 
paper by referring to the need for the formation of 
an Initiative for Health Product Innovation in low 
and middle income countries (our emphasis). 
Summing up
This report focuses on the importance of using a 
broader definition of health innovation, which rec-
ognises not just technological product innovation 
but also social innovation. Specifically, it stresses 
the importance of social innovation as a necessary 
determinant of successful technological product 
innovation. Such social innovations form part of 
any health innovation system as they have been de-
scribed in the literature to date. 
However, despite the increasing recognition of 
the importance of systems thinking in the health 
policy field (see Chapter 2) or the efforts of schol-
ars who straddled the health and innovation fields 
(this Chapter), the emphasis of much policy and 
practice - indeed of much intellectual debate, too 
- is still heavily focused on technological prod-
uct innovation.
The continued dominant focus on innovation 
only in terms of technological product innovation 
reduces the ability to consider innovation – social 
innovation in particular – with regards to health 
systems strengthening and efforts towards univer-
sal healthcare coverage. However, issues such as 
universal health coverage or improved financing 
for healthcare, which are increasingly recognised 
as also key for health systems strengthening, re-
quire not only technical solutions but also innova-
tive institutional and organisational solutions; so-
lutions that work to build system level strengths. 
The next Chapter, hence, outlines an approach 
that provides a means of investigating innovation 
at a health systems level.
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4. Moving health systems strengthening forward:  
lessons from innovation systems thinking
Key points:
1 The building blocks of the health system need 
‘cement’ to bind them together; social innova-
tion provides this ‘cement’ through the crea-
tion of system building competences
2 Centrally important are knowledge (and poli-
tics) flows as determinants of systems strength-
ening
3 Active government and regulatory support for 
systems strengthening are important to ensure 
a facilitatory enabling environment whereby 
knowledge flows are promoted and politics 
flows are positive rather than negative in nature
4 Such an approach moves away from ideas of 
‘healthcare systems’ to the idea of ‘innovative 
health and wellbeing systems’ for sustainable 
economic and social development
Chapters 2 and 3 have outlined the current state 
of thinking on health, innovation and health sys-
tems strengthening from the viewpoint of health 
policy, innovation systems and allied researchers 
and practitioners to both of these fields. Spe-
cifically, the two Chapters highlighted how the 
discourse around these three concepts and their 
interconnections is often heavily focused on the 
starting point of technological product innova-
tion. This is sometimes a very explicit focus as 
evidenced by the selective primary healthcare de-
bates of the 1970s and 1980s or the more recent 
focus on global health partnerships to tackle the 
big three diseases of HIV/AIDS, TB and Malaria. 
Both of these debates focused on the role of drugs, 
vaccines and diagnostics in providing solutions to 
a nation’s health problems. Alternatively, the dis-
course has focused more implicitly on technologi-
cal innovation such as in the debates on health 
innovation systems in the early and mid-2000s 
and health systems strengthening more recently. 
While these have emphasised the need for wider 
approaches to the policy and practice landscape 
and the need for less siloed thinking, they are 
often still dominated by a narrow definition of 
good health as being absence of illness and dis-
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ease, which may accentuate technological solu-
tions over socially based ones.
These Chapters have, therefore, highlighted the 
need to start from a wider definition of health in-
novation; one that encompasses different forms of 
both technological innovation and social innova-
tion. It has also placed this within the context of 
the need for a wider definition of health so that 
discussions can move beyond only curing illness 
and disease and look at wider concepts of well-
being in the context of equitable and sustainable 
economic and social development. 
As noted, there have been attempts to move be-
yond the siloed and narrow approaches and to en-
courage a more joined-up discourse. This includes 
the efforts of those who have advocated health 
systems strengthening and the need for increased 
health systems and policy research. It also includes 
those who have advocated for health innovation 
systems approaches at a policy level; including 
those from within the innovation systems commu-
nity. However, discourses are heavily entrenched in 
these more narrow understandings of health, and 
focus predominately on technological innovation. 
Thus, a question to be asked is: 
Can innovation systems thinking provide any 
alternative ways of thinking about health sys-
tems strengthening that can allow policy and 
practice to effectively move beyond silos and 
disconnects towards wider understandings of 
health and innovation, so that systems become 
more functional and sustainable? We would ar-
gue that the answer is: ‘yes’. 
Four relevant elements of innovation 
systems thinking – the 4Fs
We would argue that there are four ways in which 
arguments from innovation systems thinking can 
assist in moving arguments forward in the field of 
health systems strengthening. These offer a poten-
tial lens through which to analyse health systems in 
order to find appropriate solutions to truly make 
health systems in low and middle income countries 
strong. We call them the ‘4Fs’ of function, form, 
field and flows.
The first element of innovation systems thinking 
that can assist efforts to conceptually understand 
and practically analyse health systems strengthening 
is the philosophy of ‘inclusive development’, which 
is the starting point of most innovation systems 
thinking focused on low and middle income coun-
tries. Taking ‘inclusive development’ as the end goal 
of any development effort moves the debate beyond 
a narrow focus on good health. It puts sectoral is-
sues into a wider perspective and ensures a focus on 
equity across all discussions. 
In being the starting point for all discussions 
within innovation systems thinking for low and 
middle income countries, the notion of ‘inclu-
sive development’ becomes the ultimate goal of in-
novation efforts in these contexts. As such, sectoral 
issues are channeled into meeting this goal and not 
simply meeting their own individual goals or the 
goals of individual profit making firms. Thus there 
is a need to recognise the wider function of health 
systems. Taking this one step further, when con-
sidering a wider set of functions, moves debates on 
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health systems towards thinking even more widely 
to ‘health and wellbeing systems’ and how these lev-
erage improved economic and social development 
in the country.
The second element of innovation systems think-
ing is its recognition of the multiple actors involved 
in technological and social innovation. Specifically, 
this thinking highlights how the form that health 
and wellbeing systems take is determined by the 
actors involved; who they are and how they inter-
act and collaborate. In other words, the forms of 
organisations that are created. This thinking does 
not only focus on private sector actors or on firms, 
although a lot of the literature has focused on this 
level. Innovation systems thinking recognises the 
multitude of actors who influence innovation ac-
tivities, including the role of users, the role of the 
state and the role of private not-for-profit actors.
The third element of innovation systems think-
ing that is useful here is the recognition of markets 
and other institutions as determining the field in 
which any activity takes place. Particularly useful 
here are arguments that have been made which rec-
ognise that efforts to promote strengthened health 
systems often follow the logic of industrial activity, 
to paraphrase Gadelha et al. (2013). This resonates 
with a set of arguments already well known within 
the health policy field which argues that the health 
systems of many countries is becoming increasingly 
monetarised and commodified (c.f. Mackintosh 
and Koivusalo, 2005). That said, innovation sys-
tems thinking also recognises that while the market 
institution is important, a range of other institu-
tions, particularly the state and regulatory authori-
ties, are also responsible for determining the success 
or otherwise of the systems actors in the efforts.
A final, and perhaps the most relevant, element 
of innovation systems thinking for these discussions 
on health systems strengthening is the way in which 
the origins or creation of systems is conceptualised. 
It enables, thinking around what facilitates the abil-
ity of form and field to work towards the function 
of a health and wellbeing system and a country’s 
development goals. Innovation systems thinking 
fundamentally emphasises the importance of ‘sys-
tem making connections’ (Chataway et al., 2009; 
Metcalfe and Ramlogan, 2005), through many 
forms of social innovation, and the role of learn-
ing and knowledge flows in this. Others argue that 
these connections and flows create a ‘learning cul-
ture’ within organisations and within the system as 
a whole in order for the functional goals to be met 
(Johnson et al., 2003). 
Innovation systems thinking has been critiqued 
in the past (Dodgson et al., 2011 an overview of 
these critiques) for being very macro-level in fo-
cus. As such, it has been critiqued for not recog-
nising the inherent politics and power that sur-
round the micro-level processes of technological 
change (Weber, 2002). These originate in actors 
(field) and institutions (form) and are manifested 
through the knowledge and learning flows that 
are promoted, supported - or neglected. However, 
there is a body of literature that tackles this di-
rectly (c.f. Srinivas, 2012; Cozzens and Kaplinsky, 
2009; Papaioannou, 2014) and which is a neces-
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Health as a means 
to economic 
growth 
Health as a means to 
achieve social develop-
ment and reduction of 
inequality 
→ Health as an integrated element of 
and contributing factor to economic 
and social development built on equity 
and inclusion
Health as absence of 
disease
Health as wellbeing → Health as wellbeing
Firms and private 
sector as drivers
Role of other actors, espe-
cially state
→ Complex network of actors
Supply driven Demand driven → Problem driven
Knowledge as STI Knowledge as DUI → Multiple flows of knowledge and power 
(STI and DUI)
Health innovation as 
new products
Social innovation is key → Multiple types of innovation and combina-
tions of innovations required
Table 1 Health policy discussions and development: From two overarching opposing  
approaches to an integrative alternative
Source: Authors
sary addition to ensure that the type, strength and 
direction of flows is best understood. Such flows 
determine the strength of the system making con-
nections and degree and nature of knowledge ex-
change and learning that takes place.
The 4F’s as a lens for conceptualising 
strengthened health and wellbeing systems
Taking these 4Fs of function, form, field and flows 
together and using them as a lens for analysing 
the situation of current health systems in low and 
middle income countries provides a way of iden-
tifying where to focus policy; especially in order 
to strengthen existing, and stimulate new, knowl-
edge, learning (and positive politics) flows to sup-
port technological, but also and most importantly, 
social innovation, particularly of the organisation-
al kind. This provides the ‘cement’ around which 
different elements – or ‘building blocks’ to use the 
WHO term – of the health and well-being system 
are created and promoted and ensure that they re-
main strong. 
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Figure 5 The 4Fs and their interlinkages
Form
Nature and patterns of organ-
isations in the health field.
Field
Institutions, understood as 
norms, laws, culture and rules 
of the game + state, regulating 
authorities and international 
donors/foundations influenc-
ing rules of the game.
Flows
Mediating the three ele-
ments, includes knowl-
edge and power flows.
Function
Demands and out-
comes including 
competences, health 
outcomes and social 
and economic dev.
Source: Authors
Utilising the 4Fs as an analytical lens provides a 
means to move beyond the often-dichotomous 
debates outlined in the first two columns of Ta-
ble 1 and focus on the last column’s wider defi-
nitions of health and innovation; the complex 
and multiple connections, actors and institutions 
that are needed to create an innovative health and 
wellbeing system. 
Thinking further on each of the 4Fs
Figure 5 provides a graphical representation of the 
4Fs and their interlinkages. Below, we provide a 
further introduction to each of the 4Fs from an in-
novation systems perspective. We focus specifically 
here at the national level as the lens of analysis in 
which to use the 4Fs. However, this does not pre-
clude from recognising that form, field or flows 
maybe tied to other levels and beyond national 
boundaries. While, technically, a health and wellbe-
ing system may exist at the community level, na-
tional level, regional level or international level, tak-
ing the national system as the starting point is key 
from a policy perspective. National governments 
are responsible for their citizens’ health and wellbe-
ing and for the economic and social development 
of the country. It is therefore at this level that the 
outcomes – the functions – of the system are best 
set. Even in situations where there is a devolved sys-
tem of government (as in the case of Kenya below), 
national government still sets the agenda.
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The function of health and wellbeing systems
The health problems facing the world are chang-
ing. Most notably, the rise of non-communicable 
diseases around the world is putting further stress 
on health systems in low and middle income coun-
tries that were already stretched trying to manage 
the infectious diseases and basic primary care ser-
vices. There is also greater awareness of the linkage 
between health and social development – the need 
for good infrastructure (transport systems), hous-
ing, education and employment. The latter is espe-
cially important, both to ensure that people do not 
become sick in the first place or can afford health-
care when they first need it, but also to ensure that 
stronger and healthier individuals aid/help in en-
suring the continued functioning of infrastructure, 
housing, education etc.
Innovation is increasingly seen as a means not 
only towards economic development but also to 
health and social development. Innovation in this 
context isn’t simply the production and delivery of 
new technological combinations but is also about 
innovation at a systemic level – the knowledge 
flows that create sustainability and ensure the sys-
tem remains ‘alive’. That being said, the core issue 
of interest is, ultimately, better health outcomes 
and inclusive economic and social development 
– the focus of attention and the ultimate aims 
of most activities in the health field. This implies 
taking a normative approach to development in 
which innovative activity in all spheres of activity 
is regarded as a necessary condition for develop-
ment.1  Thus, the function of the system is two-
fold: better health outcomes and; economic and 
social development.
Focusing on function in this way places an 
emphasis on ensuring a demand driven system 
rather than a supply driven one. The system must 
function to meet the needs of its customers, i.e. a 
country’s citizens. Specifically, taking heed of the 
need to focus on outcomes, the idea of the 4Fs 
was developed in the spirit of the chain-linked 
model of innovation (Kline and Rosenberg, 1986) 
although still within a systems framework. In the 
chain-linked model of innovation, it is argued that 
market demand is the driver. Here we are defining 
the market in a very broad sense. In this context, 
for example, states effectively act as important 
drivers of demand, e.g. through public procure-
ment of medicine and services for the sick, for 
children and the elderly. 
The function of the system is the main driver of 
the system, although this doesn’t mean the other 
elements are powerless. However, by focusing on 
function, it places an emphasis on demand instead 
of only focusing on the supply side as much in-
novation and health research and practice does. It 
acknowledges the role of users and their many dif-
ferent ‘faces’ in the ‘market’.
1 We note that innovation doesn’t always have a posi-
tive outcome or is used in a positive manner. This 
does not preclude the need to continue to promote 
innovation for the positive outcomes it can create. 
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The form of a health and wellbeing system
In this way, form follows function. Form refers to 
what some have called ‘patterns of organisations’ 
(McKelvey, 1982 cited in Rindava and Kotha, 
2001) or what others talk of as the spectrum be-
tween markets and hierarchies (Williamson, 1975; 
Rindava and Kotha, 2001). Form refers to the or-
ganisations that are involved in different aspects of a 
health and well-being system. As such, this is about 
how healthcare and prevention is managed and 
provided and about the different actors involved in 
this process. It refers to the order of these organisa-
tions and the interactions between them. 
Notably, it is about user-producer relations 
(Lundvall, 1985). In the innovation literature – 
and in the organisational management and eco-
nomics literature – the focus has been mainly 
on firms, their interaction with others and how 
this affects firm performance. The innovation lit-
erature on user-producer relations is focused on 
the importance of the right kind of connections 
between firms and their customers. Specifically, 
work on the innovation performance of firms in 
the late 1980s, which appears to hold true today, 
suggests that vertical integration and hierarchy be-
tween a lead firm and a single professional user is 
not always the most beneficial; the “user who inte-
grates with one specific producer excludes himself 
from access to interactive learning with the other 
producers” (Lundvall, 2016). 
It is partly for this reason that the notion of a 
health economic industrial complex (Gadelha 
et al., 2013) has been proposed. It is argued that 
this enables actors to move beyond the tensions 
“between economic and public health logics” be-
cause it recognises that healthcare services follow 
the “logic typical of industrial activity” (Gadelha et 
al., 2008) just as much as the production of drugs 
and vaccines does. Gadelha et al. (2013) argue that 
there is a need within this system for a ‘structuring 
entity’ to ensure all actors in the various sub-sectors 
of the complex function as required. They argue 
that the state must play a key role here as both 
healthcare provider, consumer, resource provider 
and regulator. 
However, it is not only about describing the re-
lationship between firms, public research organisa-
tions, ministries and other relevant organisations. It 
is also about rethinking them in terms of ‘problem 
solving organisations’ (Cozzens, 2010). Thus, Coz-
zens (2010) argues that instead of thinking about 
‘firms’, we need to think about ‘problem solving 
organisations’. Instead of thinking about ‘research 
organisations’, we need to think in terms of ‘knowl-
edge and information organisations’. Government’s 
role should be focused on governance and provid-
ing the right enabling environment. The result of 
which is embedded learning across society leading 
not only to better health but a stronger economy 
and potentially improved social cohesion. 
The field of a health and wellbeing system
Problem solving organisations (form) and the 
problems they are working to solve (function) are 
impacted by the field. This essentially equates to 
institutions when defined in terms of norms, laws, 
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culture, rules of the game a la North (1990). How-
ever, it also includes organisations such as the state, 
regulatory authorities and even, in the world of 
global health, international donors who often ‘set 
the stage’ and define the rules of the game.
One key institution is the market. We have seen 
that discussions of health innovation are often fo-
cused on the development of technologies – new 
or improved vaccines, diagnostics and drugs. The 
argument would, traditionally, be that there is a 
case of ‘market failure’ whereby private sector firms 
are unable or unwilling to become involved in the 
market for health products. This argument is short-
sighted for two reasons. First, market relations are 
embedded in the whole of the healthcare system 
leading some to argue that healthcare is becoming 
‘commodified’ and ‘marketised’ (Mackintosh and 
Koivusalo, 2005). One of the arguments for this ac-
count of the current state of healthcare is that so 
much spending, especially in low and middle in-
come countries, is done by individuals as out-of-
pocket expenditure. However, in general, at a range 
of scales, health systems around the world are seeing 
numerous different exchange agreements in place 
that are based on someone ‘buying’ a commodity 
from someone ‘selling’ it; you have multiple layers 
of consumers – the patient, the doctor, the pharma-
cist, the medical supplier, the state, the pharmaceu-
tical company. 
A second major institution is the nation state 
and related regulatory mechanisms that are crucial 
because they set (national) standards and approval 
procedures for new products and processes and 
their use in society. National governance of health 
issues vary considerably and is influenced largely by 
the political culture, leadership and visions in spe-
cific countries – including for example the percep-
tion of the importance of inclusive solutions and 
the extent to which healthcare is seen as a private 
responsibility versus a state responsibility (or a mix). 
Flows
Mediating these three elements are the flows be-
tween them, notably knowledge flows creating 
learning cultures and learning organisations, but 
also power flows. Form and field can most effec-
tively ensure that the system functions or meets its 
goals if there are sufficient, and the right sort of, 
knowledge and learning flowing within the system 
supported by positive (as opposed to negative) pow-
er flows. 
There are three parts to knowledge and learning 
flows:
1 Creation of knowledge and learning – this re-
lates to competence building. This is more than 
just the creation and distribution of knowledge 
through formal and informal training and edu-
cation but more importantly the ‘doing, using 
and interacting’ (Jensen et al., 2007) of everyday 
experiential learning. As such, knowledge can be 
codified or tacit, it can be taught and transferred 
easily or it can only be learnt through appren-
ticeship and doing, using and interacting. The 
absorptive capabilities among individuals and in 
problem solving organisations and agencies to 
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be able to take up, utilise or transform knowl-
edge are vital. They decide to a large extent how 
well new knowledge and innovations are taken 
up and their ability to contribute to better health 
and wellbeing outcomes.
2 Implementation of knowledge and learning – 
Knowledge and learning need to be promoted 
and utilised correctly. Any system should be 
more than the sum of its parts. What makes it 
more than the sum of its parts are the connec-
tions between the parts, but also knowing what 
connections are important and how to tap into 
the flows between those connections (Cohen 
and Levinthal, 1990). Key to successful in-
novation – of any type – is the learning and 
knowledge flows between parts of the system 
and recognition by actors that such knowledge 
is important.
3 System building connections – These relations 
make for an evolutionary and dynamic system 
where there is no equilibrium; the system is con-
stantly evolving, creating winners but also losers. 
Thus, the issue is how to make the system func-
tion so that it becomes as equitable as possible 
through a focus on ‘system making connections’ 
(Chataway et al., 2007). This is important not 
least because of the continuous changes in the 
challenges experienced within the health field. 
Power also flows through the system. While origi-
nating in the field and form of the system, this is 
linked to the promotion, creation and utilisation of 
knowledge and learning. With these comes ‘bias’ – 
through action or non-action - which needs to be 
mobilised effectively (Bachrach and Baratz, 1962). 
Flows of power come with flows of knowledge. Key 
to ensuring the mobilisation of bias is the building 
of competences. Thus, it’s not knowledge per se that 
keeps systems functioning but actually the creation 
of absorptive capacity – the knowledge of how to 
take up knowledge, utilise and adapt it – across the 
system through ensuring that training and educa-
tion are included. The absorptive capacity is essen-
tial for the take-up of new inventions and for inven-
tions to become real-life innovations. For instance, 
increased knowledge about neurological issues and 
child development do no good unless actors in the 
wider system (ranging from parents over profes-
sional care takers to school teachers, psychologists 
and those working to improve the motoric of chil-
dren, for instance) are able to take up this knowl-
edge and use it in interaction with the children that 
they are responsible for.
Power in this way is not a social institution as per 
Bourdieu but has a much more complex role to 
play a la Foucault in that it is “diffuse rather than 
concentrated, embodied and enacted rather than 
possessed, discursive rather than purely coercive, 
and constitutes agents rather than being deployed 
by them” (Gaventa, 2003: 1) (Powercube, n.d.).
The important role that knowledge (and power) 
flows have on determining the success of a health 
and wellbeing system therefore suggests that what 
we need to build are not ‘health and wellbeing sys-
tems’, perhaps, but ‘competence building systems 
in the area of health and wellbeing’. Without such 
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systems, there will be little or no change of sustain-
ability in the system. That said, sustainability does 
not come from a stable system but a dynamic sys-
tem where each part is able to adapt and change to 
new situations; incorporating new knowledge and 
learning where and when needed. This requires the 
right set of competences. To build these, organisa-
tional change, supportive institutions and the right 
knowledge and power flows are required. 
Sustainability – understood as the ability of the 
system to continue to change and adapt to new sit-
uations – is necessary if the outcomes of the system 
are to be met for the long term. In this regard, com-
petence-building systems provide an opportunity 
for social and economic development to prevail.
Thus, the 4F lens, by moving beyond the dis-
connects between health and innovation and re-
search or institutions and organisations enables us 
to ask different questions when analysing existing 
health and innovation system policies (please see 
overleaf ). The questions focus on competence 
building across all the elements rather than simply 
on the need to build competences in health in-
novation that is only equated to the production of 
health technologies. This wider focus of analysis 
is essential for the building of stronger health and 
wellbeing systems.
Utilising the 4F lens to consider 
current health systems
As an example of the potential of the 4F lens we 
have conducted a review of two national health sys-
tems (Kenya and India) using the 4Fs as a means 
of delineating different elements of activities go-
ing on within the system. Each country case starts 
with a brief introduction to the country context 
and is followed by a very brief overview of the key 
components and issues affecting health related ac-
tivities in India and Kenya. The two countries have 
varying levels of maternal and child morbidity and 
mortality and are therefore at different stages in 
terms of progress towards meeting the SDG 3 on 
health. Both countries are classified as lower mid-
dle income by the World Bank. We focused specifi-
cally on Kenya and India because they are both still 
considered lower middle income countries, have a 
semblance of what anyone would easily recognise 
as a ‘health system’ in place and have an established 
local manufacturing sector involved in production 
of products for the health sector. 
The details on each country are based on a re-
view of key literature conducted for this report. 
The literature review was not comprehensive and 
therefore it is possible that the discussion below 
misses out nuances to the debates and situation 
facing each countries’ health and innovation ac-
tors. However, the review is not meant to be 
comprehensive at this point (further research is 
needed), instead, it aims to provide a preliminary 
idea of how this analytical framework might be 
used to review existing health and innovation 
systems policies. 
The two case studies are presented below, one im-
mediately after the other. A discussion of the issues 
raised by reviewing the health systems through the 
4Fs takes place after these case studies are presented. 
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On function
• What are the needs of users – what are the health issues and the eco-
nomic and social development issues that affect users?
• What are the system making connections that will build the compe-
tences needed to address both these health and development issues?
On form
• What are the problem solving organisations that are needed?
• How do these problem-solving organisations act as producers to meet 
user needs, through what organisations, and in what combinations 
(as formal or informal networks, collaborations or partnerships)?
On field
• What does the institutional landscape look like?
• In particular, what does governance within the system look like? So:
• What is the role of the state as provider and consumer? What of 
other providers and actors?
• Is regulation (including intellectual property rights) hindering or 
assisting form to follow function? 
• What is the role of policies from the state and/or other actors in 
the system?
On flows
• What knowledge flows through the system and how does it flow 
through?
• Is there a learning culture within the system?
• What are the power and politics that flow through the system? Does 
it hinder or support the creation of a learning culture?
• How do these flows influence implementation of health policies? 
How do they shape outcomes?
Key questions originating from utilisation of the 4F lens
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Reviewing India’s system of 
universal health coverage
India has significantly reduced the number of peo-
ple living on less than a US dollar a day; by 56% 
(UNICEF, 2016). It also made significant progress 
towards meeting the MDGs. But challenges re-
main. Notably, it is increasingly having to deal with 
heart disease and strokes - now the leading causes 
of death, while cardiovascular disease is the second 
highest cause-of-disease burden (WHO, January 
2015). Figure 6 outlines some key statistics relating 
to the health of India’s population.
In recent years, in efforts to meet the 2015 
MDGs on health, India introduced a universal 
health coverage scheme specifically for states with 
high disease burden. This provides increased clinic 
coverage and community health options (through 
traditional birth attendants and community mo-
bilisers) and has done much to reduce mortality. 
But the focus has been predominately on doing 
what was needed to bring mortality down. Even 
then, there are still considerable problems related 
to poorly equipped or trained staff, low motivation 
of staff, and lack of trained staff. 
In trying to understand why this is the situation, 
the relative emphasis placed on each of the 4Fs by 
policy makers needs to be analysed. The analy-
sis below makes it clear that the starting point of 
recent health and more general country level eco-
nomic and development social policy has been a 
Figure 6 A snapshot of India’s health
Various health related world development indicators Latest figures (year in brackets)
Life expectancy at birth, total (years) 68 (2014)
Under-5 mortality rate (per 1,000 live births) 48 (2015)
Maternal mortality ratio (modelled estimate, per 100,000 live births) 174 (2015)
Health expenditure per capita, current US$ 75 (2014)
Hospital beds per 1,000 people 0.7 (2011)
Nurses and midwives per 1,000 people 1.7 (2011)
Physicians per 1,000 people 0.7 (2012)
Source: World Bank database; http://databank.worldbank.org/ (accessed 07/08/16). 
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focus on function and form at the expense of flows 
and field. By implication, future policies and inter-
ventions would need to consider issues related to 
flows and field more, in order to generate a more 
balanced and effective set of interventions in terms 
of ensuring better health outcomes and well-being 
in India.
Function 
India developed a draft National Health Policy 
in 2015 which focused on provision of univer-
sal healthcare. Leading up to the development of 
this policy has been an increasing focus on uni-
versal health coverage (UHC) and the removal of 
rural-urban divides in healthcare through the crea-
tion in 2005 of the National Rural Health Mission 
(NRHM), which provided increased support to ru-
ral states that suffered the highest disease burdens.
India’s economic development path has, tra-
ditionally, been focused through a series of five-
year plans. In 2015, the government replaced the 
Planning Commission with the National Institu-
tion for Transforming India (or NITI Aayog). Its 
role is to design forward-looking plans for India’s 
economic and social development, particularly 
relating to achievement of the SDGs. That said, 
the draft national health policy does recognise the 
two-way linkage between economic growth and 
improved health.
Form: context and institutions
The NRHM has been implemented through three 
major initiatives plus a series of additional activi-
ties (for a good overview, see Patel et al., 2015). 
There were three major initiatives. The first was a 
conditional cash transfer scheme whereby pregnant 
mothers receive a cash payment (to help pay for the 
delivery) in return for attending a public health in-
stitution to give birth. The second major initiative 
revolved around increased community involvement 
in health service provision through the support of 
village health and sanitation committees and train-
ing and support of an accredited social health ac-
tivist (ASHA). The ASHAs, in particular, are seen 
as the link between the community and the health 
services; providing the community, particularly 
pregnant women and new mothers, with health 
advice and support. The third initiative has been 
more recent and sees the introduction of free basic 
hospital services to vulnerable groups through the 
introduction of a health insurance scheme. Along-
side this third initiative, the National Rural Health 
Mission has been renamed the National Health 
Mission with a widening of its mandate to cover 
also urban India. 
Field
The introduction of the NRHM and, more recent-
ly, efforts towards universal health coverage through 
a government health insurance scheme grew out of 
calls to reduce the rural-urban health divides and to 
reduce in general the levels of maternal, neonatal 
and child mortality and morbidity in the world’s 
second most populous country. The NRHM was 
the result of efforts by a new government in 2005. 
More recently, efforts to increase universal access 
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have been the result of high profile efforts, includ-
ing a series of high profile papers in The Lancet on 
universal health coverage in India culminating in a 
call for action (Reddy et al., 2011). 
Efforts to implement healthcare activities in In-
dia are helped, and hindered, by a variety of institu-
tional arrangements. A review of the literature high-
lighted the following issues (which do not make up 
an exhaustive or necessarily authoritative list but 
rather an illustrative one):
A Commentators have remarked on the role of 
public services and the difficulties they face, 
including inefficiency and lack of accountabil-
ity further hindered by the distance and size of 
populations and states. While devolved service 
provision has improved this situation, the lat-
est healthcare reforms are unable to address 
structural inefficiencies in the wider system 
(Singh, 2008) with the existence of a big gap 
between the expectations that came with de-
volved healthcare and the reality on the ground 
(Seshadri et al., 2015). 
B Others have remarked on the over-reliance on 
and the strength of private healthcare provid-
ers (Bali and Ramesh, 2015; ) and, linked to 
this, the development of a strong indigenous 
pharmaceutical sector in India (Kale and Little, 
2007) and the strength of business-based lobby 
groups (Papaioannou et al., 2016). 
C Similarly important, though, have been patient 
lobby groups (Ebrahim et al., 2013) and inter-
national debates on the governance of health and 
the need for universal health coverage within the 
context of health systems strengthening (Reddy 
et al., 2011; Patel et al., 2015).
Flows
Human resources for health are acknowledged as 
being key to the functioning of a health system 
(Lancet, 2008 and 2016; WHO, 2006) and an 
innovation system (Castellacci and Natera, 2013). 
They have also been acknowledged as a critical fac-
tor in the difficulties currently facing India’s health 
system; specifically the sheer numbers required in 
such a populous country (even when admission 
rates to training institutions are at record levels) 
and their uneven distribution (Patel et al., 2015). 
Debates and resulting power flows at an institu-
tional level outlined above have affected knowledge 
flows in terms of decisions taken with regards to 
the numbers and type of human, technical and fi-
nancial resources available for the Indian health and 
wellbeing system.
Kenya’s efforts to improve the quality 
of, and access to, healthcare
HIV/AIDS is the single largest cause of death in 
Kenya (14%) followed by predominately child-
hood diseases (ARI, diarrheal disease, malnutri-
tion and birth complications) (WHO, 2015b). 
Figure 7 provides an overview of some of the data 
on Kenya’s health system. 
Kenya is similar to India in its movement in re-
cent years towards achieving universal health cover-
age. In recent years, the government has reformed 
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Various health related world development indicators Latest figures (year in brackets)
Life expectancy at birth, total (years) 64 (2014)
Under-5 mortality rate (per 1,000 live births) 49 (2015)
Maternal mortality ratio (modelled estimate, per 100,000 live births) 510 (2015)
Health expenditure per capita, current US$ 78 (2014)
Hospital beds per 1,000 people 1.4 (2011)
Nurses and midwives per 1,000 people 0.9 (2011)
Physicians per 1,000 people 0.2 (2012)
Figure 7 A snapshot of Kenya’s health
Source: World Bank database; http://databank.worldbank.org/ (accessed 07/08/16). 
its National Health Insurance Fund (NHIF) which 
has been in operation since 1966. However, the 
scheme and healthcare services in general suffer 
from a series of constraints due to lack of resources 
as well as the growing dominance of a private sector 
that is difficult to regulate. 
The analysis of the function, form, flows and 
field of health issues in Kenya undertaken below 
reveals that the situation in Kenya is less clear cut 
than the Indian situation due to multiple players 
influencing the field which, together with the re-
source shortages (human, material and financial), 
impact on the flows of knowledge and politics 
within the system. This has implications for future 
directions and policies.
Function
The right to health was enshrined in Kenya’s 2010 
constitution, which states that every citizen is enti-
tled “to the highest attainable standard of health”. 
The relationship between health and economic 
and social development has been acknowledged in 
Kenya’s development strategy, Vision 2030. In this 
strategy, the country is tasked with strengthening 
social dimensions of society as well as the econom-
ic and political dimensions to improve quality of 
life and move the country out of poverty. It out-
lines science, technology and innovation as one of 
a number of enablers towards achieving the differ-
ent elements of the economic, social and political 
pillars or dimensions of society. 
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More recently, the Kenya Health Policy 2014–
2030, gives overall direction to health officials in 
the country to meet the requirements of the con-
stitution, Vision 2030 and ’global commitments’ 
(GoK, 2014). The key objectives of the health 
policy are to: Eliminate communicable condi-
tions; Halt and reverse the rising burden of non-
communicable conditions; Reduce the burden of 
violence and injuries; Provide essential healthcare; 
Minimise exposure to health risk factors and; 
Strengthen collaboration with private and other 
health related sectors.
Form
There have been two major activities that have re-
defined health services in Kenya in recent years 
as the country aims to meet the various develop-
mental and health objectives that the government 
and global leaders have set. As Obare et al. (2014) 
write, “[t]he most significant strategies in relation 
to UHC are the two attempts to transform the 
country’s NHIF into a compulsory social health 
insurance. The objective of these proposed amend-
ments was to shift the current health financing ar-
rangements to prepayment mechanisms, reducing 
the dependence on out of pocket payment and mo-
bilising more funds into the health sector through 
membership contributions.” 
The NHIF scheme offers outpatient services to 
all those enrolled. Every employer is mandated to 
enroll their employees into the Fund. However, 
public health facilities covered by the scheme are 
frequently affected by human resource constraints 
(strikes, walk-outs and lack of trained staff) and 
supply side challenges (stock-outs of essential drugs 
and materials). 
Furthermore, the majority (two-thirds) of the 
health facilities that are enrolled with NHIF are pri-
vate (http://www.jointlearningnetwork.org/news/
the-road-to-universal-health-coverage-in-kenya-a-
peek-at-key-nhif-reforms-t). Private health facilities 
are the dominant source of medical treatment for 
Kenyans and significant out-of-pocket expenditure 
is still required. A 2014 report (Private Sector In-
novation Programme for Health (PSP4H), 2014) 
found that the private sector provided 53% of 
health services in Kenya, the use of private insur-
ance firms (particularly for those with higher in-
comes) and multiple problems with regulation of 
the sector. Out-of-pocket expenditure on health is 
currently estimated at 26% of household expendi-
ture (GoK, 2013).
Kenya’s health research and innovation system 
is characterised by a multitude of actors from the 
public, private and not-for-profit sectors as well as 
a rising number of public-private partnerships and 
significant donor engagement. The country has a 
burgeoning indigenous pharmaceutical sector (Ka-
riuki et al., 2015) and some research institutes with 
an increasingly international reputation for con-
ducting high quality health research (Whitworth et 
al., 2008). 
Field
The health and innovation sectors are heavily politi-
cised in Kenya. Health was an election issue in 2013 
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with the current President’s campaign manifesto 
pledging universal access to free treatment (Green, 
2013). It has since been further complicated by 
devolution. While decentralisation has often been 
argued (see Nyikuri et al., 2015) to provide oppor-
tunities for enhanced primary healthcare services as 
a result of service provision becoming the responsi-
bility of local government authorities (county gov-
ernments in the case of Kenya), the case in Kenya 
has been mixed. The Kenyan Health Sector Ser-
vices Fund (HSSF) (supported by GoK, Danida 
and World Bank), which is the funding mechanism 
through which money is transferred to local com-
munities for health services following devolution, 
has been heralded as a case study of success by those 
campaigning for Universal Health Coverage (Ra-
mana et al., 2013). However, a more recent study 
of the impact of devolution on primary healthcare 
in Kenya (Nyikuri et al., 2015) found that success 
was much more dependent on the leadership ca-
pabilities of individuals, notably their soft skills in 
relationship building. 
The fight between different policy sectors for a 
portion of the government’s budget also affects the 
Kenyan health system. The latest figures published 
by the Kenyan government (GoK, 2012) show that 
the health sector received just 6.1% of government 
budget. This is much less than the 15% commit-
ment that the government made in 2001 when it 
signed the Abuja Declaration on Health (Green, 
2013).
The institutional landscape in Kenya’s health 
sphere during 2013/14 was dominated by a Health 
Sector Wide Approach programme (SWAp) which 
ensured coordination of all stakeholders through 
a single programme. With the creation of a new 
health policy, the SWAp is being replaced from 
2013 by a Health Sector Intergovernmental Con-
sultative Forum (HSICF) with funding channelled 
through two basket funds, the HSSF and a similar 
fund for essential medicines. 
Flows
Much of the discussion in the literature has focused 
on the shortage of health workers and quality of 
training of healthcare workers. The exception to 
this has been two papers that have looked at the 
importance of strengthening the leadership skills of 
health workers (Nyikuri et al., 2015 and Le Rue 
et al., 2012). Interestingly, these papers make use 
of elements of organisational theory as part of their 
conceptual frameworks. A paper reviewing the first 
three years of the HSSF also highlights the impor-
tance of another soft skill, financial management 
expertise across the health sector (Waweru et al., 
2013). Finally, there has also been a focus on reclas-
sifying and task shifting and bringing in traditional 
healthcare providers (in a move similar to that in 
India). 
Not specifically focused on in the literature or 
policy discussions per se, but alluded to above, is 
also the issue of political flows following devolution 
in Kenya; the management of multiple actors in 
the field since the regulation of private providers; 
arguments regarding division of public expendi-
ture across sectors; and managing the demands of 
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donors as opposed to government objectives in the 
functioning of the HSSF. 
Discussion
There are several issues raised by the review of the 
health systems of India and Kenya through the 
4F lens:
1 The function of health related activities – wider 
thinking needed
 In both examples, efforts in the field of improv-
ing health is predominately focused on reducing 
morbidity and mortality through expansion of 
health services, improved access to health ser-
vices and increased efficiency. There is some at-
tempt to link health to economic development 
and to recognise the place of innovation in the 
development of improved healthcare.
Wellbeing is absent from policy objectives, 
although it should be acknowledged that while 
reviewing the literature, wider definitions of 
health and the importance of social determi-
nants of health is acknowledged.
The emphasis in these high level objective 
discussions on issues of system making con-
nections is made, but tangentially, through 
recognition and goals relating to more efficient 
and functioning components of the health 
systems; the health system building blocks. 
However, increased recognition of the system 
building connections is needed; these are the 
‘cement’ that binds the building blocks of a 
health (and wellbeing) system together and 
keeps them strong. 
2 Relationship between health and other sectors of 
the economy is often missing
 As noted, there is some recognition in the two 
case studies of the linkage between health and 
other sectors of the economy. For example, in 
Kenya where Vision 2030 explicitly links good 
health with improved economic and political 
development efforts. However, health policy 
and innovation or industrial policy do not mix. 
In Kenya, the new health policy discusses in-
novation solely in relation to the development 
and access to health products and technologies. 
It does recognise the need to develop indigenous 
capabilities to produce essential medicines but 
does not discuss how this will be done or the 
linkages required with other policy mechanisms 
or arms of government, except in relation to en-
hanced collaboration with the food industry for 
better regulation of that industry to safe guard 
the nation’s health. 
In India, a similar situation is found in the 
draft National Health Policy 2015. Innovation 
is referred to simply in terms of medicines pro-
duction. It does recognise the need to build an 
‘innovation ecosystem’ but only in this respect. 
In doing so, it does recognise the need for policy 
committees to be made up of representatives for 
multiple sections of government including the 
Department of Industry Policy and Promotion.
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3 Human resources for health acknowledged, but 
not knowledge flows and need for a learning 
culture per se
 In the case of India, it appears that efforts to fo-
cus on health systems strengthening have made 
the emphasis on form and function stronger; 
actors at the field level have intensified efforts 
and push for UHC. This is at the expense of 
developing the flows within the system.
The issue of flows is not just a problem of hu-
man resources for health per se (although this 
is a massive issue) but of making the best use 
of the resources available. It is this latter issue 
that many of the discussions are not focusing 
on. Uneven distribution of human resources is 
part of the problem, but the latter also consists 
in having or lacking a learning culture within 
the system, which will ensure that the system 
can operate even in times of scarcity. This is why 
the development of so-called ‘problem-solving 
organisations’ is so important. 
4 Using power and politics to create stronger 
linkages
 The two case studies highlight two elements 
of power and politics that appear in general to 
be used to explain the difficulties faced in the 
health systems of each country. In India and 
in Kenya, this is predominately with regards 
to the allocation of resources. In India, it of-
ten appears to be a matter of internal debate 
within state institutions but in Kenya the role 
of external actors, especially donors, has been 
highlighted. Differences must be worked with 
– relationships have to be managed – in such a 
way as to create stronger linkages rather than 
weaker ones within the system; to provide the 
opportunity to create a learning culture. This 
requires a well-coordinated and clearly defined 
functioning government structure. It also re-
quires willingness among external development 
partners to support national coordination and 
priority setting.
Summing up
This chapter has introduced a new lens for analys-
ing health systems, which takes concepts and ideas 
from innovation systems thinking and adapts them 
to the health system context. It does this in order 
to provide a means of analysing health systems in a 
way that emboldens current debates about the im-
portance of building systems competences. It does 
this by moving away from only focusing on health 
related actors, i.e. on health systems, and focuses on 
the need to build innovative health and wellbeing 
systems. In so doing, it focuses on the importance 
of more interaction across traditional sectoral lines 
(health, finance, education etc.) and the importance 
of building problem solving organisations within a 
wider learning culture. The two case studies given 
provide an illustration of the way in which the lens 
can be utilised but also highlight the continued si-
loed status of health systems building and strength-
ening efforts. 
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5. Conclusion and deliberations for policy
In an era when health problems are changing but 
not necessarily getting less around the world, efforts 
to enhance the functioning of systems of preven-
tion and care for health and wellbeing continues to 
be essential. Health policy makers and practition-
ers around the world are focusing on the need to 
increase universal health coverage – to make health-
care accessible and affordable to all – but this is only 
part of the solution. Recognition of the need for 
wider understandings of health that focus on well-
being and recognition of its complex interplay with 
wider economic and social development – with 
livelihoods – is also increasing. Taken together, this 
report has called for a need to focus on strength-
ening health and wellbeing systems and not just 
health systems.
We argue that one way of doing this is to build 
on work from within the health field around sys-
tems strengthening and incorporate more ideas 
from within innovation systems thinking. We not 
only point to a need to focus on technological 
product innovations; these have resulted in mas-
sive reductions in mortality and morbidity around 
the world through the introduction of new drugs, 
vaccines and diagnostic tools. We are arguing for 
a need to focus also on social innovation; particu-
larly the introduction of new organisational and 
institutional arrangements to the way that health 
and wellbeing are promoted and healthcare is de-
livered around the world; especially in low and 
middle income countries where disease burdens 
and poverty levels are highest. We have outlined 
examples of such social innovations in various 
places in the report. 
Specifically, we argue that the promotion of 
health systems strengthening in low and middle 
income countries can be supported more effective-
ly through a focus on four elements (the 4Fs) of 
thinking from within innovation systems think-
ing relating to function, form, field and flows. We 
argue that the last of these is the most important 
as it is the ‘cement’ that enables actors within dif-
ferent forms of organisations and the institution-
al field to perform more effectively towards the 
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achievement of the health and wellbeing system’s 
functional goals. The 4Fs and their underlying 
conceptual platform within innovation systems is 
recapped in Box 3. 
These suggestions are not new. As outlined, 
some social innovations that promote learning 
and knowledge flow across traditional boundaries 
are already taking place in relation to strengthen-
ing of health and well-being systems. The report 
has also outlined the similarities in policy and aca-
demic thinking between the health and innova-
tion fields in this area. The question remains, how-
ever, how can we move such action forward; or, 
in other words, what next? This short concluding 
Chapter will address that question. 
Deliberations for policy to widen the impact 
of systems thinking for health and wellbeing
Below, we outline three main areas of deliberation 
that we believe must be undertaken at a policy 
level if systems thinking and specifically relevant 
elements of innovation systems thinking are to be 
effectively incorporated into health policy discus-
sions to create not just stronger health systems but 
stronger health and wellbeing systems in low and 
middle income countries. 
4Fs Innovation systems thinking 
Function Focus on inclusive development as a starting point and on how that relates to 
health (and vice versa).
Form Multiple actors determine system functioning; and, more importantly, how do 
they interact?
Field Actors’ interactions are determined by the market, the state and other institu-
tions. It is important for the state and regulators to provide a positive enabling 
environment for effective and efficient flows to occur.
Flows The most important element, without which the system will not function ef-
fectively. The promotion of learning and knowledge flows are central through-
out the system. Power and politics that flow (through form and field) deter-
mine the success of learning and knowledge flows.
Table 4 Innovation systems thinking, the 4Fs, for health and wellbeing systems strengthening
Source: authors
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However, these deliberations are predicated on 
two assumptions relating to the policy process 
perspective and the need for multiple policy pro-
cesses to be involved. These two assumptions will 
be outlined before we turn to the deliberations 
for policy.
Assumption 1:
Change in perspective by policy processes
For the deliberations to be fully considered, a range 
of policy processes are required to fundamentally 
change their perspective. We would argue that pol-
icy discussions tend to be dominated by two types 
of questions: 
a How can money best be spent to achieve better 
health outcomes (which investments to make)?
b What modalities are needed to achieve better 
health outcomes (which policies and mecha-
nisms should be strengthened)?
Such questions are operationally important but 
they are not sufficient. It is important that they are 
set within contextualised knowledge of the situ-
ation in question. There are two ways in which 
knowledge should be contextualised. First, it is not 
possible to simply transfer knowledge from one 
context to another. Instead, there is a need to en-
sure that reflection takes place on similarities and 
differences between the contexts in question and 
the details of a policy activity to make use of lessons 
learned from other countries or contexts. Second, 
the policy process must recognise the value of learn-
ing and knowledge not just within what might be 
defined as implementation elements of the health 
and wellbeing system but also within the policy 
process of such a system. Learning cultures must 
be built across the board, especially through learn-
ing by doing, using and interacting. Implementers 
and policy makers alike must realise the need for 
learning and reviewing/adjusting policies, strategies 
and modalities in view of experience and in view 
of the rapidly changing conditions and contexts, 
influenced not least by globalisation and radical in-
novations/new technologies.
Assumption 2: 
Involvement of multiple policy processes
The deliberations below are based on the assump-
tion that policy discussions become less siloed. This 
requires a completely new way of thinking and 
acting in some country contexts while in others it 
requires a further and wider continuation of exist-
ing efforts. The report has emphasised the fact that 
improving health of populations links to so many 
other areas of development because of the inter-
linkages between health, wellbeing, livelihoods 
and development. Thus, it is not sufficient if the 
required deliberations take place only in the health 
policy sphere. It requires cross-fertilisation of ideas 
and exchange of ideas between policy spheres as di-
verse as finance and education, agriculture and en-
ergy. For example, science and technology policies 
should be mandated to not just foster economic 
growth but also improvements in livelihoods and 
wellbeing through an additional focus on, and 
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greater connection with those working in, health, 
education etc.
Areas of deliberation needing attention
What follows is a list of areas for deliberation or 
analysis by policy makers that provide a starting 
point for, or enhanced scrutiny of existing efforts 
towards, systems strengthening for improved health 
and wellbeing enabling social and economic devel-
opment. These areas of deliberation do not provide 
answers; they provide further questions and issues 
from which to consider development of contextu-
ally focused solutions.
Deliberation area 1: Should investments be 
made in technological or social innovation?
A broad understanding of innovation including 
technological innovation and social and organi-
sational forms of innovation is required. This is 
particularly important because technological inno-
vation won’t be successful without strong social in-
novation. Encouraging system-making connections 
is particularly important in order to ensure social 
innovations work towards the creation of improved 
technological innovations and vice versa. Without 
a stronger emphasis on social innovations, a lot of the 
investments made in the development of technological 
innovations related to health may very well be a waste 
of time and resources.
That said, technological innovation is still impor-
tant. Various ‘breakthrough technologies’ have ena-
bled new capabilities and create huge improvements 
in health systems of low and middle income countries. 
The case of Cuba is an obvious example here of the 
creation of a symbiotic relationship between local 
technological innovation activities and their local 
health and wellbeing system, together with their ef-
forts to become internationally competitive in the 
pharmaceutical sector. In the case of Cuba, this has 
been a very deliberate effort by government but, 
in other instances, this might be more about the 
opening up of windows of opportunity that had 
not been foreseen. Such ‘disruptive technologies’ in 
other sectors (e.g. mobile money applications) have 
been found to change the way that whole sectors are de-
fined, interact and the types of learning and knowledge 
that are important.
Deliberation area 2: Should investments be 
made in building local capabilities and, if so, 
how should this be promoted?
Breakthrough technologies and disruptive tech-
nologies will only be possible, however, if there is 
sufficient strengths in science and complex new 
technologies built in low and middle income coun-
tries and/or knowledge and skills on how to utilise 
them. This report has not focused in any depth on 
the issue of domestic pharmaceutical capability 
building, but it is an important issue, which needs 
tackling. This is an area where there is evidence – 
from medical devices in Pakistan to the production 
of active pharmaceutical ingredients in various Af-
rican countries – that building local capabilities has 
a win-win effect on local healthcare systems as well 
as efforts to industrialise and strengthen economic 
growth in low and middle income countries. How-
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ever, this requires a much stronger interaction be-
tween different elements of government and policy 
to ensure adequately trained staff and sufficient in-
puts to enable the production, delivery and use of 
these technologies. It also requires that the global 
intellectual property rights system allow such devel-
opment to take place.
In many low and middle income countries, the 
lack of strengths in science and complex new tech-
nologies does not have to be a hindrance. As out-
lined in this report, some commentators within 
the innovation systems field in fact argue that the 
ability to solve health problems in situations of 
scarcity – whether of materials, skills or financ-
es – creates opportunities for ‘frugal innovation’ 
and ‘innovation in scarcity conditions’. Therefore, 
while at the same time promoting the creation 
of traditional science and technology related ca-
pability building, it is important for countries to 
also promote opportunities for frugal innovation. 
This requires much more recognition and promotion 
of problem solving organisations, the promotion of 
learning cultures at all levels and an acceptance of all 
forms of knowledge. 
There are various mechanisms that can be used 
to encourage the development of domestic produc-
tion capabilities in technological products of any 
and all kinds together with the development of in-
stitutional arrangements to enable the creation of 
skilled labour and the promotion of learning, ac-
ceptance of all forms of knowledge and its transfer 
and uptake. Some of those mentioned in this report 
include social innovations, particularly financial in-
novations. More analysis is needed of the potential of 
public procurement mechanisms as a means of promot-
ing local capabilities. 
Deliberation area 3: How can policy and prac-
tice becomes less entrenched in silos?
A future focus at national – and global levels - 
should be on building competences and a learning 
culture that enables good use of resources for better 
health outcomes and well-being. This requires ap-
propriate investments in capacity and competence 
development as well as a strong focus on commu-
nity involvement at local levels. It is about systems 
level innovation at the level of policy discussions. 
This requires thinking about health as an integrated 
element of, and contributing factor to, economic 
and social development and making an explicit link 
to equity and inclusion. Health is not just absence 
of disease but also wellbeing, which implies that ef-
forts outside the health system per se are required. 
A multi-sectoral approach and breaking down of silos 
is essential.
We have focused this report on building up 
functioning systems of health and well-being at a 
national level. However, these policy deliberations 
need to be considered not only by national level ac-
tors but also by regional and global level stakehold-
ers engaged in promoting better health outcomes, 
wellbeing, livelihoods and economic and social 
development more generally. As already acknowl-
edged, it is difficult to boundary a system, and 
while it is functionally useful to boundary a health 
and wellbeing system at a national level to enhance 
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the achievement of improved health and wellbeing 
within a national level population, policy and practice 
involve a wider range of actors, especially at regional 
and international levels.
There are multiple actors involved in the health, 
innovation and economic development of a coun-
try. This is further complicated by the interplay of 
national and global issues as well as by the compet-
ing demands of supply and demand (or producers 
and users, to use the language of this report). As a 
result, the use of “forgotten knowledge” relating to 
improvement of national systems for better health 
outcomes and well-being should be promoted. 
This includes a strong focus on national ownership 
and commitment and willingness by international 
funders to support national policies and systems 
rather than bypassing these.
What next?
We have already acknowledged the entrenched 
nature of policy and practice discussions and ac-
tion that are making it difficult to ensure wider def-
initions of health, as well as innovation and systems 
strengthening becoming mainstreamed into dis-
course and practice. Yet, some authors claim that a 
‘grand convergence’ is possible if sufficient financ-
ing and support is made available to low and mid-
dle income countries to reduce the differences in 
disease burden around the world (Jamison et al., 
2013). However, others have acknowledged that 
this requires a closing of the gap between health 
and innovation experts (c.f. Moran, 2016). As 
such, our report would seem very timely; in terms 
of both the current push to finally reduce the gap 
between the rich and the poor but also the in-
creasing recognition of the need to reduce aca-
demic and policy siloes that exist.
Working on this report has highlighted three 
ways in which the breaking down of these siloes 
might be undertaken in order to effectively push 
forward efforts to build stronger health and well-
being systems. Specifically, there is a need for the 
following action in order to move discussions and 
practice forward and reduce levels of entrenchment:
1 Support for more inter/multi/trans-discipli-
nary research and practice
 One of the reasons why health and innovation 
have rarely successfully been considered together 
(or, for that matter, wider questions of the rela-
tive merits of economic development over other 
forms of development) is that academic silos 
entrench ways of thinking and acting in train-
ing and education for the future practitioners 
and policy makers of tomorrow. As such there 
is a need for more funding opportunities to 
bring together health and innovation research-
ers to conduct joint research that specifically fo-
cuses on building health and wellbeing systems 
through technological product and social inno-
vation. Findings from this research must then be 
used in teaching and education. 
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2 Utilisation of a new analytical lens to inves-
tigate the current status of health systems 
in LMICs
 The 4Fs framework outlined in Chapter 4 pro-
vides an example of a potential alternative lens 
of analysis. In the health field of the 1990s, Walt 
and Gilson’s (1994) work on the ‘Policy Tri-
angle’ led to a similar alternative approach to 
analysing health systems (focusing on content, 
context, process and actors) that has become 
relatively well utilised since then. The concept 
of innovation systems, similarly, when first sug-
gested in the early 1990s, has over the years pro-
vided an alternative approach to analysing the 
enabling environment for innovation. A frame-
work such as the 4Fs has the potential to move 
beyond the siloes of health and innovation and 
enable a wider analytical lens through which to 
focus on more than one set of outcomes and im-
pacts across a range of sectors.
3 Sharing of lessons learnt: building a stronger 
research and practice learning culture
 Finally, the report has highlighted the impor-
tance of not just technological product inno-
vations but also the importance of social in-
novations. These need to be widely publicised, 
researched further and critiqued. Just as we have 
argued that it is important for learning to take 
place within the practice and implementation 
arenas of health and wellbeing system strength-
ening, such learning is important in the research 
arena, too. As part of the efforts to break down 
silos in terms of research and practice, a more 
open international research learning culture is 
also required. 
4 Increasing interaction between academics, 
policy makers and practitioners 
 Finally, working on this report has also high-
lighted the need for new ways of interaction 
between academics, policy makers and practi-
tioners. Again, this is not something new! How-
ever, with increased pressure on public institu-
tions and policy makers, including reductions 
in budgets for keeping policy makers up-to-date 
with research results, there is dire need to make 
new knowledge available, and not just in scien-
tific journals and books. This is important, but 
needs to be accompanied by more direct ways of 
interaction from increased use of social media to 
face-to-face encounters.
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6. Postscript
This year’s Globelics report is a welcome challenge 
to us to think a-fresh about our understanding of 
the relationship between research, innovation and 
well-being. Focusing on health, Hanlin and Holm 
Andersen highlight inadequacies associated with 
conventional frameworks for analysing both how 
research and innovation capabilities take shape 
and grow but also how they can be encouraged 
to best serve social needs. The report quite rightly 
notes the limitations of much research which is 
judged by conventional standards to be ‘excellent’ 
in translating to innovation. At the same time, it 
is also clear that technological innovation which 
may generate wealth may also not meet social 
need. Whilst all of that is true, it is also the case 
that research and innovation are essential to meet-
ing the needs of low income populations in low 
and middle income countries; a focus on health 
systems without consideration of the role of in-
novation is also limited in the extent to which it 
can address critical health challenges in low and 
middle income contexts.
In addressing these issues, the authors of the re-
port redefine health systems to include a broader 
focus on well-being and prevention and make 
clear that frameworks for thinking about innova-
tion and innovation systems thinking must also 
be redefined and particularly must include a more 
normative and outcomes based orientation. Re-
search and innovation involves a range of activi-
ties to do both with new research and innovation 
and adapting existing knowledge (Srinivas and 
Sutz, 2008).  
The report lays out a very useful framework for 
helping us think about how both to understand 
and encourage the generation of research and in-
novation that will more directly meet health needs. 
The 4Fs (form, function, field, flow) can be used 
both to analyse efforts at innovating for wellbeing 
and health and to stimulating new policy initia-
tives that are conceived with reference to a broader 
framework. This thinking about the 4Fs and the 
way that they might inform and structure analy-
sis is relevant to low and middle income countries 
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(LMICs) and also to high income countries (HICs) 
where barriers to a more holistic conceptualisation 
of health and wellbeing is also often evident.
The preface of the report revisits writing on tech-
nological innovation and learning in relation to 
health innovation activities. Much of this work de-
rives from the Globelics community and is essential 
to taking forward an agenda which aims to enrich 
our understanding of how innovation takes shape 
and the kinds of knowledge needed to both increase 
innovation output and relate that output to social 
need. The preface argues that technological capabil-
ity building in LMICs is essential to longer term 
ability to meeting global health needs and reviews 
thinking about how increased innovation might be 
achieved but also some of the obstacles to initiatives 
to build capabilities. There is a rich scholarship on 
this subject and it is continuously being enhanced 
by Globelics scholars and others, some of whom are 
focusing on health innovation and asking questions 
that can be used to explore the territory laid out 
by Lundvall, Hanlin and Holm Andersen. A recent 
book by Maureen Mackintosh and colleagues, for 
example (Mackintosh et al., 2016), points to nu-
merous ways in which health and pharma R&D 
and innovation is happening in low income con-
texts and the ways in which policy makers and prac-
titioners are viewing this activity as a part of broader 
efforts to address health and wellbeing needs. 
Building on this annual report, I see one of our 
next tasks as a community as identifying ways to 
mainstream the findings and framework and to 
think about what might be the drivers of change. 
The report correctly frames health and wellbeing 
as being a terrain in which both public and private 
actors are active. Although the constellation of ac-
tors differs across contexts, there is widespread and 
growing concern to find ways to bridge the aims 
and agendas of public and private sector across 
LMIC and indeed also high income contexts. The 
report also highlights the need to build bridges 
across the health, social and industrial sectors and 
to create commonly understood framings of the key 
problems and issues amongst key actors in public 
and private sectors. Hanlin and Holm Andersen 
make a compelling case for the benefits of thinking 
anew about the way we go about linking analysis 
and activity across these different domains.  
Ultimately, the success of bringing about the 
changes advocated by Hanlin and Holm Andersen 
will depend on power and political will and acu-
men. It will depend on a commitment from na-
tional and international powers to develop insti-
tutional and technological capacity and capability 
to address health needs. There is no way to avoid 
the central importance of that commitment. It 
may be that power entrenched in existing private 
and public organisations resistant to change, and 
with powerful economic interests to defend, will 
prevent constructive development along the lines 
laid out in the report. It is impossible, however, to 
imagine that no change will happen. The context 
of desperate need for better health, the limitations 
of previous approaches to provide health solu-
tions, a diversity of aims, ambitions and interests 
and of public and private health product and 
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service providers looking for new models, will all 
provoke change.   
From this angle, our work can be seen as an effort 
to identify the spaces and mechanisms for push-
ing forward an agenda for capacity and capability 
building based on an understanding of the type 
of frameworks and tools needed. Techno-fixes, or 
quick fixes of any kind that do not recognise the 
vital underpinning of institutional development 
including a supportive environment for learning 
and competence building at different levels, are 
doomed to failure. But without analysis, strategies 
and plans such as those being developed in this re-
port, understanding of power imbalances will not 
inspire positive change either. As much as anything 
else, the framework and agenda for change laid out 
in this year’s report is a political project. Political 
and social requirements for change should there-
fore not be ignored in future work that builds on 
this year’s report.
Procurement: A possible driver of change?
One lens with which to consider further increas-
ing linkages between different domains is the area 
of health procurement. The potential role of value 
based pricing (VBP) mechanisms is a subject that 
is increasingly high on policy agendas in high in-
come countries. Procurement is important to think 
about because efforts to lower the cost of health-
care and derive greater value for public and private 
payers and patients is currently one of the main 
drivers of change in healthcare. Over the past few 
decades, pharmaceutical companies have found 
it increasingly difficult to compete on the basis of 
R&D productivity alone and are looking for new 
ways to establish advantage and this has also con-
tributed to keeping discussion of VBP’s potential 
on the agenda.
Value-based pricing (VBP) is seen by some as 
a flawed approach that does not acknowledge the 
particular characteristics of health products and 
the underlying interests of health innovators (Ar-
zymanow and Manning, 2013), but for others it 
represents a possible, although not unproblematic, 
route to  achieving a common framework for valu-
ing the contribution of drugs and technologies in 
different contexts (Persson et al., 2012; OECD, 
2013; Sussex et al., 2013). In Europe, Sweden, Italy 
and Portugal, amongst others, have developed VBP 
based schemes and the debate about how pharma-
ceuticals and medical technologies are valued has 
occupied centre stage in policy debate about health 
innovation during recent years. Although Brazil’s 
attempt to link social policy and health innovation 
policy has not been traditionally thought of as com-
ing under the VBP rubric, it shares many common 
characteristics with VBP approaches.
In my view, VBP is a mechanism that can be 
thought about as a way of trying to incentivise the 
common framing of how to value innovation in 
different contexts. I say this not because I am con-
vinced that VBP is a proven mechanism, or because 
I am unware of the political or technical difficul-
ties involved, but because the need for new ways of 
envisioning the connections between domains and 
for creating  a common view of value is clear. VBP 
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may offer a route to that common valuation, or at 
least discussion of the need for approaches that hold 
a spotlight to value designations, and it could con-
stitute a driver for introducing some of the changes 
advocated by Hanlin and Holm Andersen.
Value-based pricing is an umbrella term used 
to describe a variety of approaches to determin-
ing the value of new pharmaceutical innovations 
and other health interventions. VBP approaches 
are significant because they shift the attention of 
procurement policy from a standardised and often 
crude Quality Adjusted Life Years (QALYS) de-
rived patient level assessment of price to a measure 
that also encompasses factors beyond individual 
health improvement, i.e. differential pricing ac-
cording to a drug’s performance in relation to 
health benefits to distinct groups of patients (dis-
tinct either with respect to physical or social and 
economic differentiation) and its impact on par-
ticular healthcare and social pathways and systems. 
In the latter context, this may require rethinking 
healthcare systems. A new medicine, or therapeu-
tic intervention, might yield benefits to certain pa-
tients but might necessitate heavy involvement of 
clinicians and nurses, and using a VBP approach 
implies that the value determined by payers would 
reflect the overall cost and benefit of the drug to 
individuals and to the health system, and perhaps 
society more generally. On the other hand, a new 
treatment implemented in a certain way might re-
duce health and social care costs significantly and 
that benefit would also be reflected in the price 
under VBP arrangements. Some VBP schemes 
take impact on industrial structure into account 
and thus incorporate consideration of develop-
ment of industrial and innovation capabilities di-
rectly into reimbursement strategies.
The opportunities are also significant for phar-
maceutical companies in that VBP mechanisms 
can provide stronger incentives to redirect resources 
in R&D, whilst improving their ability to differ-
entiate their pharmaceuticals against competitors 
through higher value achievement. A range of new 
agreements have been established on this basis. For 
example, Proctor and Gamble provided provision 
to reimburse insurance companies in the US in cas-
es where Actonel, their osteoporosis drug, failed to 
meet a range of clinical expectations. AstraZeneca 
and Pfizer are implementing plans for real-world 
data gathering about drug performance in clinic 
that will allow for new approaches to payment and 
procurement packages (Deloitte, 2012). At a na-
tional level, Sweden is one of the countries that has 
invested heavily in real-world monitoring of health 
innovation performance over time.
Both LMICs and HICs are grappling with ris-
ing healthcare needs and funding constraints. Both 
sets of countries need to find ways of incentivising 
innovation while sustaining effective market rela-
tionships with national and international industrial 
suppliers. This implies finding some way to deal 
with competing valuations among stakeholders and 
populations of the options available. They confront 
these challenges with a backdrop of acute popula-
tion inequality reflected to a greater or lesser extent 
within healthcare (Jayadev and Stiglitz, 2009; Ag-
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garwal et al., 2014). For manufacturers and health-
care funders, pricing of medicines and technologies 
is a focus for conflicts of interest but also an emerg-
ing arena for collaboration.
Procurement using VBP potentially supports 
R&D whilst incentivising pharmaceutical firms to 
compete on a more socially beneficial basis. It can 
do this precisely because VBP expands valuations 
from cost-effectiveness measures, using calculations 
such as QALYs, to encompass wider factors such 
as health benefits to distinct groups, broader health 
system impacts, and social costs and benefits of 
treatments. One could imagine a scenario where it 
becomes the norm rather than interesting experi-
ments for private providers to develop packages of 
care rather than simply products. Some packages 
could indeed include local production and inno-
vation strategies in instances where this is called. 
Indeed, there is potential to go further and reward 
private and perhaps also public bodies to work 
together to provide care aimed at prevention and 
keeping people away from overloaded hospitals.
VBP also potentially represents a shift away 
from an “access to medicines” framework focusing 
on lowest cost procurement towards procurement 
incentives for cost effective innovation for patient 
benefit and with the overall health and care sys-
tem performance in mind (Chataway et al., 2016; 
Nguyen et al., 2015). And, whilst ‘vertical’ ap-
proaches to addressing health needs on a disease-
by-disease basis have delivered some successes, the 
same underlying need for overall health and well-
being system development remains (Harman and 
Williams, 2013). A refocusing of policy thinking 
towards incentivising industry-health linkages to 
improve health system performance is now visible 
in international debate (Sidibé et al., 2014; Mack-
intosh et al., 2016).  
VBP approaches also chime with Hanlin and 
Holm Andersen’s call for a new definition of health 
and well-being rather than narrower definitions of 
innovation or health systems. A major issue, how-
ever, is that VBP, and perhaps any procurement 
scheme that aims to derive greater value from in-
novation, will rely heavily on real-world data col-
lection. If this is a challenge in HICs, it is likely to 
represent even more of an obstacle in many LMICs. 
VBP, and value-based healthcare initiatives more 
broadly, also blur the boundaries between regula-
tion and procurement, and raise largely unexplored 
and difficult issues at different governance levels. As 
indicated earlier, VBP schemes cannot be used to 
avoid any of the underlying issues around capac-
ity and capability development, political will or 
governance complexity. They may simply offer an 
approach and mechanisms that can feed into and 
strengthen efforts.
While the HIC literature offers a strong theo-
retical case for VBP (Levaggi, 2014; Danzon et al., 
2015), empirical evidence of its effectiveness is lim-
ited to a number of country cases (Towse, 2010; 
Persson et al., 2012; Sussex et al., 2013). Current 
debate in HICs focuses on the nature and scope 
of value criteria such as extending relevant costs of 
disease and treatment options beyond health servic-
es to those falling on other social services. The issue 
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of how valuations might be weighted to reflect the 
severity of illness and patient experiences at the 
end of life is a particularly difficult one (Rafferty, 
2013). The issue of how VBP interacts with other 
pricing arrangements such as international refer-
ence pricing is also contested (Persson and Jöns-
son, 2015; Danzon et al., 2015). So, for all its 
potential and possibility it is important to recog-
nise that there is no consensus on the inclusion of 
quality of life outcomes with social determinants 
outside medical care, or the impact of treatments 
on wealth generation.   
These unresolved, often politically contentious 
and socially difficult, areas point to thorny issues 
that are at the heart of this year’s Globelics report. 
Hanlin and Holm Andersen also notes that patients 
must be central to a problem solving approach and 
their views, needs and judgments must be config-
ured into valuation of innovation, treatments and 
health/wellbeing frameworks. Patient views of VBP 
schemes are to date largely absent from considera-
tions of VBP.   
In summary, Hanlin and Holm Andersen stress 
the need to understand the complex and multiple 
links between social innovation and technological 
innovation. VBP offers potentially new ways to 
include a broader array of stakeholder assessment 
for technology innovation and thereby could intro-
duce a system of valuation that better represents the 
contribution of new products. VBP thereby consti-
tutes one possible approach to forging new syner-
gies between social and technological innovations. 
However, evidence is very limited on how ‘value’ 
is variously understood, what appropriate valua-
tion metrics should look like, and how VBP might 
lead to realigned incentives in practice. Much more 
work could be done to establish the extent to which 
progressive VBP approaches are politically viable 
in different contexts and whether they can be use-
ful in generating new framing of value of products 
and technologies across HIC and LMIC contexts 
in order to help build the kind of approach that 
Hanlin and Holm Andersen envision. Amongst 
many other ways in which the framework might be 
deployed, the 4Fs could potentially be used to help 
understand how VBP might work in different con-
texts and what opportunities and limitations might 
be associated with its introduction. 
Joanna Chataway
Professor of Science and Technology Policy
SPRU, Sussex University, UK
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Annex 1: Research methodologies
This report was written following an in-depth desk 
review of various literatures together with consulta-
tive talks with a number of different academics and 
policy makers. This Annex outlines the details of 
these activities in a little more detail. 
Desk review
There were three elements to the desk review pro-
cess. This involved a general overview of work 
that has been written on the subject – both aca-
demic and grey literature. It also involved a more 
defined literature review of both the innovation 
and health literature. 
General overview work
This was conducted throughout the report writing 
process in order to provide a notion  of the litera-
ture of a range of disciplines. The material read and 
reviewed forms the basis of much of the literature 
reviewed in Chapters 2 and 3 of this report. 
The desk review consisted of a review of the glob-
al health and health innovation literature through a 
review of four databases (Scopus, Web of Science, 
GoogleScholar and PubMed). A combination of 
the following search terms in these exact phrases 
and in various combinations of the individual 
words was used: ‘global health’, ‘health research’, 
‘health innovation’, ‘developing countries’, ‘inter-
national development’, ‘learning’, ‘competence 
building systems’. In addition, a google search was 
conducted using the same search terms to find 
relevant grey material that would not have been 
available through the academic databases.
Each set of references found was reviewed and rel-
evant literature read and integrated into the report 
as appropriate.
A literature review of innovation literature on health 
issues affecting low and middle income countries 
A search of all Globelics conference papers and 
key innovation journals was conducted from 2000 
to 2016 using the keyword ‘health’, filtering out 
those papers that focused on high income coun-
tries where the content was deemed irrelevant. This 
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material is utilised across the report but especially 
in Chapter 3.
An in-depth literature review of all health literature 
that discusses innovation and health issues 
affecting low and middle income countries
This consisted of a review of journal papers listed in 
ISI Web of Knowledge database from 2000 to 2015 
that included the terms ‘health’ and ‘innovation’ in 
the title together with other databases as necessary. 
The material collected is utilised across the report 
and predominately in Chapter 2.
A very specific review was conducted of this lit-
erature. A decision was taken to utilise the ISI Web 
of Knowledge database as the most comprehensive 
set of journals across the two main fields: health 
and social sciences. The following search process 
was followed:
1 An initial search was made for papers that in-
cluded the key words ‘health’ and ‘innovation’ in 
their title. This resulted in an initial list of over 
1500 papers.
2 These papers were then further refined using the 
following parameters: 
a English papers only published between 1st 
January 2000 and 30th June 2015
b Papers published in the top 20 ranked jour-
nals in the ISI citation index from public 
health and health policy sub-fields. Added 
to these, 22 further journals that are key 
journals in the field of health systems and 
policy research.1
3 A total of 220 papers were left for consideration 
after the parameters were introduced.
4 93 of these papers were rejected as not relevant 
following a review of their abstracts, were una-
vailable as full papers or were duplicates of an-
other paper.
5 This left a final 127 papers, which were included 
in the review. 
1 The final list of journals utilised contains: Health Af-
fairs; Jama Journal Of The American Medical Associ-
ation; Health Affairs Project Hope; Implementation 
Science; European Journal Of Public Health; Ameri-
can Journal Of Public Health; British Medical Jour-
nal; Lancet; Social Science Medicine; Bmc Health 
Services Research; Plos Medicine; Bulletin Of The 
World Health Organization; Nature Medicine; Bmc 
International Health And Human Rights; Nature 
Biotechnology; Global Public Health; The New Eng-
land Journal Of Medicine; Health Policy And Plan-
ning; Sociology Of Health Illness; Journal Of Health 
Economics; Globalization And Health; Jama; Lancet 
North American Edition; Journal Of Health Ser-
vices Research Policy; Human Resources For Health; 
Health Policy Amsterdam Netherlands; Implementa-
tion Science Is; Health Research Policy And Systems; 
Social Science Medicine 1982; Journal Of Health 
Politics Policy And Law; Science Or Health Policy; 
Value In Health; Bmj Open; New England Journal 
Of Medicine; Lancet London England; Health Ser-
vices Research.
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Consultative process
The contents of the report have been discussed 
and ideas collected from members of the Globelics 
community and others as follows:
1  A two-day workshop involving 30 academics, 
mostly from within the Globelics communi-
ty was held in Rio de Janeiro in March 2015 
to discuss themes and issues to be discussed 
in the report. 
2  The first draft of the report was reviewed by 
members of the Globelics Scientific Board and 
Secretariat in August 2015.
3  The draft report was circulated to a first round 
of four reviewers in September 2015. These re-
viewers were an even mix of innovation schol-
ars and health policy scholars.
4  The main arguments of the report were dis-
cussed during a special session of the Globe-
lics conference in September 2015 in Havana, 
Cuba.
5  The second draft of the report was circulated 
to eight further reviewers – two of whom were 
from outside of the Globelics community – in 
early 2016.
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Annex 2: Globelics Conference papers referring to 
health issues in low and middle income countries 
(2006 – 2016)
The following is an analysis of papers on health 
from the Globelics conferences from 2006 to 2016. 
The conferences are:
• The 4th Globelics Conference, Trivandrum, In-
dia in 2006
• The 5th Globelics Conference, Saratov, Russia in 
2007
• The 6th Globelics Conference, Mexico City, 
Mexico in 2008
• The 7th Globelics Conference, Dakar, Senegal in 
2009
• The 8th Globelics Conference, Kuala Lumpur, 
Malaysia in 2010
• The 9th Globelics Conference, Buenos Aires, Ar-
gentina in 2011
• The 10th Globelics Conference, Hangzhou, Chi-
na in 2012
• The 11th Globelics Conference, Ankara, Turkey 
in 2013
• The 12th Globelics Conference, Addis Ababa, 
Ethiopia in 2014
• The 13th Globelics Conference, Havana, Cuba 
in 2015
• The 14th Globelics Conference, Bandung, Indo-
nesia in 2016
There is a total of 113 papers related to health from 
these conferences1. By examining titles, keywords 
and abstracts of these papers, the distribution of 
papers among 5 categories are analysed. The cat-
egories are:
1 This does not include papers accepted for poster 
presentation.
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• Product innovations – papers that discuss tech-
nological product innovations, i.e. papers that 
discuss the drug, vaccine or diagnostics devel-
opment, the pharmaceutical innovation pro-
cess etc.
• Process innovation – papers that relate to chang-
es or innovations at intra-firm level, i.e. new or 
improved ways of managing people, processes in 
organisations etc.
• Inter-organisational innovation – papers about 
partnerships, networks, clusters, university-in-
dustry linkages etc.
• Institutional innovation – papers about gov-
ernance or regulation related subjects, i.e. in-
33%
32%
25%
10% Institutional Innovation
System Innovation
Inter-organisational 
Innovation
Process Innovation
tellectual property rights, innovative finance 
mechanisms etc.
• Systems innovation – papers about health in-
novation systems or related topics.
There are no papers in the category “Product In-
novation” defined as technological product innova-
tion. But there are papers on the conditions and 
strategies for product innovation. 11 papers (10%) 
are in the category “Process Innovation”, 28 papers 
(25%) are in the category “Inter-organisational in-
novation”, 38 papers (33%) are in the category “In-
stitutional innovation” and 36 papers (32%) are in 
the category “System innovation”. 
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Process Innovation 
Alakärppä, Ismo and Valtonen, Anu (2010). Toward a Practice-Based Framework of Technology Ac-
ceptance: A Case Study on Bioactive Point of Care Testing. Paper presented at the 8th Globelics Confer-
ence, Kuala Lumpur, Malaysia.
Badarudin, Ahmad Ezainuddin bin and Abdullah, Zaini bin (2010). Using Balanced Scorecard as perfor-
mance measurement system at private hospitals: making everybody happy, while taking care of the 
bottom line! Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Becerra, Lucas (2011). Learning and Insights from Management Technologies for Social Inclusion: A Socio-
Technical Analysis Of The Drug Production Unit Of Talleres Protegidos De Rehabilitación Psiquiátrica 
De La Ciudad De Buenos Aires. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Engel, Nora (2011). New Diagnostics for Multi-Drug Resistant Tuberculosis in India: Innovating Control 
and Controlling Innovation. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Kale, Dinar (2013). Reconfiguration of firm capabilities from emerging country firms as a response 
to the emergence of biosimilar markets: Evidence from the Indian pharmaceutical industry. Paper 
presented at the 11th Globelics Conference, Ankara, Turkey.
Madhavan, Harilal (2008). Knowledge origin, innovations and growth in ayurvedic bioprospection: refer-
ences from Kerala. Paper presented at the 6th Globelics Conference, Mexico City, Mexico.
Mohd-Nor, Rohaya (2010). Medical Imaging Innovative Features and Their Implications on Radiology 
Work Practices: Evidence from Malaysian Hospitals. Paper presented at the 8th Globelics Conference, 
Kuala Lumpur, Malaysia.
Rajan, Rony Thomas (2010). Organisational, Structural, Individual and Contextual Characteristics that 
can predict the adoption of Technology by a private for-profit hospital: A case of private for-profit hospi-
tals in Kerala. Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Santiago, Fernando (2012). Learning to do Pharmaceutical Innovation Drawing from Internal and Ex-
ternal Sources of Knowledge: Exploring the Role of Human Resource Management Practices in the 
Case of Mexico. Paper presented at the 10th Globelics Conference, Hangzhou, China.
Santiago, Fernando and Alcorta, Ludovico (2008). The influence of human resource management practices 
on learning and innovation: pharmaceutical firms in Mexico. Paper presented at the 6th Globelics Con-
ference, Mexico City, Mexico.
Complete list of papers on health from Globelics Conferences 
from 2006 to 2016 distributed by category
Urias, Eduardo (2010). The Brazilian pharmaceutical industry: a co-evolution process between technology, 
institutions and industrial organizations. Paper presented at the 8th Globelics Conference, Kuala Lum-
pur, Malaysia.
Inter-organisational innovation
Chataway, Joanna Caroline; Banda, Geoffrey; Cochrane, Gavin and Manville, Catriona (2015). In-
novative procurement for health and industrial development. Paper presented at the 13th Globelics Con-
ference, Havana, Cuba.
Chataway, Joanna Caroline; Castle, Sophie Clarke and Wield, David (2014). Disruption and experimenta-
tion in health research and innovation: New building blocks and architectures for public and private 
sectors. Paper presented at the 12th Globelics Conference, Addis Ababa, Ethiopia.
Chataway, Joanna Caroline; Hanlin, Rebecca; Mugwagwa, Julius and Muraguri, Lois (2010). Global 
health social technologies: reflections on evolving theories and landscapes. Paper presented at the 8th 
Globelics Conference, Kuala Lumpur, Malaysia.
Contreras Romero, Carmen (2013). Social Networks, Location of Firms and Cluster Formation: A Mix-
Method Study of the Biomedicine Sector in Chile. Paper presented at the 11th Globelics Conference, 
Ankara, Turkey.
D’Amore, Rosamaria; Iorio, Roberto and Stawinoga, Agnieszka (2010). The role of institutions and firm 
characteristics in the networks of firm publications. An analysis of the Italian biotech sector through the 
Social Network Analysis. Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Ebrahimipour, Hosein; Dehnavi, Reza; Esmaeilzadeh, Hamid and Jafari, Mehdi (2006). The evaluation of 
University- Industry linkage in Medical Universities of Kan. Paper presented at the 4th Globelics Confer-
ence, Trivandrum, India.
Gutman, Graciela Elena and Laverello, Pablo José (2015). Early imitators in the context of the new techno-
logical paradigm: the (incipient) experience of Argentina’s biopharmaceutical industry. Paper presented 
at the 13th Globelics Conference, Havana, Cuba.
Hanlin, Rebecca (2008). International product development partnerships: Innovation for better health? 
Paper presented at the 6th Globelics Conference, Mexico City, Mexico.
Hardiyati, Ria; Fizzanty, Trina and Aminullah, Erman (2016). Building Capacity For Innovation Through 
R&D Consortia In Health Projects: From Network Interaction To Systemic Transformation. Paper 
presented at the 14th Globelics Conference, Bandung, Indonesia.
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Jasso, Javier; Calderón, Guadalupe and Torres, Arturo (2015). Innovation and academia-industry linkages in 
health. Multinationalization of companies in developing countries. Paper presented at the 13th Globelics 
Conference, Havana, Cuba.
Kale, Dinar (2014). Where now for drug development innovation? Paper presented at the 12th Globelics 
Conference, Addis Ababa, Ethiopia.
Kale, Dinar; Watkins, Andrew; Papaioannou, Theo and Mugwagwa, Julius (2015). Why industry as-
sociations matter in development of healthcare industries in emerging countries? Evidence from Indian 
biotechnology and medical device industries. Paper presented at the 13th Globelics Conference, Havana, 
Cuba.
Lavarello, Pablo José (2011). Biotechnological Opportunities in Biopharmaceuticals And Firm Organi-
zation In Argentina. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Mantovani, Andrea and Naghavi, Alireza (2009). South-South Parallel Import and Cost Reducing In-
novation in the Pharmaceutical Industry: An Alternative Approach. Paper presented at the 7th Globelics 
Conference, Dakar, Senegal.
Marjanovic, Sonja; Hanlin, Rebecca; Diepeveen, Stephanie and Chataway, Joanna (2012). Research Ca-
pacity-Strengthening in Africa: Networks, Institutions and Local Ownership. Paper presented at the 
10th Globelics Conference, Hangzhou, China.
McMahon, Dominique S. and Thorsteinsdóttir, Halla (2010). All the eggs in one basket: a look at regen-
erative medicine clusters in Brazil and China and India. Paper presented at the 8th Globelics Confer-
ence, Kuala Lumpur, Malaysia.
Niosi, Jorge (2011). Catching-up And Leapfrogging In Biopharmaceuticals The (Slow) Rise Of Emerging 
Countries. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Niosi, Jorge (2013). The Internationalization of Chinese and Indian Pharmaceutical Companies. Paper 
presented at the 11th Globelics Conference, Ankara, Turkey.
Niosi, Jorge (2013). The Internationalization of Chinese and Indian Pharmaceutical Companies - chal-
lenges for internationalization theory. Paper presented at the 11th Globelics Conference, Ankara, Turkey.
Pradhan, Jaya Prakash and Alakshendra, Abhinav (2006). Overseas Acquisition versus Greenfield Foreign 
Investment: Which Internationalization Strategy is better for Indian Pharmaceutical Enterprises? Paper 
presented at the 4th Globelics Conference, Trivandrum, India.
Ray, Monali and Thorsteinsdóttir, Halla (2008). Canada-India firm collaboration in health biotechnol-
ogy. Paper presented at the 6th Globelics Conference, Mexico City, Mexico.
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Sampath, Padmashree Gehl (2010). Sectoral Systems for Health Innovation and Development. Paper pre-
sented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Szogs, Astrid (2014). Investigating linkages with external actors: An analysis of three Tanzanian universi-
ties. Paper presented at the 12th Globelics Conference, Addis Ababa, Ethiopia.
Thomas, Jayan Jose (2006). India and China in the Knowledge Economy: Rivals or Allies? Case Studies 
of Pharmaceuticals and Biotechnology. Paper presented at the 4th Globelics Conference, Trivandrum, 
India.
Thorsteinsdottir, Halla and Chaturvedi, Sachin (2014). An Analysis of the Impacts of South-South Co-
operation: The Case of Health Biotechnology. Paper presented at the 12th Globelics Conference, Addis 
Ababa, Ethiopia.
Thorsteinsdóttir, Halla; Kapoor, Andrew; Adly, Nefertiti; Aly, Sahar; Chaturvedi, Sachin; Konde, Victor; 
Ke, Wen; Li, Lexuan; Madkour, Magdy A.; Saenz, Tirso W. and Paula, Maria Carlota de Souza (2010). 
Changing Landscape of International Collaboration? A Study of South-South Collaboration in Health 
Biotechnology. Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia. 
Torres, Arturo Torres and Villazul, Javier Jasso (2012). Research and Innovation in the Health Sector in 
Mexico: The Role of Public Research Organizations. Paper presented at the 10th Globelics Conference, 
Hangzhou, China.
Vargas, Arturo Torres (2013). Social Mission of the University: A Case Study in the Health Sector in Mexico. 
Paper presented at the 11th Globelics Conference, Ankara, Turkey.
Institutional Innovation
Abrol, Dinesh; Dhulap, Sivakami and Singh, Nidhi (2016). Foreign Firms, Product Patent and Pharmaceu-
ticals in India after TRIPS. Paper presented at the 14th Globelics Conference, Bandung, Indonesia.
Abrol, Dinesh; Prajapati, Pramod and Singh, Nidhi (2010). Globalization of the Indian pharmaceutical in-
dustry: Implications for the direction, distribution and diversity in drug innovation. Paper presented 
at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Afolabi, Michael Olusegun (2012). A Disruptive Innovation Model for Research into Indigenous Medicines: 
A Perspective from Nigeria. Paper presented at the 10th Globelics Conference, Hangzhou, China.
Bianchi, Carlos (2011). The role of innovation policies in the Brazilian biotechnology-health regime. 
Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Bourgain, Arnaud ; Pieretti, Patrice and Zou, Benteng (2009). The Shortage of Medical Workers in 
Sub-Saharan Africa and Substitution Policy. Paper presented at the 7th Globelics Conference, Dakar, 
Senegal.
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Caliari, Thiago; Mazzoleni, Roberto and Póvoa, Luciano Martins Costa (2011). Innovation in The Bra-
zilian Pharmaceutical Industry Post-Trips. Paper presented at the 9th Globelics Conference, Buenos 
Aires, Argentina.
Chaturvedi, Kalpana and Chataway, Joanna (2006). Innovation in the Post-TRIPs Regime in Indian Phar-
maceutical Firms: Implications for Pharmaceutical R&D Model. Paper presented at the 4th Globelics 
Conference, Trivandrum, India.
Chaudhuri, Sudip (2011). Re-Introduction of Pharmaceutical Product Patent Protection and Pharma-
ceutical Industry In India. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Chowdhury, Samik (2009). “Medical Poverty Trap” and the Urban Poor in India. Paper presented at the 7th 
Globelics Conference, Dakar, Senegal.
Chowdhury, Samik (2010). Health Shocks and the Urban Poor: A Case Study of Slums in Delhi. Paper 
presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Correa, Carlos M. (2011). Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing. 
Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Fiedler, Beth Ann (2009). Institutional Reform and Innovative Health Care Service Solutions via Mi-
croeconomic Intentional Community Business Development. Paper presented at the 7th Globelics 
Conference, Dakar, Senegal.
Guennif, Samira (2009). From TRIPS to “TRIPS Plus” provisions. Patents protection and public health 
promotion in developing countries: raising the stakes for drugs accessibility. Paper presented at the 7th 
Globelics Conference, Dakar, Senegal.
Guennif, Samira (2010). Intellectual property rights and other institutional matters influencing medi-
cines accessibility in Thailand. Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Guennif, Samira (2011). The Importance of Generic Drugs in the South: Behind the Brazilian Anti-AIDS 
Program, the Indian Performance in the Pharmaceutical Sector. Paper presented at the 9th Globelics 
Conference, Buenos Aires, Argentina.
Habiyaremye, Alexis and Gachino, Geoffrey (2010). Optimal Patent Protection for Pharmaceuticals. 
Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Hati, Moutushi (2006). Does the New Intellectual Property Rights Regime Impede Innovation in Develop-
ing Countries: A Case Study of The Indian Pharmaceutical Industry. Paper presented at the 4th Globe-
lics Conference, Trivandrum, India.
Juncal, Santiago Eduardo; Mancini, Ezequiel; Lavarello, Pablo and Sztulwark, Sebastián (2016). Crea-
tive imitation in late industrializing countries: the case of biosimilars in South Korea and India. Paper 
presented at the 14th Globelics Conference, Bandung, Indonesia.
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Kalarivayil, Rajesh and Desai, Pranav N. (2016). The Tale of Three Technologies: Examining Inequality in 
Health Research in India. Paper presented at the 14th Globelics Conference, Bandung, Indonesia.
Kale, Dinar (2013). Regulation quagmire, inclusive innovations and arrested development: evidence from 
the Indian medical device industry. Paper presented at the 11th Globelics Conference, Ankara, Turkey.
Kale, Dinar (2015). New sources of growth under the TRIPS compliant patent regime for emerging country 
pharmaceutical industries? Investigating the development of biosimilar capabilities in the Indian phar-
maceutical sector. Paper presented at the 13th Globelics Conference, Havana, Cuba.
Nanda, Nitya; Barpujari, Indrani and Srivastava, Nidhi (2010). Securing Access to Patented Knowl-
edge in Biotechnology: Can Patent Pooling Offer a Solution for India? Paper presented at the 8th Globelics 
Conference, Kuala Lumpur, Malaysia.
Ouma, Marisella (2006). Pharmaceuticals, Innovation and product patents; a lesson from India. Paper 
presented at the 4th Globelics Conference, Trivandrum, India.
Pandey, Poonam (2015). Visions and Practices of ‘Technology for the Poor’ in the Case of Diagnostics Develop-
ment using Nanobiotechnology in India. Paper presented at the 13th Globelics Conference, Havana, Cuba.
Ramani, Shyama V. and Urias, Eduardo (2013). Acccess to critical medicines: when are compulsory li-
censes effective in price negotiations? Paper presented at the 11th Globelics Conference, Ankara, Turkey.
Rashmi, Rakhi (2009). Changed patent policy and biopharma innovation in India by foreign invest-
ment and technology transfer. Paper presented at the 7th Globelics Conference, Dakar, Senegal.
Rashmi, Rakhi (2011). Product Patent Regime and International Partnering For The Biopharmaceutical 
Innovations In India. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Sampat, Bhaven (2006). The Effects of Indian Pharmaceutical Product Patent Protection: An Analysis 
of the Mailbox Applications. Paper presented at the 4th Globelics Conference, Trivandrum, India.
Sampath, Padmashree Gehl (2006). Breaking the Fence: Patent Rights and Biomedical Innovation in 
“Technology Followers”. Paper presented at the 4th Globelics Conference, Trivandrum, India.
Sampedro, José Luis (2011). Knowledge Management from an Institutional and Evolutionary Approach: 
The Case of Telemedicine in Mexico. Paper presented at the 9th Globelics Conference, Buenos Aires, 
Argentina.
Sutz, Judith (2014). Relation between innovation policies and social policies: Institutional arrangements 
for the promotion of innovation in health in Brazil and Uruguay. Paper presented at the 12th Globelics 
Conference, Addis Ababa, Ethiopia.
Tomassini, Cecilia (2016). Economic and social orientations in the policies and programs to promote 
Science, Technology and Innovation in health in Brazil during the period 2000 – 2014. Paper presented 
at the 14th Globelics Conference, Bandung, Indonesia.
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Urias, Eduardo (2014). The Brazilian experience on price negotiations for universal access to antiretro-
virals drugs: a game theoretical explanation. Paper presented at the 12th Globelics Conference, Addis 
Ababa, Ethiopia.
Urias, Eduardo and Furtado, João (2009). Institutional changes and their impacts on the Brazilian Pharma-
ceutical Industry: Is there an Innovation System on the way? Paper presented at the 7th Globelics Confer-
ence, Dakar, Senegal.
Urias, Eduardo and Ramani, Shyama V. (2015). Access to medicines: A scoping study on the challenges 
of the current IPR system. Paper presented at the 13th Globelics Conference, Havana, Cuba.
Vargas, Marco Antonio; Britto, Jorge and Szapiro, Marina (2016). Innovation and Public Procurement in the 
Health Sector in Brazil: a preliminary analysis of the Partnership for Productive Development (PDPs) 
program. Paper presented at the 14th Globelics Conference, Bandung, Indonesia.
Wong, Lissy; Zaldivar, Dionisio and Vera-Cruz, Alexandre O. (2015). Barriers for the introduction of new 
products based on biomaterials in the Cuban health system: the case of TISUACRYL®. Paper presented 
at the 13th Globelics Conference, Havana, Cuba.
Zhukov, S.S. (2010). Constitutional foundations of medical aid regulation: issues and trends. Paper pre-
sented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
System innovation
Afolabi, Michael Olusegun (2009). Exploring the Technologies of Laboratory Science for Social Change: 
an Examination of the Nigerian Healthcare System. Paper presented at the 7th Globelics Conference, 
Dakar, Senegal.
Afolabi, Michael Olusegun (2014). An Ubuntu-driven Innovation System for Public Health in Africa. 
Paper presented at the 12th Globelics Conference, Addis Ababa, Ethiopia.
Al-Bader, Sara (2010). Features of science-based health innovation in Ghana, and implications for ap-
proaches to African innovation: an empirical study. Paper presented at the 8th Globelics Conference, 
Kuala Lumpur, Malaysia.
Arora, Parveen (2007). Biotechnology innovation systems in India: Role of Government. Paper presented 
at the 5th Globelics Conference, Saratov, Russia. 
Bailey, Henry Hugh (2014). Entrepreneurship and Health Status in the GEM Caribbean Countries. Pa-
per presented at the 12th Globelics Conference, Addis Ababa, Ethiopia.
Bianchi, Carlos (2010). Brazilian Health Biotechnology System: an essay about the firm’s selection process. 
Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
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Bianchi, Carlos (2014). Between central coordination and bottom up experience: What policy mix 
for health innovation in Uruguay? Paper presented at the 12th Globelics Conference, Addis Ababa, 
Ethiopia.
Bianchi, Carlos (2015). Health innovation pathways in Uruguay. Paper presented at the 13th Globelics 
Conference, Havana, Cuba.
Chen, ShihHsin (2012). Networking and Knowledge Transfer in the Taiwanese Biopharmaceutical Innova-
tion System. Paper presented at the 10th Globelics Conference, Hangzhou, China.
Engel, Nora (2009). Drivers and Barriers of Innovation Dynamics in Healthcare Towards a frame-
work for analyzing innovation in Tuberculosis control in India. Paper presented at the 7th Globelics Con-
ference, Dakar, Senegal.
Gadelha, Carlos Augusto G.; Vargas, Marco Antonio; Maldonado, José and Barbosa, Pedro (2010). 
The Health Economic Industrial Complex in Brazil: modes of coordination and implications for NIS in 
the health area. Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Guennif, Samira (2013). Institution and public health in the developing world: Institutional, industrial 
and health dynamics in the pharmaceutical sector in Thailand. Paper presented at the 11th Globelics 
Conference, Ankara, Turkey.
Guennif, Samira and Ramani, Shyama V. (2008). Catching-up in the pharmaceutical sector: Lessons from 
case studies of India, Thailand and Brazil. Paper presented at the 6th Globelics Conference, Mexico 
City, Mexico.
Guzmán, Georgina Alenka and Viquez, Hortensia Gómez (2008). Technological gaps and converging 
process between emerging and industrialised countries in pharmaceutical industry. Paper presented at the 
6th Globelics Conference, Mexico City, Mexico.
Haenssgen, Marco Johannes and Ariana, Proochista (2015). Does the Rapid Mobile Phone Diffusion in 
Rural Low- and Middle-Income Contexts Undermine Equitable Access to Healthcare? Survey Evi-
dence from Rural India and China. Paper presented at the 13th Globelics Conference, Havana, Cuba.
Hanlin, Rebecca (2010). Building capacity through innovation for integrated health solutions in developing 
countries. Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Helder, Osorio Moranchel (2006). Latin American Pharmaceutical Innovation in the context of global 
economy: Brazilian and Mexican industrial integration. Paper presented at the 4th Globelics Confer-
ence, Trivandrum, India.
Kale, Dinar (2011). In Search of the Missing Hand of the State? The Case of the Indian Medical Device 
Industry. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
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Kraemer-Mbula, Erika; Ndabeni, Lindile and Maharajh, Rasigan (2013). Rural health systems in South 
Africa: the role of local innovation in social inclusion. Paper presented at the 11th Globelics Conference, 
Ankara, Turkey.
Madhavan, Harilal (2007). Does institutions matter for commercialization? - Ayurveda and traditional chi-
nese medicine in comparative perspective. Paper presented at the 5th Globelics Conference, Saratov, Russia.
Mani, Sunil (2006). The incremental innovator Vs. the trader: Contrasts between the sectoral systems of 
innovation of the Indian pharmaceutical and telecommunications industries. Paper presented at the 4th 
Globelics Conference, Trivandrum, India.
Matos, Marcelo Gerson Pessoa de; Soares, Maria Clara C.; Cassiolato, José Eduardo and Queiroz, J. (2013). 
Health and innovation in the territorial sphere: Evidence from Brazilian local production and innovations 
systems. Paper presented at the 11th Globelics Conference, Ankara, Turkey.
Mcmahon, Dominique and Thorstiensdóttir, Halla (2011). Southern Innovation in Emerging Technologies: 
A Look at Regenerative Medicine Innovation in Brazil, China and India. Paper presented at the 9th Glo-
belics Conference, Buenos Aires, Argentina.
Olivier, Koudou Zohore and Gregoire, Guei Sosthene Auguste (2010). Accessibility of health services in 
West Africa: the case of Ivory Coast. Paper presented at the 8th Globelics Conference, Kuala Lumpur, 
Malaysia.
Pérez Sánchez, América Martiza; Molina García, Jose Ramón and Pérez de Hoz, Grisell (2015). Techno-
logical innovation in health development in Cuba. Paper presented at the 13th Globelics Conference, 
Havana, Cuba.
Plahte, Jens (2008). Actor-networks, interests and boundary objects in the Cuban biotechnology sector 
and vaccine industry. Paper presented at the 6th Globelics Conference, Mexico City, Mexico.
Ray, Monali; Thorsteinsdóttir, Halla (2010). Canada-Emerging Economies Collaboration in Health Bio-
technology: Linking Systems of Innovation Framework to analyzing North-South Partnerships. Paper 
presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
Rodriguez, Fernando Santiago and Dutrenit, Gabriela (2010). Determinants of PRO-industry interac-
tions in latecomer pharmaceutical R&D: the case of Mexico. Paper presented at the 8th Globelics Confer-
ence, Kuala Lumpur, Malaysia.
Santiago, Fernando (2011). Learning To Do Pharmaceutical Innovation: The Human Resource Manage-
ment Dimension. Paper presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Simiyu, Ken (2010). Business models in health innovation in Africa: The case of an African research insti-
tute. Paper presented at the 8th Globelics Conference, Kuala Lumpur, Malaysia.
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Singh, Nidhi (2015). In-Vitro Diagnostics Innovation for Resource Poor Settings: Indian Experience. 
Paper presented at the 13th Globelics Conference, Havana, Cuba.
Soares, Maria Clara Couto and Cassiolato, José Eduardo (2013). Innovation Systems and Social Inclu-
sion: Preliminary evidences based on empirical work on health local systems. Paper presented at the 
11th Globelics Conference, Ankara, Turkey.
Thorsteinsdóttir, Halla (2011). Building up Expertise in Health Biotechnology: The Case of Cuba. Paper 
presented at the 9th Globelics Conference, Buenos Aires, Argentina.
Vargas, Marco and Britto, Jorge (2015). A systemic innovation policy with an inclusive perspective: the 
evolution of the Brazilian policy to the pharmaceutical sector. Paper presented at the 13th Globelics 
Conference, Havana, Cuba.
Yacoub, Nejla (2011). Assessing the Pharmaceutical Innovation in Tunisia: Empirical Survey on the Firms? 
Knowledge-Capital and Analysis of the Innovation System. Paper presented at the 9th Globelics Con-
ference, Buenos Aires, Argentina.
    Zucoloto, Graziela and Cassiolato, Jose Eduardo (2007). Brazilian Health Innovation System: An Ap-
plication of the Concept in the Case of HIV Drugs. Paper presented at the 5th Globelics Conference, 
Saratov, Russia.
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